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Current challenges in vascular medicine (e.g., bypass grafting, stenting, and angioplasty.) have 
driven the field of vascular regenerative medicine.  Bone marrow-derived mesenchymal stem 
cells (BMMSCs) are adult stem cells which may be a suitable cell source for vascular 
regenerative medicine applications.  While it is well known that BMMSCs readily differentiate 
into musculoskeletal cells, recent studies have provided evidence for their differentiation into 
smooth muscle cells (SMCs) and endothelial cells (ECs).  We and others have demonstrated the 
ability of the mechanical stimulus of cyclic stretch to drive BMMSC differentiation towards 
SMCs in vitro, but a rigorous, systematic analysis of other relevant forces is lacking.  The 
working hypothesis that this work addressed is that mechanical stimuli relevant to the 
vasculature will guide BMMSC differentiation towards SMCs and ECs.   
To test this hypothesis, rat BMMSCs were exposed to physiologically relevant 
magnitudes and frequencies of a Mechanical Panel, which consisted of cyclic stretch, cyclic 
pressure, and shear stress, each applied in parallel to subcultures of BMMSCs.  Quantitative 
changes in morphology, proliferation, and gene and protein expression were assessed to 
determine the differential effect of each stimulus in a dose- and frequency-dependant manner.  
Next, we investigated the importance of the duration of applied stimulation to BMMSC 
differentiation as well as tissue commitment (i.e., cell plasticity) following mechanical 
stimulation. 
 iv 
Our results demonstrate that mechanical stimulation differentially altered BMMSC 
morphology, proliferation, and gene and protein expression towards the cardiovascular lineage 
while limiting expression for other lineages including bone, fat, and chondrocyte.  This was 
particularly evident for cyclic stretch, which caused an elongated, spindle-shape and expression 
of the SMC proteins α-actin, calponin, and myosin heavy chain.  Furthermore, we found that 
cyclic pressure and shear stress tended to increase endothelial gene expression when these 
stimuli are applied to confluent BMMSCs.  While our findings as a whole tended to support our 
hypothesis, our data indicate that SMC protein expression is more readily increased by 
mechanical stimulation, and is highly variable, even without associated changes in gene 
expression.  Future work employing systems biology approaches that take into consideration the 
resulting transcriptional and proteomic changes in BMMSCs from these mechanical stimuli will 
be necessary to more accurately identify how mechanical stimulation can be used as a tool for 
regenerative medicine.   
 v 
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1.0 INTRODUCTION 
1.1 VASCULAR DISEASE 
Cardiovascular disease continues to be the number one cause of death in this country, affecting 
more than 79 million Americans at an average cost of more than $283 billion [2].  One of the 
most life-threatening cardiovascular diseases is coronary artery disease, in which the blood 
vessels feeding the heart become obstructed due to atherosclerotic lesions, depriving the heart 
muscle of much needed oxygen and leading to myocardial infarction.  In 2004, more than 6.3 
million cardiovascular procedures were performed, including 427,000 coronary bypass surgeries 
in 249,000 patients, 615,000 stent placements, and 1.6 million angioplasties [2].  Another, related 
sub-type of cardiovascular disease is peripheral vascular disease, which although not as life-
threatening as coronary artery disease, causes significant morbidity including loss of limbs.  
Each year approximately 150,000 additional patients receive peripheral bypass grafts to relieve 
perfusion deficits in the leg [3].  In 2002, approximately 400,000 patients underwent surgical 
placement of a vascular access graft for dialysis [3, 4].  Currently accepted treatments for 
coronary artery and peripheral vascular disease include surgical bypass with native or synthetic 
grafts, as well as stenting. 
Bypass grafting is the surgical implantation of a biocompatible conduit for shunting 
blood around a blocked segment of a blood vessel.  In nearly all instances, an autologous vein or 
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artery or prosthetic graft is employed to provide circulation or vascular access. While vascular 
grafting has been around since the early twentieth century, cardiovascular surgeons still face 
many challenges when bypassing small diameter (<6mm) blood vessels [5].  Currently, the 
majority of patients receive the left internal mammary artery as a graft for the left anterior 
descending coronary artery bypass and the saphenous vein for all other bypass positions [6].  
Research has indicated that 30% of vein grafts become occluded in the first year and one half of 
those occlusions occur within the first month [7]. Moreover, only 60-70% of patients can reach a 
10–12 yr period free of reoperations or angioplasty [6, 8].  Other, less common autologous 
grafting materials include the radial artery and the gastro-epiploic artery [5].  Complications 
from vascular access grafts, including infection, thrombosis, and intimal hyperplasia, account for 
nearly 25% of all hospital admissions each year [9-13].   
1.1.1 Vascular conduits 
Much effort has been focused on creating an ideal bypass or access graft.  Moderate success has 
been achieved with expanded polytetrafluoroethylene (ePTFE) and polyethylene-teraphthalate 
(Dacron) in large diameter applications, but small diameter graft performance has been 
unacceptable [14-21].  Newer grafting materials, including polyurethanes [18], decellularized 
extracellular matrix (ECM) [22, 23], and cryopreserved allografts [24] show some promise for 
improving long-term patency, but are still in the experimental stages.   
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1.1.2 Angioplasty and vascular stenting 
Angioplasty, which involves the use of a balloon or other mechanical device to open a stenosed 
or occluded artery – either by physical expansion of the lumen, or compression or removal of 
atherosclerotic plaque – is often employed as a first step approach because of it low immediate 
risk and relative non-invasiveness.  The major drawback to this simple procedure is that it causes 
damage to the endothelial lining, leading to subsequent platelet adhesion and/or SMC 
proliferation and intimal hyperplasia [25].  Subsequently, stenting, which is the placement of a 
metal scaffold to prop open the vessel, is often employed to hold open an artery that cannot 
maintain its lumen following angioplasty or was not a suitable candidate for angioplasty [26].  
The major drawbacks to stenting are the thrombotic events that can occur from blood contacting 
the metal struts of the stent, as well as vessel restenosis via intimal hyperplasia as the vessel 
grows over the stent struts and into the lumen of the vessel [27].  Second-generation stents are 
beginning to employ controlled-release of certain drugs, such as Tacrolimus and Paclitaxel, 
which are intended to prevent cellular division and therefore reduce intimal hyperplasia [28-30].  
Anti-platelet drugs, such as Plavix, are also being employed in drug-eluting stents to provide 
local anti-platelet activity instead of the systemic dosing that many patients typically undergo.  
However, the use of these types of stents often still requires additional anti-thrombotic agents, 
such as thienopyridine, of which one-in-seven patients requires premature discontinuation, 
leading to increased mortality [31]. Recent reports also suggest that stenting may increase 
peripheral thrombotic events, also leading to increased morbidity and mortality [28, 29, 32]. 
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1.1.3 Regenerative medicine 
In addition to advances in bypass grafting and stenting, a new field of regenerative medicine has 
been developing as a potential treatment for a number of diseases, including cardiovascular 
disease.  Regenerative medicine, which includes tissue engineering and cellular therapy, aims to 
replace damaged vessels with living, functional tissues instead of synthetic devices which cannot 
mimic the complex biological function of blood vessels.  Additionally, in pediatric 
cardiovascular surgery, regenerative medicine promises replacement materials that will grow 
with the child.  The first attempts at tissue engineering were endothelialization of ePTFE and 
Dacron grafts [33-35].  While research is still ongoing in this area [16, 36, 37], more attention is 
being focused on a complete vascular equivalent [38-42].  However, no tissue-engineered 
vascular graft has progressed beyond the experimental stage [39, 43-45], with animal studies 
demonstrating lower patency rates than synthetic materials [39, 46]. 
One of the biggest challenges for vascular regenerative medicine is finding an appropriate 
cell source for populating the vessel with smooth muscle (SMCs) and endothelial cells 
(ECs)[43].  It is widely believed that autologous cells are most appropriate for tissue engineering 
applications to avoid the use of anti-rejection therapies, but terminally differentiated cells 
derived from vascular tissue may be predisposed to the same pathology as the diseased tissue.  
Additionally, quick expansion of fully differentiated cells to the numbers required for tissue 
engineering is difficult and often results in cellular transformation [47, 48].  Clearly, an 
alternative cell source is needed, and autologous progenitor cells have been identified as a 
plausible candidate [43].   
Progenitor cells have the capability of becoming any of a number of cell types given the 
right environment.  Of the tissues containing adult progenitor cells, the bone marrow is viewed 
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by many as having the greatest potential for providing progenitor cells for clinical therapy 
because it is a site of rapid cellular turnover [49, 50].  Bone marrow progenitor cells have 
become widely used in cellular therapy [51-54] and are thought to have many applications in 
cardiovascular tissue engineering [43, 55].  Bone marrow presents a readily available source of 
autologous progenitor cells that have the ability to become many types of tissue, provided they 
receive the proper cues [56-58].  However, in order to effectively apply the necessary stimuli for 
the generation of functional smooth muscle and endothelial cells, an understanding of the 
developmental paths and basic biology for these cells is necessary.  
1.2 
1.2.1 
SMOOTH MUSCLE CELLS 
Development and basic biology 
Smooth muscle cells (SMCs) are spindle-shaped cells found in the walls of almost every hollow 
organ in the body [59].  They arise primarily from the mesodermal layer during embryonic 
development [60].  SMCs play a fundamental role in many tissue types where the organism 
requires rhythmic slow or sustained contraction.  Across an organism, SMCs in different tissue 
beds have many unique characteristics, including expression of contractile protein isoforms and 
response to adrenergic agents.  Even within a single tissue, SMCs exhibit many different 
phenotypes, ranging from a prototypical fibroblast that contains very few contractile proteins and 
produces and organizes ECM, to an intermediate myofibroblast that contains some contractile 
proteins and continues, to participate in matrix production to a fully-differentiated SMC 
expressing the complete assortment of contractile proteins, intercellular signaling molecules 
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(e.g.,, connexins), and responding to biological agents including epinephrine, nitric oxide, and 
acetylcholine [61].   
The state of the SMC depends heavily upon the local biochemical and biomechanical 
milieu, each regulating the cellular state in a continuum between a synthetic fibroblast-like 
phenotype and the fully contractile phenotype found in the vessel media.  The possibility for 
stem cells to enter into this cycle has been hypothesized, initially becoming a fibroblast-like cell 
with potential to differentiate to the fully contractile phenotype (Figure 1.1) [62].  Of the variety 
of proteins expressed by SMCs (including SM22α, myocardin, smooth muscle α-actin, 
smoothelin, calponin, caldesmon, and myosin heavy chain), only myosin heavy chain (isoform 
SM-2) and smoothelin appear to be exclusive to SMCs (Table 1.1) [61, 63-65].  However, the 
presence of myosin heavy chain and smoothelin does not necessarily imply functionality.  A 
functional SMC requires abundant K+ and Ca2+ ion channels, as well as the receptors for 
vasoconstrictors and -dilators. To determine the true contractile/functional state of a presumed 
SMC, one needs to perform a multitude of protein and functional assays to elucidate the true 
phenotype [66].  The proceeding sections describe the various proteins involved in SMC 
development and their restriction to the SMC phenotype. 
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Figure 1.1: SMC phenotypic switching occurs from various external stimuli.  Reprinted with permission from [62]. 
 
 
Table 1.1: Comparison of SMC contractile proteins, their exclusivity to SMCs, and presence in different SMC 
phenotypes.  ++ indicates definitively positive expression; +/- indicates transient expression or conflicting reports; 
and -- indicates definitively negative expression. Table adapted from [66]. 
 
Protein Exclusive to SMCs Contractile 
Synthetic/ 
developmental Expression  in other cells 
SMA N ++ ++ Fibroblasts, myoblasts, inducible in ECs in vitro 
SM22α N ++ ++ 
Inducible by stretch, TGF-β, 
and loss of cell-cell contact 
in ECs in vitro 
Caldesmon N ++ +/- Inducible skeletal myoblasts in vitro 
h1-Calponin N ++ +/- Myoepithelium, inducible in ECs in vitro 
Myosin heavy chain   
(SM-1 and SM-2) Y ++ --  
Smoothelin Y ++ --  
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1.2.1.1 Smooth muscle α-actin  
Smooth muscle cells arise during vasculogenesis as early as two days into development 
(in chicken and quail embryos), enveloping the newly formed aortic tube [61, 67, 68].  These 
cells are morphologically different from the rounded endothelial cells lining the newly formed 
vessel, and are distinct from the surrounding mesoderm by the expression of smooth muscle α-
actin (SMA) [61].  SMA is a 42 kDa protein and is one of many forms of actin expressed 
throughout the body in addition to cardiac α-, skeletal α-, smooth muscle γ-, nonmuscle γ-, and 
β-actin [61, 69].  These isoforms are the product of different genes, but only differ from each 
other in the first ten amino acids, suggesting a highly conserved and efficient protein utilized for 
contraction, cellular locomotion, and intracellular transport [61].  Only SMA and γ−actin are 
considered to be contractile associated proteins, while the other isoforms part of the non-
contractile cytoskeleton [70-73].  The amount of SMA produced in the early SMCs continues to 
increase as the cells mature, eventually making up 40% of the total protein produced and 70% of 
the actin isoforms produced by the SMC [61, 69].  Although the expression of SMA was once 
thought to be highly specific for SMCs, since its expression in the normal adult organism is 
relatively restrictive, studies in wound healing and tumorigenesis, as well as other cell types 
treated with specific growth factors, have shown that non-SMCs can express SMA [61, 74-78].  
Thus, SMA does not appear to be sufficient to positively identify SMCs (contractile or 
synthetic); other proteins are necessary. 
1.2.1.2 Calponin 
Calponin is a 34kDa regulatory protein that is associated with actin and tropomyosin 
binding [79].  Several isoforms of calponin are known to exist, but only h1-calponin is found in 
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vascular SMCs [61].  A more recently discovered isoform, h2-calponin, is the product of a 
separate gene and is found in skeletal muscle and other non-muscle cells including platelets and 
fibroblasts [79].  The functional significance of calponin is demonstrated by its ability to bind 
actin in the same stoichiometry as tropomyosin, suggesting that it acts as an inhibitory protein to 
SMC contraction.  Indeed, addition of calponin to a simple contractile system consisting of free 
actin, myosin, tropomyosin, calmodulin, and myosin light chain kinase reduces ATP 
consumption by more than 80% [80]. 
The expression of h1-calponin occurs early in the development of the aorta and is 
maintained in adult, contractile SMCs [61].  Although h1-calponin is relatively restricted to 
SMCs in the normal adult, calponin expression has been reported in platelets and tumor cells.  
However, the h1 isoform has not been confirmed in these studies, lending the possibility that it is 
in fact the non-muscle h2-calponin isoform [61, 81, 82].  Additionally, h1-calponin expression 
has been noted in ECs subjected to cyclic stretch [83], to fibroblast growth factor [84], or to 
transforming growth factor-β stimulation [85] in vitro. 
1.2.1.3 SM22α 
SM22α is a 22kDa protein of similar structure and developmental specificity to calponin 
[68, 86].  Although SM22α and calponin share certain homologous regions, SM22α has had 
conflicting reports on its ability to bind actin, and the functional importance is still in dispute [72, 
87, 88].  SM22α appears developmentally after day 4 (in chicken and quail embryos), but before 
other late markers of differentiation such as calponin and myosin heavy chain [61, 72].  There 
are reports that SM22α is identical, both in mRNA and amino acid sequence, to transgelin, 
which is an actin-polymerization chaperone protein [89, 90]. Knockouts of the SM22α gene 
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develop normally but show changes in actin cytoskeletal arrangement, further supporting the 
theory that it participates in actin polymerization [91].  Although SM22α is inducible in ECs in 
vitro [83, 85], it has yet to be found in non-muscle cells in vivo [86].   
1.2.1.4 Caldesmon 
Caldesmon is a calmodulin, tropomyosin, and actin-binding protein found in SMCs and 
some non-muscle cells [64].  Two isoforms, h-caldesmon (120kDa) and l-caldesmon (70kDa), 
exist, with h-caldesmon restricted primarily to SMCs.  Neither isoform is found in skeletal or 
cardiac muscle cells in vivo [61], but, h-caldesmon can be induced by serum deprivation in 
skeletal myoblast culture [92].  Caldesmon’s primary function is to regulate actin-myosin 
interactions during contraction, and it is localized in the thin filaments of SMCs and along stress-
fibers in non-muscle cells [65].  It appears as a later marker than calponin and SM22α but prior 
to myosin heavy chain [61]. 
1.2.1.5 Smoothelin 
Smoothelin has been proposed as protein restricted to muscular arteries of the vasculature 
[93].  Since its discovery, two isoforms, smoothelin-A (59kDA) and smoothelin-B (100kDa), 
have been identified that are predominantly found in the visceral and vascular SMCs, 
respectively, but only one gene has been identified thus far [94, 95].  It appears relatively late in 
development (around 10 weeks in humans) in the blood vessels surrounding the placenta.  In the 
adult, smoothelin is found in only 10% of the aorta SMCs, more than 50% of the muscular 
arteries, but not in veins or capillaries [95].  Smoothelin is also found in developing 
atherosclerotic lesions, usually isoform –B [96], and is usually co-expressed with desmin [97].    
Upon explant, transcription of the smoothelin gene ceases very quickly [93].  Smoothelin 
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expression is essential for normal contractile function in SMCs of the vasculature and gut, 
suggesting it is part of the contractile apparatus along with actin and myosin heavy chain [96, 
98].    
1.2.1.6 Myosin Heavy Chain 
Myosin is a hexameric protein principally responsible for cellular contraction and is 
found in nearly every muscle and nonmuscle cell [61].  Myosin heavy chain (MHC), one of the 
subunits of myosin, is expressed in several isoforms across muscle and nonmuscle cells, but 
there are two isoforms, SM-1 (204kDa) and SM-2 (200kDa), that are believed to be exclusively 
expressed by SMCs [61, 99].  A third isoform, SMemb (198kDa), is found in most developing 
and cultured SMCs as well as atherosclerotic lesions.  It can be induced in other cell types, such 
as fibroblasts, with mechanical or growth factor stimulation [100] and during wound repair 
[101].  However, in mature functional SMCs, SMemb is typically replaced by SM-2 late in 
development, thus making SM-2 the latest marker for SMC differentiation [102].  SM-2 
expression continues to increase postnatally, which may be related to the increasingly sustained 
or rhythmic contraction that is a hallmark of SMCs.   
1.2.1.7 Myocardin 
Like its relatives, skeletal and cardiac muscle, many researchers have postulated that 
SMC differentiation should be governed by a specific family of transcription factors that control 
a significant portion of the transcription of contractile proteins.  There has been much difficulty 
in identifying such a master switch, but the best candidate to date is myocardin.  It plays a 
significant role in both SMC and cardiac muscle differentiation and has been used as an indicator 
of SMC potential [103].  Myocardin is part of a complex set of transcription factors that 
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transcribe numerous SMC-specific genes.  Knockout studies of myocardin have demonstrated 
embryonic lethality by day 10.5 in mice with no evidence of any SMC differentiation [104].  
Ectopic expression of myocardin has demonstrated the ability to turn on SMC proteins in non-
muscle cells [105, 106].  Although many of the SMC-restricted genes are under the promotion of 
myocardin, there are a few exceptions.  In particular, smoothelin-B, the isoform specific for 
vascular SMCs, does not appear to be regulated by myocardin [107, 108].  Although relying on a 
single transcription factor to promote the expression of most of the necessary proteins for 
contraction seems fairly intuitive, the functional purpose for this separation of transcriptional 
control for smoothelin is not yet understood. 
1.2.2 Response to biological factors 
Because SMCs provide such an important function in all major organ systems, they need to 
develop and adapt to changing demands and injury.  As part of this development and remodeling 
process, SMCs are exposed to a variety of growth factors that alter their proliferation rates, 
matrix production, and differentiation (see Figure 1.1).  Four key growth factors in SMC 
development and biology – platelet derived growth factor, transforming growth factor β, 
fibroblast growth factor, and vascular endothelial growth factor- are discussed here. 
1.2.2.1 Platelet derived growth factor (PDGF) 
PDGF is a ~30kDa growth factor expressed by numerous cells types (Table 1.2) [109, 
110].  There are four known isoforms - PDGF-A, PDGF-B, PDGF-C, and PDGF-D – that exist 
as homo-dimers.  Only PDGF-A and PDGF-B are known to exist naturally as a hetero-dimer 
[111].  Each PDGF isoform is transcribed from a separate gene, meaning that cells transcribing 
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PDGF-A and PDGF-B can produce equal amounts of PDGF-AA, PDGF-BB, and PDGF-AB 
[109, 111].  PDGF acts upon a receptor (either the α- or β-isoform) on the cell surface belonging 
to the tyrosine kinase family of growth factor receptors.   
 
Table 1.2: Multiple cell types express different isoforms of PDGF and PDGF receptor (PDGFR) [109].   
 
Cell Type PDGF-A PDGF-B PDFGR-α PDGFR-β 
Fibroblast + + + + 
Skeletal myoblast +   + 
Vascular SMC + + + + 
Vascular EC + +  + 
Macrophages + +  + 
Platelets + + +  
 
The expression of PDGF and its receptor varies depending upon the cell type (Table 1.2) 
and local milleu, especially in development and disease states.  For instance, PDGFR expression 
is increased in vascular SMCs following injury to increase mitosis and accelerate tissue repair 
and regeneration [112-114].  Likewise, PDGF expression by newly forming vascular ECs rises 
and falls during vasculogenesis and angiogenesis to attract pericytes expressing PDGFRs [109].  
Normal SMCs do not express high levels of PDGF-Rα, but do increase their levels in response to 
hypertension, mechanical stimulation [110, 115-117], inflammation states such as injury or 
atherosclerosis [110, 118], and fibroblast growth factor stimulation [119]. 
During development, PDGF plays an important role in the formation of the vasculature as 
knockouts of the PDGF-A and -B isoforms as well as their receptors are either embryonic lethal 
or suffer severe growth retardation and poor vascular development [111].  PDGFR stimulation 
induces myocardin expression, which in turn activates the gene expression of calponin, SM22α, 
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and smooth muscle γ-actin [61, 120].  Hellstrom et al. [121] developed a two-stage theory on the 
role of PDGF in vascular development that describes a temporal-spatial signaling between 
PDGFR-β positive pericytes and ECs.  This model of induction followed by co-proliferation is 
also evident during the epithelial to mesenchymal transition of coronary artery development 
[120].  In addition to the direct effects on SMCs during vasculogenesis and angiogenesis, PDGF 
has also been shown to have indirect effects on vessel growth through an increase vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in SMCs 
(see Section 1.2.2.3)[122, 123]. 
In adult quiescent SMCs, PDGF plays a very different role.  As stated previously, 
expression of PDGF-Rβ in arterial SMCs is low until acted on by an external mechanical or 
biological stimulus, or placement into tissue culture [109, 124].  Once these conditions are met, 
PDGFR expression increases, and the cells are primed for stimulation by PDGF, which has been 
shown to cause increased proliferation [125-127], decreased expression of contractile protein 
expression in SMCs including SMA, calponin, and SM-α tropomyosin, and MHC (SM-1) [120, 
125, 127-132], suppression of collagen synthesis [133, 134], and increased production of matrix 
metalloproteinases -2 and -9 [135, 136].  These processes are important for both normal vascular 
remodeling and pathology.   
1.2.2.2 Transforming growth factor beta (TGF-β) 
TGF-β is a 25 kDa polypeptide in a superfamily also containing activins, inhibins, 
myostatin, bone morphogenic proteins (BMPs), and others that play an important role in 
mitogenesis and morphogenesis throughout the body in both development and tissue remodeling 
[137-140].  There are three isoforms of TGF-β, each is differentially expressed in almost every 
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cell type in the body.  TFGβ is produced as a latent inactive dimer, which is activated in the 
extracellular space and binds to receptors forming a dimeric complex consisting of two subunits, 
TGF-βR-I and TGF-βR-II, to activate intracellular signaling [137, 139, 141].  TGF-βR-II is the 
predominantly expressed in normal SMCs, whereas TGF-βR-I is found in atherosclerotic plaques 
[139, 142].  A third receptor, TFGβR-III (also known as endoglin) found predominantly in ECs 
(see Section 1.3.2.2) does not appear to have signaling capability, but may aide in chaperoning 
active TGF-β to TGF-β receptors [138, 139]. 
During vascular development, TGF-β is expressed by ECs and SMCs participating in 
vasculogenesis and angiogenesis [139, 143, 144].  Knockouts of TGF-β, its co-receptors 
(including Alk1 and endoglin) [145], or the downstream TGF-β signaling molecule SMAD5  
[146, 147],  result in embryonic lethality from widespread hemorrhage due to a lack of mature 
SMCs surrounding the newly forming blood vessels [138, 139, 144].  This evidence has led to 
the hypothesis that TGF-β is essential for the induction and maturation of SMCs during 
vasculogenesis and angiogenesis [138, 148]. Recently, an embryoid body culture system has 
definitively shown that TGF-β contributes SMC differentiation and maturation in development 
[149].    
In adult SMCs, TGF-β alters SMC proliferation in a biphasic manner.  Low 
concentrations of TGF-β (1-2 fg/ml) induce SMC proliferation through PDGF-AA and PDGFR 
production (similar to developmental processes) [139, 144, 150, 151]. The effects of TGF-β at 
lower concentrations are consistent with reports that TGF-β and PDGF-A are increased in 
damaged vessels, leading to the initiation of intimal hyperplasia through SMC proliferation and 
matrix production [114, 119, 152].  Further evidence of this phenomenon has been found through 
increases in both vascular endothelial growth factor [122] (an EC mitogen; see Section 1.3.2.1) 
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and bFGF [122, 123] (both an EC and SMC mitogen; see Sections 1.2.2.3 and 1.3.2.3) following 
treatment of SMCs with TGF-β.  
Higher concentrations (10 pg/ml-10 μg/ml) of TGF-β have been shown to inhibit SMC 
proliferation by downregulating PDGFRβ protein synthesis [139, 144, 150, 151] and extending 
the G2 phase of the cell cycle [153, 154].  TGF-β also inhibits proliferation by downregulating 
FGF binding proteins, thus reducing the effective binding capacity and mitogenic effects of FGF 
[155].  Additionally, at these concentrations TGF-β has been shown to help maintain SMCs in 
their differentiated states through production of α-SMA, SM22α, calponin, and MHC (SM-1) 
[127, 139, 156-158].  TGF-β has also been shown to induce α-SMA and other contractile 
proteins including calponin in non-muscle cells such as fibroblasts (converting them to 
myofibroblasts) [78, 159, 160], 10T1/2 SMC precursor cells [160, 161], macrophages [162], and 
neural crest cells [160, 163]. 
In addition to changes in proliferation and contractile markers, TGF-β has been shown to 
be a potent inductor of ECM production.  TGF-β promotes the expression of α2 type I collagen, 
reduces the activity of matrix metalloproteinases (MMPs) [139, 154, 164, 165], and upregulates 
inhibitors of MMPs (TIMPs) [166].  There are, however, reports that show an increase in MMP 
expression when TGF-β is induced by mechanical stretch in vitro [167] or when low doses of 
TGF-β accompany PDGF [135].  These two opposing effects may demonstrate a unique 
balancing act by TGF-β in normal vessel homeostasis, and this balance may depend upon 
amount of TGF-β and the other signaling mediators involved [135, 139, 142, 168]. 
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1.2.2.3 Fibroblast growth factor (FGF) 
FGF is a 16-34 kDa polypeptide that is a strong mitogen and morphogen for most cell 
types, including SMCs and ECs, which plays a critical role in developmental processes and in 
tissue growth and remodeling in adults [156, 169, 170].  There are at least 23 members of this 
polypeptide family binding to four receptor isoforms.  Two isoforms, acidic and basic FGF 
(aFGF and bFGF, respectively) play large roles most cellular processes [171, 172]. FGF is 
localized to heparin sulfate proteoglycan molecules on the cellular surface and the ECM, which 
protects it from proteolytic degradation and acts as a co-receptor for FGF receptors [171, 173].  
Although it lacks a secretory peptide for packaging and release outside the cell, FGF is 
predominantly found in the basement membrane of blood vessels where it is released following 
vessel injury [169, 174, 175].  Current theory postulates that the extracellular FGF is derived 
from apoptotic cells, possibly a byproduct of developmental processes of cell regression 
following tissue formation [174]. 
In early development, bFGF plays a role in differentiation and patterning for multiple 
structures, including the induction of the vasculature from the mesoderm [169, 176-178].  
Furthermore, FGF has demonstrated different effects depending upon concentration and 
embryologic timing.  For instance, high concentrations of bFGF are more chemotactic than 
mitogenic, and bFGF can either delay or accelerate myogenesis depending upon cellular state 
and the timing of the stimulation [179, 180].  Additionally, during angiogenesis, bFGF increases 
the secretion of VEGF from SMCs leading to increased vessel sprouting [174].  This model of 
bFGF's role in angiogenesis has been further demonstrated in developing cardiac muscle 
explants where bFGF antibodies inhibited VEGF-dependent vessel sprouting [181]. 
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Postnatally, the effect of bFGF on vascular cells appears to be mainly mitogenic [60].  
bFGF has been shown to play a role in the upregulation of autocrine PDGF-induced mitosis by 
increasing the mRNA and protein production of PDGF-A [182], and PDGFRα without affecting 
PDGFRβ [119].  Without the induction of PDGFRα by bFGF, PDGF-AA is a poor SMC 
mitogen.  This signaling paradigm is supported by in vivo evidence that shows increased 
PDGFRα and PDGF-A levels in injured and atherosclerotic arteries [114, 119, 125], and 
administration of antibodies to bFGF decreases SMC proliferation.  In addition, bFGF plays a 
role in the migration of SMCs after injury by inhibiting collagen I and III production and 
increasing MMP-1 production in vascular SMCs [183]. 
1.2.3 Response to mechanical stimuli 
Vascular cells, both SMCs and ECs, exist in a mechanically dynamic environment (Figure 1.2).  
In the vasculature, these can be broken down into three separate mechanical stimuli – pressure, 
shear, and stretch – that result from the flowing blood in the vessels.  These forces arise from the 
pulsatile flow of blood through the arteries and veins.  Each pulse of blood from the left ventricle 
causes a hydrostatic pressure increase inside the vessel.  This hydrostatic pressure can be though 
of as an outward normal force distributed evenly over the lumen.  The change in pressure over 
the cardiac cycle acts mainly on the ECs lining the vessels, but there is also a transmural pressure 
distribution where it acts on SMCs residing in the medial layers of the vessel.  In addition to 
imparting a normal force on the vessel, the cyclic pressure changes lead to the forward flow of 
blood through the vessel, which results in a drag force, or shear stress, acting along the lumen of 
each vessel.  The magnitude and direction of this shear force is governed by the local geometry, 
pressure, and flow distribution and varies throughout the vasculature.  Because the vessel wall is 
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an elastic material, the cyclic pressure also causes a cyclic change in diameter in arteries.  This 
change in diameter imparts a cyclic circumferential stretch on the SMCs and ECs making up the 
vessel.  The magnitude of stretch imparted by the blood depends heavily on the ECM 
constituents of the blood vessel, mostly collagen I and elastin.  For instance, in the large arteries 
close to the heart, there is high elastin content causing these vessels to experience a greater 
change in diameter.  In the smaller arteries and arterioles, which are responsible for maintaining 
vascular tone, the ECM composition favors collagen I and an increased smooth muscle 
component that makes these vessels less compliant, therefore receiving a lower circumferential 
stretch over the cardiac cycle [184-187].   
 
 
 
Figure 1.2: Mechanical stimulation plays an important role in vascular biology because blood vessels undergo 
multiple types of mechanical stimulation throughout each cardiac cycle. Reprinted with permission from IOS Press 
[188]. 
 
These forces have significant effects on the functionality, proliferation, and protein 
expression of vascular cells.  The alteration of the mechanical environment is thought to play a 
role in development and disease states, such as hypertension where the average magnitude of 
wall stretch can be increased by more than 15% [189, 190].  Many researchers have investigated 
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the effects of mechanical forces on vascular cells, attempting to elucidate mechanisms for the 
maintenance of functionality as well as early signals of pathology (Figure 1.3).  Cells within a 
tissue can sense mechanical stimuli, such as compression, tension and shear stress, through 
various mechanisms including stretch activated ion channels, GTP-coupled proteins, integrins, 
and receptor tyrosine kinases (not shown in the figure). These sensors trigger secondary 
signaling that can include prostacyclin, cAMP, changes in membrane potential, Src, the mitogen 
activated protein kinase (MAPK) cascade, phospholipases, and protein kinase C (PKC). The 
secondary pathways converge upon the nucleus, and depending upon other environmental 
factors, initiate gene transcription leading to alterations in proliferation, survival, and protein 
synthesis. Additionally, the spatial and temporal gradients of the magnitude and frequency for a 
given mechanical stimulus within a tissue can influence the secondary signaling, ultimately 
impacting the final cellular response [191].   The following is a brief discussion of how SMCs 
respond to their mechanical environment, specifically stretch, pressure, and shear.  
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Figure 1.3: Schematic of cellular mechanisms for sensing mechanical signals which are relevant to vascular SMCs 
and ECs.  Figure adapted from [191]. 
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1.2.3.1 Stretch 
The cyclic circumferential stretching that SMCs experience with each cardiac cycle due 
to the elastic properties of the blood vessels typically ranges from 5%-15% depending upon the 
position in the vascular tree and local mechanical properties [192]. The effects of cyclic stretch 
on SMCs have been widely studied as this stimulus is believed to play a major role in SMC 
differentiation and pathology (see Figure 1.1) [127, 130, 167, 193-195]. 
Upon explant, isolation, and in vitro culture in a static environment, SMCs begin to take 
on a synthetic phenotype by downregulating their expression of contractile proteins, such as 
myosin heavy chain (MHC) and calponin, producing more extracellular matrix proteins, and 
proliferating at higher rates than SMCs with a contractile phenotype [189, 196-198]. Cyclic 
stretch has been shown to alter proliferation [116, 117, 127, 131, 199-202], increase the 
production of several biological factors (PDGF-A and -B  [116, 117, 131, 183, 201, 202], IGF 
[203], VEGF [204], TGF-β [167, 205, 206], and FGF[207]), matrix components (collagen I  
[167, 205, 208-210], collagen III [208], collagen IV [206], elastin [211, 212], and fibronectin 
[167]), and contractile proteins (SMA, calponin, caldesmon, SM-1, and SM-2) [130, 189, 213-
215].  
Overall, the response of SMCs to stretch appears to be highly dependent upon several 
factors including extracellular matrix [130, 194, 213, 216, 217], the magnitude and frequency of 
stretch [116, 117, 127, 131, 201, 202, 210], cellular state , and soluble factors [189].  Wilson et 
al. [216] demonstrated that stretch increased DNA synthesis on collagen, fibronectin and 
vitronectin, but not laminin or elastin.  They went on to further demonstrate the response to 
stretch was inhibited by β3 and αvβ5 but not β1 antibodies, thus defining a link between integrins 
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and mechanotransduction and demonstrating the importance of ECM in cellular responses to 
their environment.   
Stretch magnitude and frequency also play important roles in the response of SMCs to 
mechanical stimulation (Figure 1.4)  Stretch frequency has been demonstrated to have an effect 
on ECM production and turnover with physiologic adult (1 Hz) and neonatal (2.65 Hz) 
frequencies both stimulating collagen I and MMP-1 production, but only neonatal frequency 
stimulation increases TIMP-1 [127, 210].  Proliferation increases have consistently been 
demonstrated at lower stretch magnitudes (1-7%).  This process has been shown to be mediated 
by autocrine signaling loops involving angiotensin II, PDGF, and PDGF receptors [116, 131, 
201], which can be auto-phosphorylated directly through integrin-mediated mechanosensing 
[117, 202]. 
Physiologic stretch magnitudes (5-15%) help maintain SMCs in a contractile, quiescent 
phenotype [189], and may also prevent calcification of tissues in vivo [218]. Nikolovski et al. 
[218] demonstrated that without stretch, osteoblast genes including osteopontin, matrix gla 
protein, and alkaline phosphatase are increased as is calcium uptake. Although contractile protein 
expression is consistently increased with physiologic levels of stretch [130, 213, 219], changes in 
proliferation have been reported to vary [127, 199, 200, 202].  The variance in proliferation as a 
result of cyclic stretch is likely due to differences in the starting cell population or ECM and may 
be mediated through a balance between PDGF [130, 220] and TGF-β signaling [127, 167, 221] 
that can result from the application of cyclic stretch. 
 
 23 
  
Figure 1.4:  Various levels of cyclic stretch can induce multiple phenotypic changes in SMCs.  Adapted from [189]. 
 
Supra-physiologic magnitudes (>15%) tend to increase proliferation, apoptosis, matrix 
production, and some contractile protein expression in SMCs, most of which are mediated by 
TGF-β signaling [167, 189, 209, 213, 221].  These higher stretch magnitudes have also been 
shown to cause FGF2 release as a response to vessel damage, which may in turn activate 
proliferative mechanisms (see Section 1.2.2.3) leading to intimal hyperplasia [207, 222].  Indeed, 
there is evidence that these higher stretch magnitudes induce apoptosis in mature SMCs through 
decreases in the pro-survival protein, Bcl-2, and increases in Bcl-2 associated death protein 
(BAD) [223].  This process was demonstrated by Wernig et al. [217] to be mediated through p38 
MAPK pathways and required collagen I matrix, thus demonstrating that the same signaling 
mechanism can lead to very different results depending upon the type of matrix, level of stretch, 
and the state of the SMC. This mixture of contractile and synthetic states produced by higher 
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levels of stretch may reflect local imbalances in TGF-β and PDGF signaling, leading the tissue 
towards a pathologic state [189, 220]. 
While species variability, age of SMC source (adult vs. neonatal), matrix content, 
exogenous signaling, magnitude and frequency of stimulation, and contractile state may account 
for much of the variability seen in SMC response to stretch, there is also an apparent paradox 
resulting from increased ECM production, proliferation, and contractile proteins in some SMCs 
as a result of stretch [189, 220].  One possible reason for this is the hypothesis that growth and 
differentiation may not be mutually exclusive events in adult animals, but rather SMCs are 
capable of returning to developmental processes in order to repair and maintain homeostasis in 
the vessel wall [68, 189].   
1.2.3.2  Pressure 
SMCs also experience cyclic pressure through transmural pressure gradients as a result of 
the pulsatile blood flow.  While most experiments dealing with models of hypertension have 
studied increased stretch as an indirect effect of the increased hydrostatic pressure, little research 
has been conducted on the direct influence of pressure on SMCs.  The overall effects of 
hypertension are reported to be increased cellular and matrix components as well as increased 
matrix remodeling [194, 224]. 
Watase et al. [225] appear to be the first to expose SMCs to direct hydrostatic pressure.  
Using a custom-built apparatus, they exposed aortic SMCs to control, 105mmHg static pressure, 
and 120/90mmHg cyclic pressure at 1Hz.  They found that the increased pressure, whether 
constant or cyclic, increased SMC proliferation beginning at day 5 and increasing through day 9, 
with no effect on cellular viability.  In addition, cyclic pressure altered the morphology of SMCs, 
leading to a more elongated phenotype, characteristic of the contractile phenotype found in vivo.  
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In a related study, Ozaki et al. [226] demonstrated that steady atmospheric pressures above 140 
mmHg stimulated dose-dependent DNA synthesis in SMCs within 3 hours, while lower 
pressures showed no change.  Other research in vivo has demonstrated that the pulse-pressure 
instead of a mean pressure elevation was critical for the initiation of hypertension-mediated 
vessel remodeling [227]. 
Cappadona et al. [228] have shown that increased pressure in a capillary perfusion model 
can increase contractile, but not synthetic, SMC proliferation.  Subsequent research by Birney et 
al. [229] has demonstrated that transmural pressure pulses result in time- and pressure-dependent 
increases in apoptosis as measured by activated caspase-3.  Lower pulse pressures (6mmHg) 
were significantly less apoptotic than higher pulse pressures (>34mmHg).  While EC signaling 
(either pro-survival or pro-apoptotic) was shown to have no influence on SMC apoptosis, the 
pressure-induced apoptosis was dependant on the differentiation status of the SMCs.  More 
differentiated cells were prone to pressure-induced apoptosis while embryonic or immature 
SMCs demonstrated decreased FasL and p53 expression upon exposure to pressure.  The fact 
that the contractile phenotype of SMCs is capable of rapid proliferation and is susceptible to 
apoptosis may be related to insufficient time spent in the G0/G1 cycle resulting in insufficient 
DNA repair [229, 230]. 
1.2.3.3 Shear stress 
While shear stress is predominantly associated with ECs lining the lumen, SMCs can 
exposed to this force through interstitial fluid flow and because of EC denudation following 
vessel injury [231].  SMCs react very differently to shear stress by orienting perpendicular to the 
direction of flow [232, 233], whereas ECs align parallel [233].  Hu et al. [117] have 
demonstrated that 5 dynes/cm2 shear stress increased proliferation, most likely through a direct 
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activation of growth factor receptors by shear stress similar to cyclic stretch (see 1.2.3.1) because 
supernatant from shear stimulated cells failed to increase proliferation.  The increased 
proliferation of SMCs had been previously reported [117, 234, 235] and is a common response 
mechanism to endothelial injury or denudation in vivo [125, 236].  Higher levels of shear stress 
(>10 dynes/cm2) have been shown to initiate SMC contraction [237] as well as inhibit 
proliferation [232, 238, 239] and migration [240].  These responses appear to be in line with 
theories that sub-physiologic and oscillatory shear stresses contribute to atherosclerotic plaque 
formation [241, 242], and are similar to the responses of ECs under shear (see Section 1.3.3.3).  
In a recent study, Wang et al.[243] discovered that a murine SMC cell line (P53LMAC01) 
exposed to 15 dynes/cm2 shear stress induced the mRNA expression of EC markers (CD31, von 
Willebrand factor and VE-cadherin) and proteins while decreasing the expression of SMA, h1-
calponin, and MHC.  While the use of a cell line may not be representative of SMCs in vivo, it 
raises the possibility that SMCs are capable of transdifferentiation into ECs through mechanical 
stimulation; an exciting possibility for regenerative medicine. 
1.3 
1.3.1 
ENDOTHELIAL CELLS 
Development and basic biology 
Epithelial cells are polarized cells that line the cavities of all hollow organs in the body and 
perform many important functions.  Vascular endothelial cells (ECs) are a specialized sub-type 
of epithelial cells that line blood vessels and are responsible for providing a permeability barrier 
between flowing blood and the surrounding tissue as well as the production, secretion and 
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metabolism of bioactive substances, and the maintenance of hemostasis and vascular tone [244].  
Even throughout the vasculature, ECs in different vessels exhibit very different morphologies 
and functions in accordance with their particular role in that environment [245].  During 
development, simultaneous with cardiac formation, the vasculature develops through a process 
known as vasculogenesis.  Vasculogenesis is the de novo development of blood vessels in 
separate parallel structures.  The process begins as small islands of specialized cells, known as 
angioblasts, are derived from the mesoderm.  The development of the circulatory system is 
believed to begin as the embryo’s size begins to limit diffusion, and a new method of 
transporting nutrients and waste throughout the embryo is necessary [246]. These islands form 
throughout the embryo proper, creating the first vessel structures that begin to coalesce, forming 
larger and larger vessel structures.  SMCs are recruited to stabilize these new vessels, and a 
continual process of vessel merging, branching, and apoptosis continues throughout the rest of 
development and adult life in a process known as angiogenesis.  The progression from 
angioblasts to endothelial cell is marked by the expression of several key proteins distinguishing 
ECs and their precursors from surrounding SMCs and other cells that also have functional 
significance [246-249].  What follows here is a brief description of these proteins and their role 
during developmental and post-developmental endothelial biology. 
1.3.1.1  Flk-1 
The first protein to be expressed by differentiating angioblasts during development is the 
vascular endothelial growth factor receptor 2 (VEGFR2), also known as flk-1 [246, 250-252].  
Flk-1 is a 150-230 kDa tyrosine kinase receptor that is one of several VEGF receptors, and is 
crucial for the vasodilation, destabilization of mature vessels, migration, inhibition of apoptosis, 
proliferation, and differentiation response seen in ECs and EC precursors following VEGF 
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stimulation (see Figure 1.5)[246, 253-255].  Flk-1-/- knockout mice are embryonic lethal very 
early in development from a complete lack of vascular and hematopoietic development [251, 
256].  Flk-1 expression is believed to be specific for ECs and EC precursors and persists 
throughout EC maturation as VEGF is an important signaling molecule for angiogenesis and 
normal vascular function [245, 246].  However, there have been reports of flk-1 expression in 
other cell types including neural cells [245, 257-259] and pericytes [260-262].  Flk-1 expression 
in ECs continues, albeit in a downregulated fashion, throughout adulthood in stable, mature 
vessels.  However, flk-1 upregulation is a hallmark of angiogenesis and tumor formation [245, 
263, 264].   
1.3.1.2 Platelet-endothelial cell adhesion molecule (PECAM) 
PECAM (130kDa) is one of several molecules expressed very early in angioblasts 
development [247, 265].  It is present in the yolk sac immediately upon implantation and is also 
found in the developing heart structure as well as intestinal portals [266].  There is some 
evidence that PECAM precedes flk-1, but is later downregulated and then returns following flk-1 
expression [267].  The functional significance of PECAM is that it plays a role in homotypic 
cell-cell adhesions necessary for lumen formation, cell polarity, and vascular permeability [247, 
266, 268].  PECAM expression during development proceeds in thread-like projections down the 
dorsal aorta as ECs are differentiated from their surrounding mesoderm, resembling primitive 
vascular networks [266].  Although PECAM is present in some megakaryocytes and other cells, 
it is still considered an EC-specific molecule as it is expressed in every adult EC [247, 266, 268-
270]. PECAM is required for neutrophil and macrophage movement across ECs, and PECAM 
binding causes integrin clustering on lymphocytes [266, 271, 272]. 
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1.3.1.3 Tie Receptors  
Tie receptors (Tie-1 and Tie-2) are 117-125kDa tyrosine kinase receptors that are 
primarily involved in vessel stabilization and EC survival [245, 249, 273].  Tie receptors have 
extracellular domains with immunoglobulin-, fibronectin, and EGF-like repeating elements.  
They appear very early in vascular development and persist through adult-hood in an EC-specific 
manner [245, 274]. While the ligand for Tie-1 is unknown, angiopoietins have been identified as 
the ligands for Tie-2 receptors.  Ang1 and 3 act as Tie-2 agonists while Ang2 and Ang4 act as 
Tie-2 antagonists.  Ang1 binding to Tie-2 causes autophosphorylation of the receptor leading to 
vessel stabilization through recruitment of pericytes [245, 275, 276].  In fact, overexpression of 
Ang1 in the adult leads to hypervascularization in the form of many small, stable vessels[245, 
277] in an opposing manner to VEGF overexpression, which leads to hypervascularization with 
multiple leaky, immature vessels [245, 278].  
1.3.1.4 Vascular endothelial cadherin (VE-Cadherin) 
VE-cadherin is a 140kDa calcium-dependent intercellular adhesion protein that is specific 
for ECs [279, 280].  Its expression is limited to confluent cultures and is downregulated under 
the influence of vascular permeability enhancing molecules such as tumor necrosis factor-α and 
interferon-γ [247, 280].  VE-cadherin functions to control vascular permeability to neutrophils 
and solutes as well as provide adhesive structure to the blood vessel through homotypic cell-cell 
interactions [280, 281].  During development, VE-cadherin appears in close conjunction with 
flk-1 in angioblasts, specifically in a subset of angioblasts that are flk-1+ and GATA-1- [282-
284].  VE-cadherin has been shown to be exclusively expressed in ECs that have formed the first 
primitive vascular plexus [282, 285].  Indeed, VE-cadherin knockouts fail to form the primary 
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vascular plexus, indicating the importance of this cell-cell binding molecule in the formation of 
vascular structures [286].  VE-cadherin+ cells go on to produce flk-1+, VE-cadherin+, and CD31+ 
ECs in in vitro embryonic stem cell models.  These differentiated ECs are also capable of 
acetylated low density lipoprotein (Ac-LDL) uptake, a hallmark of EC functionality [282, 287, 
288]. 
After the formation of the vascular plexus, VE-cadherin is necessary for the continued 
expansion, maturation, branching, and prevention of vascular regression [254, 279].  VE-
cadherin is also responsible for mediating contact inhibition of EC growth [289, 290].  Mutant 
VE-cadherin mice surviving through the plexus formation demonstrate disintegration of EC cell 
contacts as well as vessel regression, EC apoptosis, and tissue necrosis [254, 279].  The fact that 
VE-cadherin is not necessary for the initial induction of vasculogenesis and early vessel 
formation, but is necessary for subsequent angiogenesis and EC survival implies that VE-
cadherin plays a role in maintaining cell-cell contacts under the mechanical load of more 
developed circulation and helps mediate VEGF-dependent survival signaling [279].   
1.3.1.5 von Willebrand factor (vWF) 
von Willebrand Factor (vWF) is an 250-270 kDa protein that is expressed almost 
exclusively by mature ECs [291].  vWF can be expressed at low levels on megakaryocytes, but 
has traditionally been used as a functional marker of ECs [291-293].  vWF has binding sites for a 
number of haemostatic molecules including Factor VIII and heparin, thus implicating its role in 
thrombosis [291].  It is found in three regions in vivo- free plasma, bound to blood vessel 
basement membranes, or stored within ECs [294].  vWF bound to the basement membrane has 
been shown to assist EC binding in intact and injured vessels where it increases microtubule and 
focal adhesion formation [295, 296].   
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Embryologically, vWF appears only after large vessel formation has occurred and 
precedes the onset of blood flow. In fact, vWF does not co-localize with other proteins that are 
expressed during the angioblast stage of vascular development.  The expression of vWF is 
spatially and temporally restricted to a subset of ECs in large vessels, specifically those cells 
destined to form the dorsal aorta and its major branches, but the reasons for this are as yet 
unknown [292].  This continues in the adult where the total expression of vWF varies depending 
upon the tissue bed [292, 297, 298].  vWF expression in adults in vivo is controlled by a variety 
of stimuli including inflammatory cytokines, hypoxia, thrombin, compliment, and histamines 
[291, 292, 294].    
1.3.2 Response to biological factors 
Like SMCs, ECs have a long history of research with biological stimulation.  ECs 
respond to various growth factors and cytokines during development and adult life that are 
directly related to their ability to participate in vasculogenesis and angiogenesis.  In addition to 
growth factors, ECs produce and respond to a variety of other biological chemicals including 
nitric oxide, carbon monoxide, and prostaglandins [299].  Although these factors are important in 
their own right for their roles in EC biology, their discussion will be limited to within the context 
of the major growth factors including VEGF, FGF, PDGF, and TGF-β  [256]. 
1.3.2.1 Vascular endothelial growth factor (VEGF) 
VEGF is among the most important growth factors in the study of EC biology and 
pathology throughout the lifespan of the organism.  The activity of VEGF in vascular ECs is 
mediated primarily through VEGF receptor 2 (VEGFR2 / flk-1), whereas VEGF receptor 1 
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(VEGFR1 / Flt-1) is believed to be an agonist for VEGF-mediated cell behavior [245, 300] 
(Figure 1.5)   
VEGF is of critical importance to vascular formation as evidenced in the early embryonic 
lethality of VEGF and flk-1 knockouts due lack of vasculogenesis and complete vascular 
disorganization [251, 253].  Although VEGF is not responsible for the initial differentiation of 
angioblasts from the mesoderm during development [301, 302], it is required for differentiation 
into the mature EC phenotype [301, 303] as well as EC survival through expression of the anti-
apoptotic protein Bcl-2 [300, 304].  In addition, VEGF induces dose-dependent increases in 
nitric oxide (NO) and prostacyclin (PGI2), both powerful vasodilators [289, 305, 306].  VEGF 
production is regulated by several factors including hypoxia [264, 307] and mechanical 
stimulation [204, 308]. 
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Figure 1.5: VEGF signaling in ECs is mediated through two VEGF receptors to increase survival, proliferation, 
migration, and production of vasoactive agents including NO and PGI2.  Figure reproduced with permission from 
[253]. 
Throughout vasculogenesis and angiogenesis, VEGF is responsible for EC cell junction 
disassembly, proliferation, sprouting, migration, and tube formation [253, 279, 287, 289, 309, 
310].  Cell junction disassembly allows for the extravasation of plasma into the surrounding 
tissue, providing a fibronectin substrate for EC migration [309].  Indeed, fibronectin has been 
shown to increase EC proliferation and migration in vitro and in vivo [311-313].  Sprouting and 
migration are also mediated through VEGF-induced increases in MMP, tissue-type and 
urokinase-type plasminogen activators (tPA and uPA, respectively) and decreases in TIMP 
production in ECs [309, 314-317].   
1.3.2.2 TGF-β 
TGF-β signaling in ECs is important for vasculogenesis and angiogenesis.  In addition to 
the standard TGF-β receptors (Type I and Type II) found on other cell types, ECs also have a 
Type III receptor (endoglin).  This receptor is believed to be an agonist for TGF-β signaling 
[245, 318, 319].  Targeted mutations of TGF-β and its various receptors display major, but subtly 
different vascular malformations, underlining the importance of TGF-β and its downstream 
signaling targets to vasculogenesis and angiogenesis [145, 245, 320-323].  The small differences 
in mutant phenotype have led to the hypothesis that there are two distinct signaling mechanisms 
that result from activation of different TGF-β receptor groups, and that these somehow balance 
TGF-β signaling in ECs [324] (Figure 1.6).  Overall, TGF-β appears to be responsible for EC 
differentiation [323] and vessel stabilization [145, 321, 322] as well as capillary fusion and 
vessel remodeling [324]. 
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Figure 1.6: TGF-β signaling in ECs can elicit two different responses depending upon the type of receptor the 
ligands bind.  This may account for the multiple phenotypes seen with embryonic TGF-β knockouts [325] as well as 
reports of transdifferentiation to SMCs [77, 78, 326]...   
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Like the genetic studies, the response of adult ECs to TGF-β has proven difficult to 
unravel because of the opposing results demonstrated in the literature.  In general TGF-β tends to 
slow angiogenesis by reducing proliferation [323, 327, 328] and migration [329, 330] and 
increasing matrix production [245], TIMPs, and plasminogen activator inhibitors (PAIs) [245].  
However, there appear to be specific conditions that cause the opposite effect, such as increasing 
vascular permeability [331] and proliferation [139],  thus implying TGF-β has a biphasic 
response that may be dependant on TGF-β concentration and competing intracellular signaling 
cascades [139, 245, 332].  This concept is illustrated in studies from Li et al. [333] and Schwarte-
Waldhoff et al. [334] where they found that TGF-β inhibited angiogenesis early during stages of 
oncogenesis, but promoted angiogenesis in later stages [245].   
In addition to effects on vascular formation and angiogenesis, TGF-β may play a role in 
epithelial-mesenchymal transformations [77, 85].  Although this process is relatively restricted to 
embryonic processes (specifically heart formation) [335], Arciniegas et al. [77] have 
demonstrated that aortic ECs exposed to TGF-β can downregulate their expression of vWF and 
begin to express the SMC-like protein SMA and appear to be most similar to contractile SMCs 
by their ultrastructure [336].  This process was partially reversible, with vWF returning in some 
cells within 5 days of TGF-β removal and may have implications in atherosclerosis where 
injured vessels release large amounts of TGF-β, potentially converting ECs to contractile SMCs 
during plaque formation [77, 180, 337, 338].   
1.3.2.3 FGF 
FGF is necessary for the induction of angioblasts from the mesoderm both in vitro and in 
vivo [247, 301, 339].  Mutations in FGF or its receptors lead to embryonic death prior to 
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gastrulation [339-341].  The role of FGF in vascular development is mainly an inductor of the 
angioblast into an flk-1+ cell, with flk-1 becoming maximally expressed within 24h of FGF 
stimulation [247, 342].  However, following angioblast induction, embryonic ECs do not contain 
detectable levels of FGF receptor mRNA, suggesting that they are not utilizing FGF signaling for 
the remainder of vascular morphogenesis [247, 343, 344].   
In adult ECs, the FGF receptor expression returns, suggesting its importance for repair 
and regeneration [247, 344, 345].  FGF has been shown to be an important inductor of 
angiogenesis [175, 289, 346] and is found in the ECM, although FGF has no known mechanisms 
for extracellular export (see Section 1.2.2.3) [175, 340].  FGF induces EC proliferation [347], 
survival [348], migration [349], and matrix degrading proteins including MMPs and 
plasminogen activators [346, 350].  The effect of FGF on ECs is also dependant upon their ECM.  
Kanda et al. [348] have demonstrated that ECs exposed to FGF on fibronectin proliferate and 
spread, but do not differentiate (form tubes).  Conversely, on collagen ECs do not proliferate or 
spread, but instead immediately differentiate and form capillary tubes.  This result further 
implies an interaction between growth factor receptors and integrin-mediated signaling that plays 
such a crucial role in vascular biology [351-353]. 
1.3.2.4 PDGF 
Although PDGF has been demonstrated to promote angiogenesis, early studies could not 
delineate whether its effects were directly related to ECs or indirect through SMCs and pericytes 
[247, 354, 355].  While the expression of PDGF receptors are well documented on SMCs and 
pericytes (see Section 1.2.2.1), only microvascular ECs appear to express the PDGF receptors, 
specifically PDGFRβ (see Table 1.2) and are capable of proliferation and angiogenic sprouting 
in response to PDGF [289, 355, 356].  Battegay et al. [355] have demonstrated the expression of 
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PDGFRβ is restricted to microvascular ECs undergoing angiogenesis, specifically those ECs 
within chords and sprouts, and this expression increases over time as chord formation continues.  
They further demonstrated that PDGF-BB was released from the non-angiogenic ECs that did 
not express PDGFRβ, and that the growth factor release increased the proliferation of angiogenic 
ECs.  However, PDGF-BB was not sufficient to drive sprouting, suggesting that the other factors 
such as FGF and/or VEGF are the major players in EC growth and differentiation [355, 357]. 
1.3.3 Response to mechanical stimuli 
ECs throughout the vasculature experience various degrees of all three mechanical 
stimuli (see Figure 1.2).   The magnitude of each stimulus (pressure, stretch, and shear) that ECs 
experience depends upon their position in the vasculature.  ECs in the major vessels (aorta and 
first major branches), which have more elastic content and larger diameters, experience higher 
stretch magnitudes and lower shear magnitudes.  In more muscular arteries, shear magnitudes 
increase and stretch magnitudes decrease as the caliber and composition have changed.  In the 
venous system, the magnitudes of pressure, stretch, and shear are greatly diminished [185-188, 
358, 359].  Of the possible mechanical stimuli, the effects of shear stress on ECs have received 
the most attention because of the established role of shear stress in atherosclerosis [188, 193, 
358, 360, 361].  The following is a brief discussion of how ECs respond to their mechanical 
environment, specifically stretch, pressure, and shear. 
1.3.3.1 Stretch 
The effects of cyclic stretch on ECs have shown many different effects depending upon 
the magnitude of stretch as well as the species and tissue bed origin of the ECs.  Iba et al.[359] 
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demonstrated that ECs from the aorta, pulmonary artery, and vena cava display different 
proliferation, alignment, and prostaglandin production when exposed to stretch.  Only the vena 
cava ECs oriented perpendicular to the direction of stretch, while only the aortic ECs increase 
proliferation and prostaglandin production. 
Another series of studies have demonstrated that stretch causes oxidative stress (as 
measured by superoxide release) and associated responses by arterial ECs [362-364].  These 
responses to oxidative stress include increases in endothelial nitric oxide synthase (eNOS), 
which releases NO to scavenge superoxides)[364-366], monocyte chemotactic protein (MCP-
1)[367], interleukin-6 (IL-6)[368], endothelin-1 (ET-1)[369-371], intercellular adhesion 
molecule (ICAM-1)[372, 373], and tissue plasminogen activator inhibitor (PAI-1)[372].  Some 
of these responses, such as NOS production, are highly dependent on the magnitude of stretch 
[366].  Concomitant with the increase in ICAM-1, Barron et al.[373] demonstrated a decrease in 
vascular cell adhesion molecule-1 (VCAM-1), indicating that ECs exposed to stretch might 
increase their permeability which is another response to oxidative stress [374].  MCP-1, IL-1 and 
ICAM-1 have been identified as participants in the development of atherosclerosis [375].  
However, in another study, Iba et al.[376] found that saphenous vein ECs increase expression of 
tissue plasminogen activator (tPA), but not PAI-1, upon exposure to 24% cyclic stretch, again 
demonstrating the importance of tissue source on the response of ECs to mechanical stimulation.   
Other studies have demonstrated that cyclic stretch has an important effect on the way 
that ECs function.  Matsumoto et al.[377] have demonstrated that cyclic stretch increases EC 
proliferation in 2D and 3Dculture.  Stretch also inhibited EC sprouting in 3D culture leading to 
fewer, but larger caliber capillaries.  The increase in EC proliferation as a response to stretch has 
been reported in ECs from other tissue sources as well [366, 378].  The increased proliferation 
 40 
may be resulting from changes in cell-cell contacts, which are controlled by the intercellular 
adhesion protein VE-cadherin [289, 290, 377].  Thus, vessels that are experiencing stretch may 
have a tendency to enlarge in an attempt to improve compliance or reduce stress.  This is borne 
out in other studies that demonstrate that cyclic stretch is necessary for the sustained release of 
vasodilating agents such as NO and PGI2 [365, 366, 379].  Cyclic stretch also increases Ang-2 
and Tie-2 receptors, which are important for maintaining vessel stability and are angiogenesis 
inhibitors [380], and promotes EC survival by phosphorylation of the anti-apoptotic protein Bad 
[381].  These studies all point to the importance of cyclic stretch in maintaining ECs in a normal 
functional state and leading to the prevention of atherosclerosis [381]. 
Cyclic stretch can also have other effects on ECs, including a possible phenotypic switch 
towards an SMC phenotype.  Cevallos et al. [83] have shown that 10% cyclic stretch causes 
umbilical vein ECs to express SMA and SM22α, two molecules typically restricted to SMCs.  
These results are similar to the epithelial-mesenchymal transitions in ECs resulting from TGF-β 
stimulation (see Section 1.3.2.2) [77, 85].  However, the expression of these two markers is not 
sufficient to claim a complete SMC phenotype and further work is necessary to verify the 
resultant phenotype. 
1.3.3.2 Pressure 
ECs in the lumen of a blood vessel are exposed to the cyclic pressure wave that 
propagates down the length of the vessel during fluid flow.  Although studies have demonstrated 
the importance of pressure to vascular health [115, 224, 382, 383], pressure is the least-studied 
physical stimulus on vascular cells in vitro.   
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Tokunaga et al. [384, 385] were among the first to examine the differential effects of 
pressure on both aortic ECs (AECs) and umbilical vein ECs (UVECs).  They reported an 
increase in UVEC proliferation between 0 and 80 mmHg with an inverse relationship to PGI2 
release.  Pressure between 80 and 160 mmHg caused AEC damage with continual increases in 
PGI2 release.  These studies were followed by others that showed similar trends in proliferation 
[384-390]  and PGI2 [391] release that also varied depending upon where in the vasculature the 
ECs were derived.   Additionally, these studies have identified other molecules, including 
MMP-1 [387], ET-1 [392], NO [392], and ZO-1 [393], are regulated by pressure in a manner 
consistent with the hypothesis that higher pressures may be damaging to ECs and lead towards 
atherosclerotic processes.  Although ZO-1 is regulated by pressure to increase EC permeability, 
VE-cadherin does not appear to be affected by pressure [393].   
The proliferation changes in ECs in response to pressure may be mediated through 
changes in growth factor release that include VEGF [394] and bFGF [395] but not TGF-β [388].  
Ohashi et al. [396] have recently shown that increased proliferation from pressure (up to 150 
mmHg) resulted from a decreased in VE-cadherin leading to a loss of contact inhibition.  The 
decreases in proliferation reported at higher pressures [384-390] may be a result of apoptosis 
[390].  Hasel et al. [390] have reported that pressures outside of physiologic ranges 
(200/100mmHg) initially induce apoptosis through Fas and FasL interactions within 24 hours.  
However, the ECs seem to recover after 48 hours, and this phenomenon appeared to be 
independent of the EC cell source (UVEC and AEC).  This paradoxical relationship may be 
related to the potential dual role of Fas, which can increase proliferative and pro-survival 
paracrine signaling [397].   
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1.3.3.3 Shear 
Shear stresses are arguably the most important mechanical stimuli for ECs.  During 
development, the induction of blood flow is critically important to the continued development of 
the vasculature [247].  Only after connection of the vascular plexus to the vitelline arteries and 
veins does the enlargement of the major vessels occur.  Without this connection, the vasculature 
completely regresses [247, 398].  In several elegant studies on cardiovascular development, 
Hogers at al. [399-401] have demonstrated that altering vitelline blood flow leads to heart and 
major vessel malformations in chick embryos.  In adult physiology, it is well documented that 
systemic vascular diseases such as atherosclerosis have lesion formation in geometrically distinct 
points, namely at branches and bifurcations in the arterial tree [358, 360].  The shear stresses 
along the straight portions of vessels can be considered laminar, while branching points, 
bifurcations, and stenotic areas have complex fluid profiles that typically involve recirculation 
and turbulent profiles [402].  These features are evident in EC morphology, which is ellipsoid 
and aligned with the flow in the straight portions of arteries, and more polygonal and randomly 
oriented near bifurcations [402, 403].  Studies on shear stress are numerous and varied, 
depending upon the types of shear stress studied (laminar, oscillatory, turbulent, and complex 
flow patterns) as well as magnitude, temporal effects, and EC cell source.   
Although the data presented in Table 1.3 comes from a variety of different EC sources, 
shear regimes and shear apparatuses, several trends begin to appear depending upon the type of 
shear stress, i.e., laminar vs. disturbed (which includes turbulent, impulse, step, and oscillatory).  
Laminar shear stress has consistently demonstrated decreases in EC proliferation [402, 404-406] 
and increases survival (Tie-2) as well as angiogenic (flk-1 and MMP-1) gene expression [244, 
407].  Another common response by ECs to laminar shear stress is that several genes tend to be 
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initially upregulated (0-12 hours) followed by downregulation (12+ hours) to baseline or lower 
levels [402].  These genes include PDGF [408, 409], bFGF [410], tPA [411], MCP-1 [412],and 
ICAM-1 [413, 414].  This appears to be an adaptive process for ECs since their initial state in 
culture is without shear stress [360] (see Figure 1.7).  Vasodilators (NOS, NO), SMC 
proliferation inhibitors (TGF-β), anti-oxidants (heme oxygenase, cyclooxensase-2, cytochrome 
1B1 and 1A1) and anti-thrombogenic factors (thrombomodulin, TFPI) seem to have sustained 
expression while vasoconstrictors (ET-1), pro-coagulation proteins (PAR-1 and vWF), and 
inflammatory proteins (MCP-1, ICAM-1, VCAM-1) display a sustained decrease.  Those factors 
that are initially increased, then decreased may be under the control of immediate early genes 
(ERK, JNK), which can be activated within a few minutes and peak by one hour followed by 
downregulation [415, 416].  In fact, shear stress response elements (SSREs) have been identified 
as an intermediary between these early genes and other genes such as PDGF [402, 417, 418].  In 
contrast to these early responders, the vasoactive, anti-thrombogenic, and anti-oxidant factors 
remain at elevated levels with sustained shear stress.  Therefore, it would seem that immediate 
early genes are needed for a short-term response to injury while the vasoactive, anti-
thrombogenic genes are maintained for hemostasis [363, 419].   
Low magnitude, oscillatory, impulse, and turbulent shear stress profiles favor higher EC 
proliferation [402, 406, 420, 421] as well as increased levels of adhesive, chemotactic, and 
growth factors [184, 420].  Decreased shear stress induced by coronary ligation has shown 
increased uptake of low density lipoprotein (LDL) and monocyte adhesion through increases in 
VCAM-1 [360, 422] as well as increased apoptosis [423-425].  This apoptotic response to low 
magnitude and oscillatory shear stress is in contrast to anti-apoptotic responses of ECs to higher 
magnitude laminar shear stresses [426-428].  Vasoactive factors, such as eNOS, while increased 
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under laminar flow, are held constant or decreased in turbulent flow [429], and oscillatory flow 
has been shown to increase oxidative-stress in ECs leading to increases in VCAM expression 
[430-432].  In experiments involving disturbed non-laminar shear stress, EC response has shown 
to be heterogeneous depending upon what region of flow they fall in, such as increased 
proliferation, migration, and apoptosis at the flow-reattachment site [425, 433].  This may 
indicate an activated EC state that is more susceptible to other stimuli (such as oxidative stress) 
and can lead to further progression towards atherosclerosis (see Figure 1.7).  This hypothesis is 
validated studies where VCAM-1 expression is increased by lipopolysaccharide (LPS) 
stimulation only in regions of the aorta predisposed to atherosclerosis [427, 428].  ECs at the 
reattachment point of disturbed flow also express increased levels of VCAM-1 [360] as well as 
repression of cell cycle inhibitors and survival genes [434].  Computational modeling has shown 
that increased cardiac output shifts these disturbed regions to different parts of the vessel, thus 
not allowing a single position to be constantly exposed to this fluid profile and potentially 
inhibiting atherosclerosis development in that region [358, 435]. 
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Table 1.3: The effects of shear stress on EC gene and protein expression.  Solid arrows indicate up (↑), down (↓), or 
no change (→) in gene or protein expression of each factor.   Double arrows indicate the sustainability of the signal 
as up ( ), down ( ), or returning to baseline (⇑ ⇓ ⇔ ).  The type and magnitude (in parenthesis) of each shear stress is 
indicated in the magnitude column.  L=laminar; T=turbulent; I=impulse;O=oscillatory; P=pulsatile.  Table adapted 
from [244]. 
 
Factor Change Shear Stress Magnitude (dynes/cm2) Reference 
Vasoactivity    
↑ L(6-25), P(8-12) [436-438] eNOS 
→ T(8) [429] 
 ⇑
↓ L(8-25), P(12-18), T(15) [439-443] ET-1 
↑ L(1.8-5) [444] 
 ⇓
PGI2 ↑ L(10), P(8-12) [445-447] 
Growth 
⇔⇔
   
↑ L(6-51), S(16), I (16) [408, 409, 416, 420] PDGF-A 
→ L(15-36),P(15),T(15) [410, 420] 
⇔
↑ L(3-51) [448-450] PDGF-B 
↑ L(15-36), P(15), T(15) [410] 
⇔
↑ L(15-36), P(15), T(15) [410] bFGF 
→ L(25) [411] 
↑ L(5-40) [451, 452] 
TGF-β → L(<5) [451] 
↑ T(1.5-15), I(16), [404, 406, 420, 421] 
Proliferation 
→ L(1-30) [405, 406] 
Adhesion 
 ⇓⇔
 ⇑
 ⇑
   
ICAM-1 ↑ L(2.5-46), T(10) [413, 414, 422, 453] 
→ L(2.5-46) [414, 422] VCAM-1 
↓ L(<7.2) [422, 431] 
↑ L(16) [412, 454] MCP-1 
↑ I(16), S(16) [420] 
↓ L(12) [455] PECAM 
↑ L(14) [456] 
VE-Cadherin ↑ L(12-15) [455, 457, 458] 
Coagulation 
⇔
 ⇓
 ⇓
 ⇑
   
TF ↑ L(12) [459] 
tPA ↑ L(15-25) [411, 455] 
↑ L(15-36), P(12-18), T(15) [460, 461] Thrombomodulin 
→ L(4) [460] 
TFPI ↑ L(0.27-19) [462] 
vWF ↓ L(12) [455] 
Anti-oxidant 
 ⇑
⇔
⇔
 ⇑
   
↑ L(1-30) [419, 463] COX-2 
→ T(10) [419] 
↑ L(5) [432] HO-1 
↑ O(5) [432] 
↑ L(0.6-15) [419, 432, 464] SOD 
→ T(10) [419] 
Cytochrome 1A1/1B1 ↑ L(25) [443] 
 ⇑
⇔
 ⇑
 ⇑
 ⇑
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Figure 1.7:  The effects of shear stress on ECs depend upon the temporal exposure and type of shear stress.  Chronic 
exposure to laminar shear is atheroprotective while both acute and chronic exposure to disturbed shear stress leads to 
atherogenesis.  Acute changes in the laminar shear region lead to adaptive changes such as vascular remodeling and 
arteriogenesis.  Reprinted with permission from Elsevier [360].  
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1.4 
1.4.1 
ADULT STEM CELLS 
Definition of stem cells 
The notion that primitive stem cells exist in adult humans was first suggested in 1867 by 
Cohnheim [465]. Further work pioneered by Friedenstein [466-469] and Dexter [470-472] 
confirmed the presence of hematopoietic and mesenchymal stem cells in the bone marrow. Since 
then, adult stem cells have also been isolated from striated muscle [57, 473, 474], peripheral 
blood [475-479], umbilical cord blood [480, 481], adipose [482-485], placenta [486, 487], and 
the neuronal system [488, 489].  More recently, the embryonic aortic wall was reported to 
contain mesangial-like stem cells that also share common traits with the skeletal muscle derived 
stem cell {Tavian, 2005 #3890}.  Because of this diversity in stem cell sources, future discussion 
will be limited to stem cells derived from the bone marrow with limited reference to cells from 
other sources (including embryonic) where the experimental data for bone marrow-derived stem 
cells is lacking. 
Bone marrow-derived hematopoietic stem cells are the best-characterized stem cells due 
to the focus on treating bone marrow-associated diseases.  Research in recent years has been 
devoted to purification of the bone marrow to find multipotent stem cells, particularly the bone 
marrow derived mesenchymal stem cells (BMMSCs), which could be used for other medical 
applications.  Bone marrow has been sorted based upon density and the expression of many 
different cluster designation markers and membrane receptors [57]. The main division for bone 
marrow has been along the marker for CD34, with CD34+ cells being considered the 
hematopoietic stem cells (HSCs) and the CD34- being considered mesenchymal stem cells [57].  
However, separation into the hematopoietic and mesenchymal cell types may not restrict the 
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progenitor cells to certain germ lines.  For example, research has shown that CD34+ HSCs can 
generate cardiomyocytes [490].  BMMSCs have traditionally been identified as being positive 
for SH3 (CD71), SH2 (CD105/endoglin), activated leukocyte adhesion molecule 
(ALCAM/CD166), phagocytic glycoprotein I (CD44), Thy1 (CD90), integrin β1 (CD29), 
STRO-1, and HOP26 (CD63) and negative for CD14, CD34, and leukocyte common antigen 
(LCA/CD45) [56, 491, 492].  BMMSCs have also been shown to express CD59, CD117, and 
CD90, and have been sorted accordingly using fluorescent activated cell sorting [493-498].  A 
newer marker, CD133 (a.k.a. AC133), has also been used as an indicator for endothelial 
progenitor cells [499-501]. 
1.4.2 Differentiation of BMMSCs 
As detailed in Sections 1.2.2-1.2.3 and 1.3.2-1.3.3, it is well established that SMCs and ECs, and 
indeed many other cell types, are sensitive to biomechanical and/or biochemical stimulation 
[214, 215, 219, 502-508], and data is continuously emerging to suggest that BMMSCs are no 
different.  Primary cultures of BMMSCs have consistently demonstrated multiple differentiation 
capacities [56, 58, 477, 509-513]. Specifically, in vitro biochemical and biomechanical 
conditions have been identified which stimulate the differentiation of these stem cells towards 
adipocytes [56, 514], osteoblasts [56, 466, 514, 515], stroma [516, 517], chondrocytes [56, 518, 
519], cardiomyocytes,[520-525], SMCs [42, 526-531], and ECs [49, 499, 501, 520, 532-534].  
The various chemical and mechanical stimuli that drive BMMSC differentiation will be further 
discussed in the proceeding sections.   
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1.4.2.1 Biological and biochemical factors 
As knowledge has increased about growth factors, cytokines and other bioactive 
molecules that induce cell phenotypic changes in vivo, conditions have been identified which 
may guide the in vitro differentiation of BMMSCs to specified cell lineages (see Table 1.4).  For 
example, researchers have defined conditions which lead to the derivation of osteoblasts using 
ascorbic acid, dexamethasone and β-glycerophosphate [56]; to chondrocytes using transforming 
growth factor-β (TGF-β) and pellet culture [56]; to adipocytes using isobutyl methylxanthine, 
dexamethasone and insulin [56]; to neural cells using basic fibroblastic growth factor (bFGF) 
[535] or epidermal growth factor (EGF) [536]; and to cardiac cells using 5-azacytidine [523, 525, 
537] or insulin, dexamethasone, and ascorbic acid [524].  It is important to note that several 
common chemicals, such as dexamethasone, insulin, and ascorbic acid have been utilized to 
produce varying differentiation patterns [524, 529, 538-540]. 
Extensive research also has been performed on the differentiation of BMMSCs towards 
ECs using various combinations of vascular endothelial growth factor (VEGF) alone or in 
conjunction with insulin-like growth factor (IGF), stem cell growth factor (SCF), or bFGF [501, 
541-543]. Although many researchers have utilized different growth factor cocktails, VEGF is 
the common biochemical addition for the differentiation of stem cells towards ECs [54, 493, 501, 
542, 544, 545], and it is also known that BMMSCs express the VEGF receptor, flk-1 [493, 546-
549]. VEGF is also known to be a potent inducer of mature EC functions such as nitric oxide and 
prostaglandin production [306, 550]. Work performed by Kim et al. [551] has shown that 
differentiation to ECs is possible with other chemicals such as β-mercaptoethanol and 
dexamethasone when BMMSCs are cultured in Iscove’s modified Eagle’s medium.   
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Previous research has also focused on utilizing BMMSCs as a source of SMCs. 
Observations by Charbord et al. [552] indicate that long-term culture of bone marrow results in 
cells whose cytoskeleton resembles that of SMCs. Furthermore, Arakawa et al. [529] have 
demonstrated that a clonal cell line mouse BMMSCs can be induced to express h1-caldemson, 
calponin, and myosin heavy chain (all of which are markers for SMCs; recall Section 1.2), in the 
presence of β-mercaptoethanol and ascorbic acid.  Other research has shown the importance of 
several cytokines such as PDGF-BB [42, 120], bFGF [553], TGF-β [42, 554], and retinoic acid 
[555] in the formation of SMCs from BMMSCs. One interesting finding related to competing 
signals has shown that TGF-β appears to cause an increase of BMMSC proliferation by 
synergizing with effects of PDGF [42].   
 
Table 1.4:  Differentiation of BMMSCs can be induced by a variety of biological and biochemical agents. 
 
Phenotype Biological and Biochemical Factors Reference 
Adipocytes Insulin, isobutyl-methylxanthine, indomethacin, dexamethasone [56] 
Osteoblasts Ascorbic acid, dexamethasone, β-glycerophosphate [56] 
Chondrocytes TGF-β, pellet culture [56, 556] 
bFGF [535] Neurocytes EGF [536] 
5-azacytidine [523, 525] Cardiomyocytes Insulin, dexamethasone, and ascorbic acid [524] 
PDGF-BB [42, 120] 
TGF-β [42, 554] 
bFGF [553] SMCs 
Retinoic acid [555] 
VEGF [54, 493, 501, 533, 544, 545] 
VEGF, IGF, bFGF [542] ECs 
VEGF, SCF [501] 
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1.4.2.2 Mechanical stimulation 
Although the effects of mechanical stimuli on fully differentiated SMCs and ECs has 
been extensively studied and demonstrated to be important for the normal physiologic function 
of these cells (recall Sections 1.2.3 and 1.3.3), the use of physiologically-relevant biomechanical 
stimuli have only recently begun to be employed, not only for BMMSC differentiation, but other 
stem cell sources as well.. Therefore, the powerful potential of biomechanical forces on their 
own, or in combination with biological factors, has not been fully elucidated and has gone 
underutilized in the field of vascular regenerative medicine. There have been few reports 
evaluating the effect of biomechanical forces on BMMSC differentiation which are outlined 
here.   
1.4.2.2.1 Stretch 
Our lab [526] was among the first to demonstrate that cyclic uniaxial stretch was 
sufficient to promote SMC protein production in BMMSCs (Figure 1.8) while inhibiting 
division. These results were confirmed in a three dimensional model showing that BMMSCs to 
produce SMC-specific proteins under static tension or cyclic stretch, and decreased proliferation 
(as measured by MTT) under cyclic stretch [557].  These results may be related to the redirection 
of the cells towards differentiation instead of proliferation, a concept that has previously been 
proposed for differentiated SMCs [336].  Park et al. [527] further showed that uniaxial stretch, 
but not equiaxial stretch, is necessary for the increase in SMC gene transcription and protein 
production.  Their results, however, depicted a transient increase in SMC gene expression as the 
BMMSCs oriented perpendicular to the direction of strain.  In a follow-up study, Kurpinski et al. 
[558] showed that by forcing the alignment of the BMMSCs in the direction of stretch, they 
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could achieve a stronger increase in the expression of SMC markers as well as increase 
proliferation. Song et al. [559] have also reported increased proliferation under uniaxial stretch.   
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Figure 1.8: The application of cyclic uniaxial stretch to BMMSCs leads to the production of smooth muscle 
proteins (A) SMA and (B) h1-calponin.  Control cultures (C-D) were negative for (C) SMA and (D) h1-calponin.  
Figure adapted from [526]. 
 
There have also been several studies investigating the influence of stretch on BMMSC 
differentiation to other cell types [507, 560-565]. Altman et al. [507] demonstrated that 
appropriately applied mechanical forces (stretch and torsion), without biochemical stimulation, 
induced BMMSC differentiation to a ligament cell lineage.  The results of this study, particularly 
the increase in ECM production as a result of cyclic stretch, are consistent with others [561, 566] 
that have shown BMMSCs exposed to cyclic stretch increased collagen I and III synthesis in 
similar manner to valve interstitial cells.   
Thomas and El-Haj [560] determined the dose-response of a cyclic stretch applied to 
10-day-old cultures in osteo-inductive culture medium, with an emphasis in understanding 
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osteoblast differentiation. They demonstrated that increasing stretch magnitude resulted in 
elevated alkaline phosphatase levels, characteristic of early osteoblast differentiation.  Similarly, 
BMMSCs treated with osteo-inductive media and exposed to intermittent (30 minutes-2 hours 
per day) cyclic stretching at both 1 Hz and 0.5 Hz have demonstrated osteoblast differentiation 
through increases in alkaline phosphatase, Runx2, and osteocalcin, collagen I, and collagen III 
production [562-565].  In the short-term, this intermittent cyclic stretching with media containing 
dexamethasone was found to be more osteo-inductive than dexamethasone alone [564].  In 
addition to the rise in osteoblast proteins expression, adipogenic proteins such as PPAR-γ were 
decreased by intermittent stretch, leading to the conclusion that cyclic stretching modulates 
adipogenesis in favor of osteoblastogenesis [562]. 
1.4.2.2.2 Shear  
Although shear stress is another important biomechanical force in the cardiovascular 
system (see Sections 1.2.3.3 and 1.3.3.3), there have only been a few reports on the effects of 
shear stress on BMMSC as well as embryonic stem cell (ESC) differentiation. Kobayashi et al. 
[530] determined that pressure-dominated shear stress (120/60 mmHg, 1 dyne/cm2) as well as 
combined pressure and pulsatile shear forces (120/60 mmHg, 7-14 dyne/scm2, 90o phase shifted) 
were responsible for increasing SM-MHC (SM-1 isoform) and SMA protein expression in 
BMMSCs.  This was the first study suggesting that BMMSCs are capable of moving towards 
SMC lineages as a result of fluid flow. Yamamoto et al. [567] and Wang et al. [568] each 
demonstrated that flk-1+ ESCs exposed to physiologic levels of shear stress` will express the EC 
proteins CD31, flk-1, flt-1, vWF, and VE-cadherin at both the protein and mRNA levels. Huang 
et al. [569] took this a step further by demonstrating both EC and SMC organization and 
differentiation as a result of pulsatile flow through a compliant tube seeded with ESCs.  
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In addition to cardiovascular differentiation, other studies involving shear stress and stem 
cells have focused on osteoblast differentiation.  Oscillatory fluid shear stress was found to 
increase the expression of bone-related genes such as osteopontin and osteocalcin as well as 
increase proliferation when applied to BMMSCs grown in osteo-inductive culture medium [570].  
Similar effects have been demonstrated using steady shear stress, but without any increases in 
proliferation as reported in the oscillatory shear study [571-573].  It is important to note that the 
shear stresses employed in musculoskeletal studies are on the order of about 2 dynes/cm2, which 
is much lower than the shear stresses employed in cardiovascular studies.  Also, the 
differentiation of osteo-progenitors appears to be strongly dependant upon the timing of the shear 
stress application following osteo-induction and is related to PGI2 and prostaglandin production 
[572].   
1.4.2.2.3 Pressure 
As for adult SMCs and ECs, pressure has also been an under-studied stimulus for stem 
cells.  Although Kobayashi et al. [530] reported a pressure dominated vascular differentiation 
response by BMMSCs, their study was not able to decouple the effects of pressure from shear 
stress (see Section 1.4.2.2.2).  This has been the only study to date that examined the relationship 
of pressure to cardiovascular cell differentiation in stem cells.  The majority of studies on the 
effects of simple hydrostatic pressure (both cyclic and static) on stem cells have centered on 
musculoskeletal precursors, namely osteoblast-, osteoclast- and chondrocyte-precursors derived 
from BMMSCs.  Hydrostatic pressure appears to increase differentiation potential of osteoblast-
induced BMMSCs and osteo-progenitors into osteoblasts [574, 575] and inhibit the 
differentiation potential of osteoclast-induced BMMSCs [576, 577].  A similar effect has been 
demonstrated for chondrocyte-induced BMMSCs, with pressure increasing chondrocyte-specific 
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matrix production and driving the chondrogenic phenotype [578-582].  The frequency and 
magnitude of pressure stimulation in chondrocyte-precursors appears to affect differentiation 
[582] more than osteoblast- [574, 575] and osteoclast-precursors [576, 577].  Although these 
studies indicate that BMMSCs are indeed sensitive to hydrostatic pressure, they do not decouple 
the pressure stimulus from other stimuli such as a chemical inductor or other mechanical stimuli, 
and therefore may be masking the true nature of the pressure effect.  Also, in a similar manner to 
the effects of shear stress on osteo-progenitors, pressure-induced differentiation appears to 
depend upon the timing of application following induction [576, 579]. 
1.4.2.2.4 Summary of mechanical stimulation 
Although the mechanical environment is important for maintaining the phenotype and 
functionality of terminally differentiated cells (see Sections 1.2.3 and 1.3.3) [25, 244, 358, 402, 
583-588], only recently has attention been given to the role that mechanical forces play in the 
differentiation of BMMSCs.  The previous studies described in Section 1.4.2.2 (summarized in 
Table 1.5) demonstrate the important potential of using mechanical stimulation to guide 
BMMSC (and ESC) differentiation.  From the table, it is readily apparent that most of the 
mechanical stimulation in BMMSCs has been from the musculoskeletal perspective, utilizing 
low magnitudes of stimulation (for both stretch and shear stress) as well as the intermittent 
application of these forces.  Moreover, a majority of these studies have not been conducted with 
multipotent BMMSCs, but rather have been performed following pre-differentiation or lineage 
commitment of the cells using osteo-inductive media.   
Although limited in scope, the cardiovascular-related studies to date have clearly 
demonstrated the ability of cyclic stretch and shear stress to generate SMC and EC 
differentiation in BMMSCs and ESCs  The motivation to study the role of mechanical 
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stimulation towards cardiovascular cells has be generated, in part, by recent in vivo data 
suggesting that BMMSCs have the ability to home to sites of vascular injury, and in this 
mechanically dynamic environment generate vascular SMCs and ECs [547, 589-592].  While the 
data in Table 1.5 seems to indicate that cyclic stretch predominantly guides BMMSCs towards 
SMCs, and shear stress guides ESCs towards ECs, pulsatile shear stress is the only stimulus 
demonstrating the fully contractile marker SM-MHC in BMMSCs.  In addition, there is a 
complete lack of data utilizing cyclic pressure that is physiologically relevant to the 
cardiovascular system even though there is clear evidence that pressure is an important stimulus 
for both ECs and SMCs (see Sections 1.2.3.2 and 1.3.3.2).  The few cardiovascular-related 
studies have also utilized a limited range of magnitudes and paid no attention to the effects of 
frequency despite the wide range of both that are present from early development to maturity 
throughout the vasculature.  These factors may ultimately be important in determining the 
lineage to which the stem cells differentiate but without coordinated study, we can only speculate 
as to their role in BMMSC differentiation.   
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Table 1.5:  Effects of mechanical stimulation of BMMSCs and ESCS. Solid arrows indicate up (↑), down (↓), or no 
change (↔) in each factor.  Double arrows indicate signal sustainability as up ( ), down ( ), or returning to 
baseline ( ).  CS=cyclic stretch, PF=pulsatile flow; LSS=laminar shear stress; CP=cyclic pressure; 
OFF=oscillatory fluid flow; UN=uniaxial; EQ=equiaxial; OI=osteo-inductive media; AI=adipo-inductive media; 
IM=intermittent/ <0.5 Hz; Magnitudes listed in parenthesis % for CS; dynes/cm2 for LSS, PF, and OFF; and mmHg 
for CP. 
⇑ ⇓
⇔
 
Factor Change Stimulus and magnitude Reference 
SMC  
↑ CS(10) UN; PF (1-14 ) [526, 530] 
↑  ⇔ CS(10) UN; LSS (1-14) [527, 530, 567] SMA 
↓  ⇓ CS (10%) EQ [527, 567] 
Calponin ↑ CS(5-10) UN [526, 558] 
↑  ⇔ CS(10) UN; LSS(1-5 ) [527, 567] 
SM22α 
↓  ⇓ CS(10) EQ [527] 
Caldesmon ↔ CS(10) UN [526] 
SM-MMHC ↑ PF(1-14) [530] 
EC  
↔ CS(10) UN [527] VE-cadherin 
LSS(1-5) [567] ↑⇑  
LSS(1-5) [567] Flk-1 ↑⇑  
LSS(1-5) [567] PECAM ↑⇑  
LSS(1-5) [568] vWF ↑⇑  
Osteoblast  
↑  ⇔ CS(3) EQ,IM, OI [563] 
↑  ⇑ CS(8), CP(100) IM, +/-OI [564, 574] 
↔ CS(10) UN; LSS(1.6) IM, OI [527, 572] 
Alkaline 
phosphatase 
↓ OFF(20) [570] 
↑  ⇑ CS(3-4) EQ; LSS(0.36-2.7); OFF(20); CP(100) +/IM, OI [562, 563, 570, 571] Osteocalcin 
↔ ⇔  CS(2-10) UN +/-IM, +/- OI [527, 564] 
Runx2 ↑ CS(4) EQ IM, OI [562] 
↑  OFF(20); LSS(1.6); CP(1500) IM, OI [570, 572] Osteopontin ⇑
Chondrocyte  
Collagen II ↔ CS (10) UN [527] 
Adipocyte    
PPAR-γ ↓ CS(4) EQ IM, AI [562] 
ECM  
↑  ⇑ CS(8-10) UN +/-IM; OFF(20), OI [507, 527, 564, 570] 
↔ CS(10) EQ [527] Collagen I 
↓ CP(100) IM, OI [574] 
↑  ⇑ CS(2-10) +/-OI [507, 564] Collagen III 
↔ CS(10) UN [527] 
Proliferation  
↑ CS(3-10) UN +/-IM; OFF(20), +/-OI [333, 507, 559, 563] 
↓ CS(10) UN [526]  
↔ LSS(0.36-2.7) IM, OI [571, 572] 
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1.5 SUMMARY AND LIMITATIONS OF PREVIOUS RESEARCH 
BMMSCs represent a potentially useful cellular source for regenerative medicine.  While some 
research has been performed on BMMSCs and the means by which they can be differentiated 
towards bone, cartilage, and fat [56, 510], research into using BMMSCs for vascular applications 
is still in its infancy [53, 520, 521, 528, 529, 552, 591].  Although the biological factors 
discussed in Sections 1.2.2 and 1.3.2 are important for SMC and EC differentiation and 
maintenance, the previous studies outlined in Section 1.4.2.1 have utilized concentrations, 
combinations, and types of biological and biochemical factors [42, 120, 493, 501, 529, 541-543, 
551, 554, 593-595] to differentiate BMMSCs to vascular cells which may not be found in the in 
vivo environment.  Given the documented plasticity of BMMSCs [57, 488, 520], any stimuli 
used to differentiate these cells in vitro may be required to be maintained in vivo.  Without such 
signals, the BMMSCs may not maintain their phenotype. In addition, some of the biochemical 
factors utilized for vascular differentiation have been demonstrated to cause differentiation into 
other phenotypes such as bone and cartilage [56, 524, 529, 538-540].  
In light of these issues, we believe that bioactive molecular stimulation alone is 
insufficient for the creation and maintenance of specific cell types for use in regenerative 
applications, but that, at a minimum, biomechanical stimulation is also required.  Yet, despite the 
importance of mechanical stimulation in the development and maintenance of the cardiovascular 
system, limited attention has been given to the use of mechanical stimulation for differentiating 
BMMSCs.  Section 1.4.2.2.4 identifies that our current understanding is lacking a systematic 
analysis of BMMSC differentiation under mechanical stimulation.  The limited amount of data 
that does exist (see Table 1.5) does not present a unified perspective on how mechanical 
stimulation can be effectively utilized for regenerative medicine, particularly vascular 
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regenerative medicine.  Broader interpretations of the data are complicated by inconsistencies in 
the response to various magnitudes, frequencies, and type of stimulus as well as the presence and 
absence of osteo- or adipo-inductive additives and cell source.  Therefore, there is need for 
research to elucidate the magnitude, frequency, and temporal response of BMMSCs to various 
mechanical stimuli.  A greater understanding how stem cells respond to mechanical stimuli will 
ultimately aide in their use for cell therapy and in bioreactor design for the ex vivo production of 
tissue engineered products.  
1.6  HYPOTHESIS AND SPECIFIC AIMS 
The proposed work is designed to test the following hypothesis:  
Mechanical stimulation, relevant to the vascular system, will guide the differentiation of 
BMMSCs towards vascular SMCs and ECs.  
The overall goal of this project was to systematically analyze the response of BMMSCs 
to the Mechanical Panel, which we define as the parallel application of the mechanical stimuli 
that are physiologically relevant to the vasculature – namely cyclic stretch, pressure, and shear 
stress – and to assess if BMMSC differentiation was sustained following removal of the 
stimulus.  The specific aims that were executed to test this hypothesis were as follows: 
Specific Aim 1:  To develop and validate a compact bioreactor capable of extended application 
of cyclic hydrostatic pressure. 
Specific Aim 2:  To elucidate the dose-dependent response of BMMSCs to varying magnitudes 
and frequencies of each mechanical force stimulus in the Mechanical Panel. 
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Specific Aim 3: To elucidate the temporal response of BMMSCs to the most appropriate 
frequency and magnitude determined from Specific Aim 2 for each mechanical force 
stimulus in the Mechanical Panel. 
Specific Aim 4: To determine the plasticity of BMMSCs following differentiation via cyclic 
stretch. 
This research project was broken into two main components.  The first component was the 
design and validation of a cyclic hydrostatic pressure system (Specific Aim 1).  Computational 
fluid dynamics and biological analysis of cell viability and proliferation were used as 
benchmarks for the successful completion of Specific Aim 1.  The successful design of a cyclic 
hydrostatic pressure system was necessary to complete the Mechanical Panel of stimuli that were 
to be used in Specific Aim 2 and Specific Aim 3. 
The remainder of the research project centered on the response of BMMSCs to the 
Mechanical Panel over a range of physiologically relevant magnitudes and frequencies (Specific 
Aim 2) was determined through quantitative analysis of cellular morphology and proliferation, 
and also by assessing changes in gene and protein expression.  Next, the importance of the 
duration of applied stimulation to BMMSC differentiation was assessed by examining 
quantitative changes in gene and protein expression at two different time points (Specific Aim 
3).  Finally, the plasticity of BMMSCs exposed to cyclic stretch was assessed by examining 
quantitative changes in gene and protein expression upon removal of the stimulus (Specific Aim 
4).  The knowledge obtained from these studies will ultimately aide in the design of bioreactor -
guided differentiation of stem cells for use in regenerative medicine.   
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2.0 DEVELOPMENT OF A CYCLIC PRESSURE BIOREACTOR 
2.1 
2.1.1 
INTRODUCTION 
Overall goals 
Cyclic hydrostatic pressure is thought to be important in the function and/or dysfunction of many 
different cell types, including those of cardiovascular, bone, cartilage, renal, pulmonary, urinary 
tract, and ocular tissues [576, 596, 597]. For example, elevated pulmonary pressure causes 
increased production of inflammatory mediator proteins, primarily from macrophages, which is 
important for understanding mechanical ventilation injury in the lungs [598].  In the vasculature, 
hypertension is known to be a major cause of intimal hyperplasia and atherosclerosis [115, 185, 
224, 382, 383].  In fact, it has been shown that SMCs undergo morphologic changes and increase 
proliferation under elevated static and cyclic pressure [225].  
Maintaining cell viability under defined mechanical conditions is important for studies in 
cellular mechanobiology, including those related to this project.  While the application of 
stretching and shear forces has been adequately provided for extended periods of time in vitro 
with commercially available and custom-designed devices [445, 599-602], the extended 
application of hydrostatic pressure has proven problematic.  The hurdle in conducting long-term 
(>2 days) in vitro experimentation using applied hydrostatic pressure in cell culture has been 
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maintaining proper humidification, and this is especially problematic for cyclic application.  
Because cyclic pressure generally requires constant movement of air through the culture 
chamber, water can evaporate from the culture media, upsetting the osmotic balance and 
disrupting cellular function, eventually leading to cell death.  Thus, Specific Aim 1 of this 
research dissertation was to develop a cyclic pressure bioreactor that was capable of sustaining 
cellular viability for extended periods under cyclic pressure application in order to determine the 
response of BMMSCs to cyclic pressure.  It is noted that a majority of the work described in this 
chapter was published in the Journal of Biomechanical Engineering and is reproduced with 
permission from ASME [1]. 
2.1.2 Prior art and limitations 
While several devices have been published reporting the application of cyclic pressure for less 
than two days [389, 576, 578, 596, 598], only two devices have been published that reported the 
application of cyclic pressure for longer periods of time (>2 days) [225, 597, 603].  Hasel et al. 
modified a Flexcell 4000T cyclic stretch device to apply both cyclic pressure and cyclic stretch 
to vascular smooth muscle cells for up to 96 hours [597]. In our opinion, the humidification 
system employed appears to be sub-optimal since the humidification occurred at room 
temperature, thus yielding an maximum absolute humidity of ~20g/m3, which is less than half 
the 45g/m3 typically required for maintaining cellular function [604].  Watase et al. [225] 
stimulated smooth muscle cells for 9 days with computer controlled solenoid valves regulating 
the entrance of air into a Plexiglas® chamber containing culture plates and a water reservoir.  
However, preferential evaporation from the water reservoir instead of the culture chambers is not 
expected.  Therefore, water evaporation likely occurred in both the water reservoir and the cell 
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culture media.  Using a similar approach, Xing et al. [603] separated their system into two 
compartments with a rubber diaphragm.  The lower compartment, which contained the cell 
culture plates, a water dish for humidification, was filled with 5% CO2 air and completely sealed 
beneath the diaphragm.  The upper compartment was connected to a compressed air supply, and 
ambient pressure in the lower portion of the chamber was assumed to be equal to the pressure of 
the compressed air in the upper portion of the chamber when the diaphragm was at equilibrium.  
By limiting the amount of possible air turnover, the relative humidity in the culture portion of the 
chamber was maintained at 95%.  However, by sealing the culture chamber, experiments were 
essentially limited to 48 hours before a fresh supply of air would have to be exchanged, thus 
disrupting the equilibrium vapor pressure which was established by evaporation from both the 
water dish and the culture chamber (similar to the drawback of the system described by Watase 
et al.[225]).  For the short-term cyclic pressure devices, Pugin et al. [598] created a design that in 
all likelihood could have been used much longer than the 32 hour experiments they published.  
This device applied cyclic pressure in conjunction with cyclic stretch to macrophages by using a 
clinical respirator, and included a heated humidification circuit.  The use of a heated 
humidification circuit ensured that the air entering the culture chamber was fully saturated at 
37°C (unlike the system described by Hasel et al.[597]), and no water loss would be expected to 
occur.  The main drawback to this system was the use of a clinical respirator, which added 
significant cost and space requirements to the system. 
While each of these devices have shown some ability to apply static or cyclic pressure to 
cell cultures for extended periods of time, they have either employed inadequate humidifiers or 
required costly components, computer-driven algorithms, or large volumes of space for their 
operation.  The goal of Specific Aim 1 was to create a system for the long-term application of 
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fully humidified, cyclic pressure of multiple magnitudes and frequencies.  The development of 
our cyclic pressure system (Figure 2.1) was centered on four key design goals: minimal size, 
stability of pressure and humidity, maximal accessibility, and versatility. 
2.2 
2.2.1 
METHODS 
Design considerations 
2.2.1.1 Minimal size 
In order to successfully perform our Mechanical Panel experiments, which require the 
use of all three mechanical stimulation devices at the same time, we had to minimize the volume 
occupied by the cyclic pressure system.  First, the system was designed to occupy only ~1400 
cm3 of total space within an incubator by minimizing the number of necessary components 
within the controlled environment, and keeping the rest of the system outside.  The pressurized 
culture chamber consists of a single continuous volume, into which up to 6 microscope slides, 
scaffolds, or other materials may be placed (Figure 2.1e and Figure 2.2).  Initial observations of 
fluid ripples being generated by the impinging inlet air led to the placement of two stainless steel 
bars (Figure 2.1f and Figure 2.2) placed directly below the inlet and outlet ports.  These bars, 
whose height was sufficient to protrude above the media, prevented the jet impingement from 
causing a fluid disturbance and potentially transmitting such disturbance to the cells by 
converting the downward vertical velocity of the incoming air to a horizontal velocity prior to 
the air contacting the media.  The stainless steel bars also function to constrain the slides, or 
other materials being stimulated, to the bottom of the chamber.  Stainless steel was chosen as the 
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material for these bars due to its inertness (chemical reactions between the cell culture media and 
aluminum in earlier designs resulted in widespread cellular death).   
2.2.1.2 Environmental stability 
In order to study the biological effects of a given stimulus, that stimulus must be applied 
in a constant and consistent manner throughout the duration of the experiment.  For our pressure 
system, this required a constant magnitude of pressure to be available as well as a constant 
partial pressure of the gases required for normal cell culture (i.e., 21% O2, 5% CO2, balance N2).  
The stability for the magnitude of pressure was achieved with the internal house air system 
(Figure 2.1a), which does not significantly fluctuate.  Therefore, after setting the resistors that 
control the mean and pulse pressure (Figure 2.1c and Figure 2.1j) to reach the desired pressure 
waveform, the system could operate within accepted limits without the assistance of computer 
control.  To provide a constant source of normal cell culture gas, we mixed the air from the 
house air system, which was 21% O2 balanced with N2, with a small amount of pure CO2 to 
achieve ~21% O2, 5% CO2, and balance N2.  The ratios of air and CO2 were controlled with two 
gas rotameters (FM034-39 and FM082-03, Cole Parmer, Vernon Hills, IL).   
2.2.1.3 Maximum accessibility 
Because the cyclic pressure system utilizes a constantly refreshed blend of air and CO2, 
we needed to quickly and easily sample the culture media to monitor dissolved gas 
concentrations in a sterile manner without interrupting the operation of the system.  In addition, 
future experiments may require the capability for growth factor or biochemical addition, and/or 
addition or removal of growth surfaces in a sterile manner.  All of these requirements were 
satisfied by using a single continuous culture chamber (Figure 2.1e), a central injection port 
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Figure 2.1( g) for sampling media and adding culture supplements, and sterile filters and at both 
the inlet (Figure 2.1d) and outlet (Figure 2.1h) of the chamber to allow its removal from the 
incubator as necessary.   
2.2.1.4 Versatility 
In order to investigate the dose- and frequency- response of BMMSCs to cyclic pressure 
(Specific Aim 2), we required the ability to apply several different physiologically-relevant 
magnitudes and frequencies of cyclic pressure using the same system.  To control the frequency 
of the cyclic pressure wave, we designed a simple flip-flop circuit containing three NE555 timers 
(Fairchild, McLean, VA) to apply 0.5, 1.0, or 2.75 Hz frequency signals to an electrically 
activated solenoid (98300-12, Cole Parmer).  The solenoid was placed distal to the pressure 
chamber (Figure 2.1i), and pre- and post-solenoid passive resistors were used to control the 
pressure magnitude.  Representative waveforms generated by the system were captured using a 
clinical pressure monitor (Spacelabs, Issaquah, WA) (Figure 2.1m) connected to a data 
acquisition board interfaced with LabView® (National Instruments, Austin, TX) data acquisition 
software.  The 0.5 and 1.0 Hz data were collected at 30Hz, and the 2.75Hz data was collected at 
100Hz.  The data was smoothed using the following centrally-weighted moving average filter 
equation: 
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where ys(i) is each point in the smoothed data set, and N is the number of data points on either 
side of the raw data, y(i) [605].  For the purposes of this study, N was set to be 3 to maintain 
95% of the peak pressure value. 
 
 
Figure 2.1: Schematic of the cyclic hydrostatic pressure system designed during the execution of Specific Aim 1.  A 
constant pressure source (a) provides the bulk airflow that powers the cyclic pressure system, and consists of an in-
house air pump and pure CO2 blended together to achieve 5% CO2, 20% O2, and 75% N2. A heated passover circuit 
(b) humidifies the air to ~100% before it passes through a resistor that controls the mean pressure (c).  The air then 
passes through a sterile filter (d) before it enters the culture chamber (e) and builds a static pressure in the dead 
space above the culture media.  Two stainless steel bars (f) deflect the incoming air and provide weight to stabilize 
the culture surface.  An injection port (g) provides access for media sampling or chemical injection.  The air then 
passes through a second sterile filter (h) on its way to a solenoid valve (i).  When the valve is closed, pressure builds 
inside the system.  When the valve is open, the pressure is released through a second resistor (j) that controls the 
diastolic pressure.  Two pressure transducers (k) and their associated monitor (m) display the pressure inside the 
cyclic pressure chamber.   A check valve (l), which has a cracking pressure of 250mmHg, allows the system to 
release built-up pressure in the event that one of the filters becomes obstructed.   The dashed box represents the 
interior of the incubator.  Figure reproduced with permission from ASME [1]. 
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Figure 2.2: A three-dimensional exploded view (to scale) of the cyclic hydrostatic pressure chamber (see Figure 
2.1e) depicting the lid with the inlet, outlet, and sampling ports, 6 culture slides, o-ring groove, and stainless steel 
bars.  Figure reproduced with permission from ASME [1]. 
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 2.2.1.5 Humidifier designs 
In order to achieve extended application of cyclic hydrostatic pressure, the dry air used to 
drive the system must be properly humidified.  It has been documented that cellular dysfunction 
increases with time and deviation from optimal humidity (45g/m3) [604].  From experience using 
the room temperature passover similar that used by Hasel et al.[597], we determined that the 
maximum humidity achieved as not sufficient to sustain viability in our system.  To address this, 
several different options for humidifying the air were investigated (Figure 2.3).  Each humidifier 
was evaluated, calculating the relative humidity following operation by measuring the amount of 
water and gas used during the experiment and using Equation (2.6).  The first humidifier used 
was a simple bubble humidifier.  It consisted of a 250 mL side-arm flask filled with water 
through which the air destined to pass through the pressure chamber was bubbled (Figure 2.3A).  
This was placed in the incubator in an attempt to maintain the temperature of the water and air at 
37oC; thus raising the ability of the air to hold more water.  Several experiments were attempted 
with this configuration, but all experiments resulted in substantial evaporation and cellular death 
as evident by the low relative humidity achieved (~16.8%).  The next step in improving 
humidification was attempted by installing a heating element to heat the air prior to entering into 
the bubble humidifier.  The heating element (2M8131 Variable Nebulizer Heater, Baxter, 
Deerfield, IL) was combined with copper tubing to create a small chamber to flash heat the air 
prior to entering the bubble humidifier (Figure 2.3B).  This method was determined to provide 
only a slight improvement in the calculated humidity (~33% improvement), which was still 
insufficient to sustain cell viability.  A bubbling stone was added to the tubing in the humidity 
chamber to increase the surface area-to-volume ratio of the bubbles, which increased the relative 
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humidity more than 3-fold, but still not to a level sufficient to sustain cell viability (Figure 
2.3C).  Finally, the humidifier volume was increased to 2 L to increase the residence time for a 
given molecule of air, but this did not improve humidification beyond that achieved by using the 
bubbling stone (Figure 2.3D).  Although attempts were made to maximize the humidification 
through the bubble humidifier, a more effective method was necessary in order to sustain long-
term experiments.  To that end, we employed a device which is used clinically for the 
humidification of air for respiratory ventilators.  The MR730 respiratory humidifier (Figure 
2.3E, Fisher&Paykel, Auckland, New Zealand) employs a self-feeding, heated, domed water 
reservoir and heated tubing that conducts the humidified air from the reservoir into the incubator, 
and maintains the humidity near 100% as the air enters the culture chamber.  This device has 
been used previously in the cyclic pressure system described by Pugin et al [598].  The MR730 
was determined to adequately humidify the air entering the pressure chamber (see Figure 2.3F) 
and was used for the biological validation of the cyclic pressure system (Section 2.2.3). 
 72 
Bubble 
humidifier 
Bubble 
humidifier 
↑ΔT 
Bubble 
humidifier 
↑ΔT ↑SA 
Bubble 
humidifier 
↑ΔT ↑SA 
↑Volume
MR730 heated 
respiratory humidifier 
 
A) B) C) 
D) 
E) 
F) 
Total mass used Initial Setup ΔT ΔT+SA ΔT+SA+Vol Heated Passover
water (g) 15.0 20.9 87.0 50.0 541.0
gas (m3) 2.1 2.2 3.0 1.7 12.7
16.8 67.1 66.5% Humidity 22.4 98.6
 
 
Figure 2.3:  Progression of humidification system design for the cyclic pressure system.  (A) Simple bubble 
humidifier kept at 37oC.  (B) The simple bubble humidifier with the added heating element (callout) to increase the 
air temperature prior to entry into the bubble humidifier.  (C) Adding a bubbling stone increased the surface area 
available to pick up moisture.  (D) Increasing the volume of the bubble humidifier increased the residence time for 
air.  (E) The MR730 respiratory humidifier finally chosen as the best possible humidification system.  (F) Table 
depicting the increased humidity achieved with each successive improvement to the humidification system.  The 
increase in volume did not add any increase in relative humidity.  The heated passover humidifier achieved the 
optimal humidity for the cyclic pressure system. 
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 2.2.2 Computational fluid dynamics 
Because a time-varying jet of air impacts the culture medium over the cells throughout the 
operational cycle, we wanted to ensure that the resulting hydrostatic pressure wave was evenly 
distributed along the length of the chamber, and no significant shear stress was applied to the 
cells.  To that end, computational modeling of the cyclic pressure chamber was performed using 
CFD-ACE (Version 2002.2.16, CFDRC, Huntsville, AL).   
2.2.2.1 Mesh development 
Because of the significant computational costs associated with a three dimensional 
analysis in the required model, a 2-D representation of the pressure chamber with approximately 
3,500 structured linear quadratic elements was generated by the plane passing through the 
centerlines of the inlet and outlet ports of the chamber (Figure 2.4).  A boundary layer was 
created at the air/liquid interface as well as the bottom of the chamber, the region of interest vis-
à-vis shear forces.  An inlet flow extension with a length-to-diameter ratio of 12.5 was used to 
establish a fully developed flow for the air entering the chamber.  The 2-D volume between the 
end of the chamber and the downstream solenoid was estimated by multiplying the tubing length 
by its diameter and modeled as a closed compliance volume attached to the outlet of the model.   
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Figure 2.4:  A 2-D CFD model of the pressure chamber using linear quadratic elements.  Two boundary layers were 
created, one at the air/liquid interface (+), and the other at the base of the chamber where the cells would be located 
(*).  A sealed box (arrow) with an equivalent 2-D volume to the volume of the circuit between the chamber and the 
solenoid valve was used at the outlet.  The x- and y-axes depict positional information (in meters) relevant to the 
velocity, pressure, and shear stress plots in subsequent figures.  Figure reproduced with permission from ASME [1]. 
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2.2.2.2 Boundary conditions 
The inlet boundary condition was a time-varying pressure obtained with a first-order linear 
regression of the first half of a duty cycle (80 to 120mmHg) from the 1 Hz data collected from 
the experimental system.  Since the normal operation of the system occurs as an oscillation 
between 80 and 120 mmHg, modeling only the first half of the cycle was sufficient to determine 
if any shear stresses developed on the base of the chamber.  The outlet boundary condition was 
modeled as a closed compliance chamber to simulate the air volume held between the chamber 
and the closed solenoid valve (removed during post-processing for scaling).   
2.2.2.3 Solution Parameters 
The computational model included the volume of fluid (VOF) multiphase formulation: 
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uvwhere F is the fraction of a particular element occupied by the liquid volume, t is time, and  is 
the velocity vector [606].   Equation (2.2) was solved in conjunction with the standard mass, 
energy, and momentum conservation equations to solve the fluid dynamics field and the 
air/liquid boundary geometry at each time step using an unsteady solver with implicit first-order 
Euler time integration [606].  The air/liquid interface was reconstructed using a second order 
piecewise linear interface calculation (PLIC).  Each time step was calculated via the Courant-
Friedrichs-Levy (CFL) parameter (set to 0.2), which restricts the size of the time step to ensure 
the free surface does not cross an entire element within that time step.  The air and culture media 
were modeled as a compressible gas and water, respectively.  The fluid properties are listed in 
Table 2.1.  The advection scheme was first-order upwind, and the linear equation solver was 
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conjugate gradient, and the pressure correction term was calculated using the SIMPLEC 
algorithm.  The velocity and pressure under-relaxation parameters were 0.3 and 0.7, respectively 
and iterations were continued until the residuals were reduced by more than 4 orders of 
magnitude or the maximum 150 iterations were reached. 
 
Table 2.1: Physical properties of the air and water used in the CFD model of the cyclic pressure chamber.   
 
Air Water 
Molecular weight Kinematic viscosity (υ) Dynamic viscosity (µ) Density (ρ) 
1.589 x 10-5 m2-s-1 1,000 kg-m-3 6.82x10-4 kg-m-1-s-1 29g 
 
Wall shear stress (τ) was calculated from the velocity vector along the long axis of the 
chamber according to the following equation:  
 
y
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where µ is the dynamic viscosity and  is the gradient of the x-component of the velocity 
(Vx) with respect to the y-direction [607].  Post-processing line probes were used to extract the 
pressure, velocity, and τ from horizontal and vertical planes at various time points. 
2.2.3 Biological validation 
To validate the cyclic pressure system, we wished to demonstrate that bone marrow derived cells 
remain viable throughout their exposure to cyclic hydrostatic pressure.  To that end, two different 
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cell types were used to validate the cyclic pressure system.  In addition to biological endpoints as 
described below, measurements of pH, pCO2, pO3, and calculated HCO3- and relative humidity 
were used to determine the effective operating conditions for the cyclic pressure system.   
2.2.3.1 Cell source 
The two cell types employed in this study were derived from the bone marrow.  The first 
cell type will be referred to as adherent hematopoietic cells (AHCs).  To obtain AHCs, the 
femoral bones were obtained from freshly euthanized miniature swine (25kg).  The pigs were 
obtained from unrelated studies, in accordance with the University of Pittsburgh’s Institutional 
Animal Care and Use Committee.  The bone marrow was harvested by flushing the femoral bone 
cavity with AHC media, which consisted of Media 199 (M199, Sigma, St. Louis, MO) 
supplemented with 10% calf serum (Invitrogen Carlsbad, CA), and 1% Penicillin/Streptomycin 
(Invitrogen). The isolated cells were passed through a 40μm filter (Falcon, San Jose, CA) layered 
on Ficoll® (Amersham, Buckinghamshire, England), and centrifuged at 330 x g and 22oC for 20 
minutes.  The red cell fraction at the bottom was resuspended with AHC media, and cells 
adherent after seven days were subcultured as AHCs.  For each experiment 50,000 AHCs were 
plated onto glass microscope slides (Fisher, Hampton, NH) for 24 hours, and then placed into the 
cyclic pressure chamber or kept as static incubator controls (37oC, 5% CO2, 95% humidity) for 
the duration of the experiment. 
Because the proposed research was to examine the response of BMMSCs to three 
mechanical stimuli, BMMSCs also needed to be tested in the cyclic pressure system.  BMMSCs 
were harvested from Sprague Dawley rats (2.5kg) using previously described methods [526].  
The rats were obtained from unrelated studies, in accordance with the University of Pittsburgh’s 
Institutional Animal Care and Use Committee.  Briefly, the femurs of freshly euthanized rats 
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were flushed with complete bone marrow culture medium (BMCM), which consisted of 
Dulbecco’s Modified Eagles’ Media (DMEM, Sigma) supplemented with 10% calf serum 
(Invitrogen) and 1% penicillin/streptomycin (Invitrogen).  The harvested cells were passed 
through a 40μm filter (Falcon) and plated in a Dexter culture fashion in BMCM [470].  Those 
cells remaining adherent after seven days were kept, and the non-adherent cells discarded.  Cells 
less than passage 4 were utilized for the experiments.  At the start of each experiment, 7000 
cells/cm2 were plated on collagen-coated slides (Flexcell International, Hillsborough, NC).  
Following a 48-hour incubation period, the slides were placed into the cyclic pressure system for 
the duration of the experiment while controls were kept in static incubator conditions. 
2.2.3.2 BMMSC characterization 
To determine the multipotentiality of BMMSCs, differentiation assays were performed.  
A mineralized bone matrix formation assay was performed whereby isolated BMMSCs (Section 
2.2.3.1) were cultured in BMCM supplemented with ascorbic acid (100 µg/mL), β-glycerol 
phosphate (5 mM), and dexamethasone (1 μM) for 1 week [56, 526].  Following osteogenic 
induction, BMMSCs were fixed in 4% paraformaldehyde for 5 minutes and washed 3 times with 
phosphate buffered saline (PBS, Sigma).  The presence of bone forming nodules was assessed 
using Alizarin Red dye (see Section 3.2.1.1.1). 
An adipogenic differentiation assay was also performed by culturing isolated BMMSCs 
(Section 2.2.3.1) in BMCM supplemented with 3-isobutyl-1-methylxanthine (100 µg/mL), and 
indomethacin (60 μM) for 2 weeks [56, 526].  Following adipogenic induction, BMMSCs were 
washed with PBS and fixed in 4% paraformaldehyde (Sigma) for 5 minutes followed by 3 
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washes in tap water.  Accumulation of lipid droplets in the cellular cytoplasm was determined by 
staining the samples with Oil Red O (see Section 3.2.1.1.2). 
2.2.3.3 Pressure conditions 
For initial assessment of cellular viability, AHCs were exposed to 120/80 mmHg, 0.5 Hz 
cyclic pressure.  Control cells were kept in static incubator conditions.  Each experiment lasted 5 
days.  For experiments investigating the effects of cyclic pressure on stem cell differentiation, 
proliferation, and morphology, BMMSCs were exposed to 120/80 mmHg, 1.0 Hz cyclic 
hydrostatic pressure.  Controls were kept in static incubator conditions.  Each experiment lasted 
7 days. 
2.2.3.4 Dissolved gas measurements 
Media samples were obtained every 24 hours during both sets of experiments to measure 
pH, and the dissolved concentrations of CO2 and O2 using a dissolved gas analyzer (ABL5; 
Radiometer, Copenhagen, Denmark).  HCO-3 was calculated using the Henderson-Hasselbach 
equation [608]: 
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where [CO2] and [HCO3-] are the concentrations of carbon dioxide and bicarbonate ion, 
respectively and pKa is the log of the acid dissociation constant.  pKa is calculated from [608]:  
 
))7.8log(1lg(125.6 −+−= pHantipKa (2.5) 
 
The calculation of the bicarbonate content was used as a measure of proper humidification.  
Assuming that BMMSCs cells do not produce their own bicarbonate through carbonic anhydrase 
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[609], increases or decreases in the calculated HCO
-
3 can indicate a change in the concentration 
of media components due to water evaporation or condensation, respectively.   
2.2.3.5 Relative humidity calculation 
The relative percent humidity was calculated for the system after each experiment by 
taking the ratio of the total volume of gas used to the total volume of water used with the 
maximum vapor density of water in air at 37°C.  The total volume of air used during an 
experiment (Vair) was calculated from flow rates recorded every 24 hours.  The total volume of 
water used (VH20) was determined by subtracting the total water left in the humidifier system 
from the starting volume.  Relative humidity (RH) was calculated as follows: 
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where MVD is the maximum vapor density, which was estimated by a fourth order polynomial 
extrapolation of tabular data for temperature vs. maximum vapor pressure (Figure Figure A.1 in 
Appendix A) [610].  The average inlet air temperature was measured by a temperature probe 
(Fisher&Paykel) at the end of the heated conduit and used to compute the MVD. 
2.2.3.6  Viability analysis 
At the termination of each experiment involving AHCs, cell viability was assessed by the 
Live/Dead® Kit (Molecular Probes, Carlsbad, CA) according to manufacturer’s protocols.  
Briefly, 0.1 µM ethidium bromide and 2 µM calcein were incubated on the AHCs for 1 hour 
followed by 3 washes in PBS.  The AHCs were then fixed in 4% paraformaldehyde for 5 minute, 
and rinsed 3 times with PBS.  Nuclei were stained with DAPI (Sigma) for 1 minute and washed 
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5 times with PBS before being imaged at 200x on an epifluorescent microscope (E800, Nikon).  
Ten random fields of view were analyzed per experiment.  Overlapping DAPI and ethidium 
bromide staining identified dead cells.  The average percent cell death was recorded for each set 
of 10 fields of view. 
2.2.3.7 Glycosaminoglycan staining 
At the termination of each experiment involving AHCs, samples were fixed in 4% 
paraformaldehyde for 5 minutes and washed 3 times with PBS.  Glycosaminoglycan (GAG) 
production was assessed by Safranin O staining.  Briefly, AHCs were incubated with 0.1% 
Safranin O (S8884, Sigma) for 5 minutes followed by alcohol dehydration and were digitally 
photographed (CoolPix, Nikon) at 100x on an inverted phase-contrast microscope (TS100, 
Nikon).  Increased GAG production may indicate differentiation towards the chondrocyte 
phenotype, which has been previously shown for stem cells under cyclic pressure [505, 579, 
611].   
2.2.3.8 Morphology analysis 
Morphologic analysis was performed for each experiment involving BMMSCs as described in 
Section 3.2.4.1.  The cellular surface area and perimeter were measured for each cell in the field 
of view using Scion Image (Scion Corp, Frederick, MD) and used to compute the shape index 
(see Section 3.2.4.1 and Equation (3.2)). 
2.2.3.9 Proliferation Analysis 
3.2.4.2Cellular proliferation was quantified using methods described in Section .  Briefly, 
using nuclear staining, the number of cells counted in ten random fields of view was averaged, 
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and each averaged cell count was normalized to its corresponding control and reported as a fold 
change versus control.   
2.2.3.10 Statistical analysis 
All data is presented as mean ± standard error of the mean.  Because the average cell 
counts were normalized to the control, a one-sample t-test was performed with μ=1 and α=0.05.  
For morphologic analyses, a paired Student’s t-test was used to make statistical comparisons.  
p-values less than 0.05 were considered significant. 
2.3 
2.3.1 
RESULTS 
Pressure waveforms 
Representative waveforms generated by the cyclic pressure system are shown for the oscillating 
frequency of the solenoid valve set to 0.5, 1.0, and 2.75Hz (Figure 2.5).  The maximum pulse 
pressure possible at 2.75 Hz was 20mmHg due to inertial effects of the air.  However, the 
waveform is consistent with neonatal blood pressure and frequency and could therefore be useful 
in testing the effects of such as stimulus [612]. 
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 Figure 2.5: Pressure waveforms collected with the solenoid valve frequency set to (a) 0.5 Hz, (b) 1.0 Hz, and (c) 
2.75 Hz.  Figure reproduced with permission from ASME [1].   
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 2.3.2 CFD results 
The CFD analysis of the cyclic pressure chamber revealed a uniform pressure field established 
along the length of the chamber (Figure 2.6) and rose steadily over time (Figure 2.7).  The 
pressure field did show a minor increase above the applied gas pressure due to the pressure head 
developed from the 6.3mm of media above the cells, but this was less than 1% and was 
considered negligible (Figure 2.6).  The maximum calculated wall shear stress was ~1.2x10-4 Pa, 
which is insignificant compared to the pressure that the cells experienced (~104 Pa), and 
confirmed the assumption that cyclic pressure system is truly hydrostatic.  A three-dimensional 
velocity profile (Figure 2.8) over time shows plug flow developing into the characteristic 
parabolic flow within the chamber as time advances.  At t=0.01s, a dip in the velocity occurs, 
which we believe may indicate the initiation of compression and a resultant reflection of the air 
wave.  Following this drop, the velocity profile oscillates slightly while progressing into the 
characteristic parabolic profile associated with laminar flow by 0.05 seconds, and remains 
parabolic for the rest of the simulated time (not shown).  The Reynolds number (Re) was 
calculated to be <50, thus confirming the establishment of a laminar flow in the viscous model.  
The stainless steel bars, which were used as diffusers to deflect the downward impingement 
force of the inlet air, prevented significant disturbances in the liquid layer.  However, there 
apparently is some liquid velocity (0.02 m-s-1 maximum) during the development of the air flow 
that was transferred ~0.8 mm into the liquid layer.  However, the shear stress calculations 
suggest that although liquid movement was generated, no significant wall shear stress resulted. 
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Figure 2.6:  Results for CFD analysis revealing a uniform pressure distribution across the length of the chamber.  
There is a slidght increase in pressure in the fluid layer progressing down towards the base of the chamber (inset), 
which is consistent with the expected increase in pressure from the weight of the fluid.  The dashed line represents 
the slice through which the velocity field (shown in Figure 2.8) along the y-axis was extracted.  Figure reproduced 
with permission from ASME [1]. 
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Figure 2.7:  Results for the pressure vs. time vs. the X-position across the bottom of the cyclic pressure chamber 
indicate a smooth, continuous increase in pressure over the course of the simulation and a uniform distribution along 
the length of the chamber.  Figure reproduced with permission from ASME [1]. 
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Figure 2.8:  A three-dimensional spatial velocity profile over time extracted from the dashed line  shown in Figure 
1.1 shows the development of parabolic flow in the air space, and that the velocity is zero in the liquid space (air-
liquid interface located at y=0.063 m).  Figure reproduced with permission from ASME [1]. 
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2.3.3 Dissolved gas and relative humidity results 
Dissolved gas measurements taken over the course of the experiments showed that the pH, 
pCO2, and HCO-3 values remained similar between pressure and control groups and were within 
acceptable limits (Figure 2.9).  The values for pO2 were elevated in the cyclic pressure group 
because of the increase in ambient pressure.  However, the fractional oxygen index (FiO2), which 
is the ratio of the partial pressure of dissolved oxygen to the total pressure, was nearly equivalent 
for the control and cyclic pressure groups (18.6 ± 0.1% vs. 18.1± 0.2%, respectively). The 
average relative humidity at 37oC was calculated to be 99% ± 4% (absolute humidity 49.3 ± 3.4 
g/m3).  These values resulted from the operation of the humidifier at 38-39oC to ensure full 
saturation at 37oC when the air crossed into the incubator section of tubing. 
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Figure 2.9: ABL readings demonstrate similar values between the cyclic pressure (○) and control experiments (■) 
for (a) pH, (b) pCO2, and (c) HCO-3. (n=8)  Dashed lines indicate the upper and lower limits for acceptable values 
for each measured variable.  The stability in the HCO-3 values indicates sufficient humidification. (d) pO2 values 
for pressure were elevated over controls throughout the experiments due to the increase in ambient pressure.  These 
values, although statistically different (p<0.05), had similar FiO2 values when adjusted for ambient pressure and are 
not considered biologically significant.  Figure reproduced with permission from ASME [1].   
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 2.3.4 AHC viability 
Analysis of the Live/Dead® staining (Figure 2.10) showed no difference between the cyclic 
pressure and control AHC groups at 5 days (p=0.16).     
 
Figure 2.10: Representative Live/Dead images from AHCs exposed to (a) Control and (b) 120/80 mmHg, 0.5 Hz 
cyclic pressure for 5 days.  (c)  Averaged percentage of dead cells in 10 fields of view indicates no difference in cell 
death following exposure to 5 days of cyclic pressure.  Bars indicate mean ± SEM. 
 
2.3.5 GAG production in AHCs 
After five days under cyclic pressure or control conditions, control cultures appear to produce 
more GAGs as indicated by Safranin O staining, while the cyclic pressure cultures did not stain 
strongly for Safranin O (Figure 2.11).  This may indicate that early progression into 
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chondrogenesis (detected by GAG staining), which may be followed by subsequent osteogenesis, 
is prevented by the application of cyclic pressure in AHCs.   
 
 (B) (A) 
 
Figure 2.11: GAG production is evident in controls (A) but inhibited under cyclic pressure (B) as evidenced by 
Safranin O staining (n=3). 
 
2.3.6 BMMSC morphology and proliferation, and differentiation 
BMMSCs showed a significant increase in proliferation (Figure 2.12a) and a decrease in cell 
size (Figure 2.12b) when exposed to cyclic pressure.  BMMSCs exposed to cyclic pressure also 
showed a significant increase in shape index (Figure 2.12c), which indicates a more rounded 
morphology.  
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Figure 2.12: (a) Quantification of BMMSC proliferation via cell counts revealed a 1.8 fold increase in cells exposed 
to cyclic pressure for 7 days compared to controls. (b) BMMSCs exposed to cyclic pressure demonstrated a 
significant reduction in their total area.  (c) Shape index measurements indicated a more rounded morphology for 
BMMSCs under cyclic pressure. (d) Coomassie blue stained images of pressure (left) and control (right) reflect the 
measured differences in morphology and proliferation that occurred upon stimulation with cyclic pressure. Images 
taken at 10x magnification.  Figure reproduced with permission from ASME [1]. 
 
 93 
2.4 DISCUSSION 
These results demonstrate the development of a new experimental system capable of extended 
application of cyclic hydrostatic pressure to cell culture.  CFD simulations demonstrated the 
uniformity of the pressure distribution and the lack of other forces translating to the base of the 
chamber where cells would be cultured.  The use of a heated passover humidifier provided 
sufficient vapor saturation to ensure minimal to no media loss in the culture chamber. This was 
evident in the stability of the HCO3
-
 measurements (Figure 2.9d).  Such results were not 
achieved with other humidifier designs assessed, including a room temperature passover system 
[597] and several modified bubble humidifiers (Figure 2.3).   There is also some evidence, both 
in our own experimentation as well as in the literature [604], that media changes every 24 - 48 
hours can mask the cell damage resulting from inadequate humidification.  Importantly, our data 
demonstrated that there was no effect on cellular viability due to exposure to cyclic hydrostatic 
pressure through 7 days.   
In addition to maintaining cellular viability, our experiments have also shown that cyclic 
pressure alters the GAG production of AHCs and the cellular morphology and proliferative rates 
in BMMSCs, indicating that these cells can respond to cyclic pressure (Figure 2.11 and Figure 
2.12).  To our knowledge, this was the first evidence that bone marrow derived cells are 
responsive to cyclic pressure alone; i.e., without other stimulation such as D3 [576], or 
chondrogenic medium [578].  The ability of the BMMSCs to respond to other physical stimuli 
(i.e., cyclic stretching) was recently reported by our laboratory [526].  Of particular interest is the 
finding that cyclic pressure enhances the proliferation of BMMSCs (Figure 2.12a).  These 
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results are consistent with Rubin et al.[577], who reported a trend towards increased proliferation 
when D3-stimulated BMMSCs were exposed to an increase in static pressure and other work 
involving cyclic pressure on ECs [386, 388, 394, 395].  However, during cyclic stretch we have 
previously shown that BMMSC proliferation is inhibited [526].  Cyclic hydrostatic pressure, 
therefore, may provide means to stimulate BMMSC proliferation without the addition of 
biochemicals and may prove to be useful for the ex vivo expansion of these cells for use in cell 
therapy.  For example, the use of cyclic pressure could potentially decrease the expansion time 
required for adequate numbers of cells for use in these therapies, and the be followed other 
forces, such as cyclic stretch, that could halt proliferation and guide differentiation of the 
BMMSCs [526]. 
2.4.1 Limitations 
While the cyclic pressure system developed here has been demonstrated to be versatile and 
space- and cost-efficient, it does have some limitations.  If one wished to test the potential 
synergistic effects of different chemical stimuli acting under pressure, separate culture chambers 
with independent solenoids and resistors may have to be used, increasing the cost, complexity, 
and space requirements for such a system.  However, the same humidifier and gas source could 
be used for several systems in a similar manner to the system described by Hasel et al [597].  
Enlarging the device slightly to fit a six well dish or the development of a small barrier system to 
isolate the individual glass slides used in the current system are two other methods that may be 
used to address this issue.  Additionally, the cyclic pressure waveform is a saw-tooth wave with a 
50% duty cycle.  More complicated waveforms can be generated but would require the use of an 
external controller to regulate the inlet and outlet resistors independently and reduce the cost-
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efficiency of the system.  Though the number of experiments performed in the validation of the 
cyclic pressure system was relatively small, quantification of morphology and proliferation did 
show statistical differences between stimulated and non-stimulated BMMSCs.  Furthermore, it 
did not show any statistical different in AHC cellular viability, and the increased proliferation of 
BMMSCs indirectly confirms this.    
2.5 CONCLUSIONS 
In conclusion, the newly developed cyclic pressure system is versatile, compact, and does not 
require complex control algorithms to operate in its current configuration.   The cyclic pressure 
system was shown to allow the culture of bone marrow derived cells under cyclic hydrostatic 
pressure for up to 7 days with no noticeable effects on cellular viability.  In addition, the 
exposure of BMMSCs to cyclic hydrostatic pressure for 7 days demonstrated their ability to alter 
their morphology and proliferation as well as demonstrate an altered differentiation capacity as a 
result of cyclic pressure stimulation. 
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3.0 THE MECHANICAL PANEL 
3.1 
3.1.1 
INTRODUCTION 
Definition and advantages of the Mechanical Panel 
The major experimental portion of this project, as outlined in Specific Aim 2 and Specific Aim 3, 
involves the systematic analysis of three different mechanical stimuli over a range of 
magnitudes, frequencies, and time points.  In order to efficiently accomplish this, a unique 
experimental setup was developed, which was termed the Mechanical Panel (Figure 3.1).  The 
Mechanical Panel permits the simultaneous exposure of a single population of cells (e.g., one 
T175 flask of BMMSCs) to cyclic stretch (CS), cyclic hydrostatic pressure (CP), and laminar 
shear stress (LSS) in a parallel manner.  This experimental setup reduces the biologic variability 
by using the same population of cells in each of the experimental systems and permits the paired 
comparison between each of the stimuli as well as the control.  As a result, the total number of 
experiments required to analyze the cellular response to the three proposed mechanical stimuli 
are reduced by a factor of three.  Furthermore, it allows careful examination of the differential 
response of cells to the variety of biomechanical forces that are present within blood vessels.  
This is a distinct advantage over the previous studies outlined in Sections 1.2.3, 1.3.3, and 
1.4.2.2, which analyzed only one type of force while ignoring others.  By analyzing the 
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differential response to the mechanical stimuli, we can quickly identify areas for possible 
synergism or antagonism when combining these stimuli together.  This may ultimately aide in 
the development of new bioreactors for the stem-cell based development of complex tissues in 
vitro.   
 
Cyclic Pressure[1]
Laminar Shear Stress  
(StreamerTM)Control 
Static incubator 
conditions 
Cyclic Stretch  
(FX4000T) 
 
Figure 3.1:  The Mechanical Panel applies mechanical stimulation in parallel from a single population of cells to 
determine a differential response to each of the stimuli. 
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3.2 
3.2.1 
METHODS 
Cell source 
The BMMSCs utilized for the experiments in Specific Aims 2-4 were obtained from the Tulane 
Center for Gene Therapy (TCGT) under an existing material transfer agreement and will be 
hereafter referred to as tBMMSCs.  The TCGT is funded by the NIH to provide well-
characterized BMMSCs to researchers in an effort to reduce the variability within the results of 
different researchers from different cell sourcing techniques.  The tBMMSCs were harvested 
from the femurs of adolescent Lewis rats and have been characterized as CD90+ and CD59+ stem 
cells [613].  The tBMMSCs were expanded in alpha modified Eagle’s media (α-MEM, 
Invitrogen) supplemented with 20% fetal bovine serum (FBS, Atlanta Biologicals, Atlanta, GA), 
1% antibiotic/antimicotic (Invitrogen), and 10 mM L-glutamine (Invitrogen).  The FBS used for 
the Mechanical Panel experiments was lot-selected for optimal growth (see Figure Figure B.1 in 
Appendix B.1).  The tBMMSCs were expanded using the seed-lot method (see Appendix B.2) 
to provide cells within a few passages of each other throughout the study [614]. 
3.2.1.1 Assessment of the multipotentiality of tBMMSCs 
Because the goal of this work was to assess the effects of mechanical forces on the 
differentiation of BMMSCs, it was necessary to confirm the multipotentiality of the tBMMSCs 
obtained from the TCGT.  The ability of tBMMSCs to differentiate into osteoblasts and 
adipocytes confirmed their multipotentiality.   
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3.2.1.1.1 Osteogenic culture 
To perform osteogenic differentiation assays, tBMMSCs were seeded at 200 cells/cm2 in 
6-well plates (Corning, Lowell, MA) and cultured with complete αMEM until 80% confluent.  
Thereafter, the complete αMEM was supplemented with ascorbic acid (100 µg/mL), β-glycerol 
phosphate (5 mM), and dexamethasone (1 µM) for 2 weeks [56, 526].  Following 2 weeks of 
osteogenic culture, tBMMSCs were fixed in 4% paraformaldehyde (Sigma) for 5 minutes and 
washed 3 times in PBS (Sigma).   
The presence of bone forming nodules was assessed using Alizarin Red dye (A5533, 
Sigma), which stains calcium phosphate deposits.  Fixed tBMMSCs were stained with Alizarin 
Red (40 mM, pH 4.2) for 10 minutes with gentle swirling.  Excess dye was removed by gently 
swirling the dish with PBS for 15 minutes.  The samples were then digitally photographed 
(CoolPix, Nikon, Melville, NY) at 100x on an inverted phase-contrast microscope (TS100, 
Nikon). 
3.2.1.1.2 Adipogenic culture 
To perform adipogenic differentiation assays, tBMMSCs were seeded at 200 cells/cm2 in 
6-well plates (Corning) and cultured with complete αMEM supplemented with 3-isobutyl-1-
methylxanthine (100 µg/mL), and indomethacin (60 µM) for 2 weeks [56, 526].  Following 
adipogenic induction, tBMMSCs were washed with PBS (Sigma) and fixed in 4% 
paraformaldehyde (Sigma) for 5 minutes followed by 3 washes in tap water.   
Accumulation of lipid droplets was determined by Oil Red O (O0625, Sigma) staining.  
Fixed tBMMSCs were incubated with 60% isopropanol for 5 minutes.  Fresh Oil Red O solution 
(0.3% in isopropanol mixed 3:2 with deionized water) was added for 5 minutes with gentle 
swirling followed by a brief rinse with tap water.  The cells were counterstained with Harris-
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Hematoxylin (HS80, Sigma) for 1 minute followed by a tap water rinse.  The samples were then 
digitally photographed (CoolPix, Nikon) at 100x on an inverted phase-contrast microscope 
(TS100, Nikon). 
3.2.2 Device descriptions 
3.2.2.1 Cyclic stretch apparatus 
The cyclic stretch for these experiments was provided via the FX4000T cyclic tension 
system (Flexcell International, Hillsborough, NC).  The FX4000T has been well established as a 
means to impose cyclic stretch on cell monolayers [526, 599, 615-618].   In brief, the system 
works by applying a vacuum to the underside of the culture plates, deforming the membrane with 
negligible shear stress and hydrostatic pressure variation (Figure 3.2).  Computer control over 
the valves regulating the vacuum allows user-specific stretch regimens to be used.  Rigid posts 
positioned under the membrane provide a defined stretch direction to the membranes.  In the 
experiments described here an arctangle loading post was used to impart uniaxial stretch.  The 
FX4000T unit is designed such that up to 4 plates (24 total wells) can be stretched at a desired 
level during each use. 
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 Figure 3.2: Cyclic stretch in the FX4000T is controlled by the FlexCentral® computer, which opens valves in the 
FlexLink® controller that shuttle vacuum in and out of the Baseplate (far left).  The applied vacuum from below 
pulls the deformable culture surface downward.  Rigid pots constrain the deformation to achieve uniaxial tension 
(far right).  Figure adapted from www.flexcellint.com.  
3.2.2.2 Shear stress apparatus 
Laminar shear stress for these experiments was provided by the Streamer® (Flexcell) 
system (Figure 3.3).  This system has been previously established as a means to impose shear 
stress on a cellular monolayer [602, 619, 620].  Briefly, culture medium is pumped from a central 
reservoir via a computer-controlled peristaltic pump (MasterFlex® L/S® 7550-30, Cole Parmer) 
through two pulse dampeners (MasterFlex® L/S® 7596-20, Cole Parmer) that eliminate high 
frequency noise and establish a steady flow rate.  The culture medium then enters into a stainless 
steel parallel plate chamber (Figure 3.3 inset) that holds 6 microscope slides upon which the 
cells are grown before returning to the reservoir.  Gas exchange occurs through the platinum-
cured silicone tubing (MasterFlex® L/S® 17, Cole Parmer) that connects each component.  The 
applied shear stress (τ) is controlled by the flow rate of the culture media, which is given by   
 
2
6
wh
Qμτ = (3.1) 
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where Q is the flow rate in each channel, and w and h are the width and height of each channel, 
respectively.   
 
 
Figure 3.3: The Streamer® consists of six identical parallel plate chambers (inset).  Fluid flow is imparted by a 
computer-controlled roller pump, and two serial pulse dampeners that ensures a steady laminar flow is delivered to 
the shear stress chamber.  The entire setup can be contained in a standard CO2 incubator, as shown.  Figure adapted 
from www.flexcellint.com.  
 
3.2.2.3 Cyclic pressure apparatus 
The cyclic pressure apparatus employed in these studies (Figure 2.1 Figure 3.4 and ) was 
developed in our laboratory and is fully described in Chapter 2.0 and in Maul et al.[1].  This 
apparatus holds 6 microscope slides that are identical to those used in the Streamer® shear stress 
system (see Section 3.2.2.2) and is housed in the same incubator as the Streamer®.   
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Figure 3.4: Images of the cyclic pressure system (left) and cyclic pressure chamber (right) during an experiment.  
As detailed in Chapter 2.0, the respiratory humidifier is fed with a pressurized sterile IV water source, and a clinical 
pressure monitor displays the pressure of both the cyclic pressure chamber and the humidifier.  The cyclic pressure 
system was designed to take up minimal space in the incubator to allow the Streamer® to fit into the same incubator 
(seen in lower part of the right image) for the Mechanical Panel experiments. 
 
3.2.3 Experimental Design 
3.2.3.1 Substrate 
The goal of this research was to determine what role mechanical forces play in the 
differentiation of BMMSCs towards SMCs and ECs for use in vascular regenerative medicine. In 
addition to the mechanical environment, stem cell differentiation is modulated by numerous 
other stimuli, including exogenous growth factors (discussed in Section 1.4.2.1), oxygen tension 
[621-623], and ECM [545, 556, 624, 625].  Therefore, the potential ECM molecules upon which 
to culture the tBMMSCs during experimentation included collagen I, fibronectin, laminin, and 
collagen IV since these are predominantly found within the vasculature [625]. Because the focus 
of this study is on the mechanical stimulation of BMMSCs, the choice of substrate must be 
motivated first by the ability of the substrate to maintain cellular adhesion. Salasznyk et al. [624] 
determined that, of the above choices, BMMSCs adhere best to fibronectin, followed by collagen 
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I.  Furthermore, both fibronectin and collagen I are known to facilitate angiogenesis and are 
found in abundance in areas of vascular remodeling and injury, whereas laminin I is known to 
arrest cell growth and migration in vivo [625]. Fibronectin has been previously shown to have no 
effect on differentiation of BMMSCs [624], but has also been used in research inducing EC and 
SMC differentiation from BMMSCs [42, 262]. Collagen I has been shown to facilitate 
osteogenic differentiation in BMMSCs [624, 626, 627], but has also been used by our laboratory 
[628] and others [527] in generating SMC precursors from BMMSCs under cyclic stretch.  
Based on previous experience, collagen I was chosen as the substrate for our experiments, but 
fibronectin would have been a viable alternative and may be considered for future work.    
3.2.3.2 Dose-response of tBMMSCs to mechanical stimulation 
Experiments performed to address Specific Aim 2 were designed to determine dose-
dependent response of tBMMSCs to varying magnitudes and frequencies of each separate 
mechanical force stimulus; i.e., laminar shear stress, cyclic stretch, and cyclic hydrostatic 
pressure.  Because the ultimate goal of this research is to determine how to appropriately utilize 
mechanical stimulation to create a tissue engineered blood vessel, the magnitudes and 
frequencies utilized for these experiments were chosen to be consistent with the magnitudes and 
frequencies found in the vasculature [192, 612].   
For each experiment, tBMMSCs were obtained as described in Section 3.2.1 and seeded 
at 200 cells/cm2 on collagen I coated BioFlex™ (Flexcell) deformable substrates for CS and 
control conditions, or Culture Slips™ (Flexcell) for LSS and CP conditions.  Forty-eight hours 
after seeding, the tBMMSCs were loaded into each of the systems described in Sections 3.2.2 
while control samples were placed in static incubator conditions.  For some experiments, a T0 
sample was also obtained immediately following the 48 hours culture but prior to stimulation in 
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the event that the particular subset of cells for that given experiment were needed to determine 
the baseline values for the endpoints listed in Section 0.   
The mechanical stimulation regimens used for these experiments can be found in Table 
3.1.  Neonatal stimuli for CS and CP are consistent with magnitudes and frequencies associated 
with vital signs shortly after birth [612].  Hypotensive, normotensive, and hypertensive 
magnitudes and frequencies were chosen to be consistent with those values reported for adults 
[192].  For the neonatal/sub-physiologic and hypotensive CS and CP stimuli, the magnitudes 
were chosen to not only be consistent with physiologic ranges of magnitude, but also to be 
identical in magnitude so as to provide a pure frequency response.  Shear stress values for 
hypotensive, normotensive, and hypertensive stimuli are consistent with those found throughout 
adult circulation [192].  Each of the stimuli was applied in parallel to provide the benefits of 
Mechanical Panel stimulation as described in Section 3.1.1.  Because the shear stress system 
used for these studies was not capable of applying cyclic shear stress, no frequency response 
could be determined for LSS.  The shear stress found under the heading of neonatal/sub-
physiologic stimulus was set as the lowest shear stress capable of being generated by the 
Streamer® to determine the effects of minimal flow.  Although it may not be necessarily 
reflective of neonatal physiology, it was grouped with the neonatal/sub-physiologic stimuli (see 
Table 3.1). 
Each of the dose-response experiments lasted for 5 days. Dissolved gas measurements 
(see Section 2.2.3.4) were made in the systems to track dissolved gas and pH changes throughout 
the experiments.  The endpoints for these experiments included morphology (see Section 
3.2.4.1), proliferation (see Section 3.2.4.2), histology (see Section 3.2.4.3), antibody staining (see 
Section 3.2.4.4), and gene expression (see Section 3.2.4.5).   
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Table 3.1: Applied stimuli for Mechanical Panel experiments to determine the dose-response of tBMMSCs to 
different magnitudes and frequencies of mechanical stimulation.  See text for further detail about stimulus headings.  
Parenthetical terms denote abbreviations for each of the stimuli.  For example, CS-1 denotes 1% 1 Hz cyclic stretch, 
and LSS-1 denotes 1 dyne/cm2 laminar shear stress.  CS-1HF denotes cyclic stretch at 1% at 2.75 Hz stimulation 
(high frequency).   
 
Neonatal/      
Sub-physiologic  
Stimulus 
Hypotensive 
Stimulus 
Normotensive 
Stimulus 
Hypertensive 
Stimulus Stimulus 
1%, 2.75 Hz 1%, 1 Hz 5%, 1 Hz 10%, 1 Hz Cyclic Stretch (CS-1HF) (CS-1) (CS-5) (CS-10) 
180/140 mmHg, 
1 Hz 
120/80 mmHg, 
1 Hz 
90/70 mmHg,    
1 Hz 
90/70 mmHg, 
2.75 Hz Cyclic Pressure 
(CP-180) (CP-120) (CP-90) (CP-90HF) 
1 dyne/cm2 5 dynes/cm2 10 dynes/cm2 20 dynes/cm2 Shear Stress (LSS-5) (LSS-10) (LSS-20) (LSS-1) 
Static incubator conditions (37oC, 5% CO2, 95% humidity) Control 
 
3.2.4 Endpoint assessment 
3.2.4.1 Morphology 
At the termination of each experiment described in Section 3.2.3.2, designated samples 
were fixed with 4% paraformaldehyde for 5 minutes and washed 3 times with PBS.  Next, the 
samples were incubated with Coomassie Brilliant Blue R-250 (Pierce, Rockford, IL) total protein 
stain (to enhance contrast) for 5 minutes followed by 5 washes with PBS.  Ten random fields of 
view were digitally photographed (CoolPix, Nikon) under 100x magnification on an inverted 
phase-contrast microscope (TS100, Nikon).  Artificial borders were drawn as necessary to 
separate the cells for the edge-detection function in Scion Image [526, 629, 630].  Area, 
perimeter, major axis, minor axis, and angle of orientation were measured automatically within 
Scion for each cell.  A photograph of a hemocytometer with Neubauer rulings was used for 
measurement calibration and was input into a custom-built Excel macro (see Appendix D) that 
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handled all data exported from Scion Image (Version 4.0.3.2, Scion Corporation, Frederick, 
MD). In addition, the macro used these measurements to calculate the shape index (SI) for each 
cell in the field of view, which is defined as: 
 
 4SI 2P
Aπ= (3.2) 
 
where P and A are the perimeter and area of the cell, respectively, measured by Scion Image.  
The value of SI is 1 for cells that are perfect circles and approaches 0 for cells that are spindle 
shaped [631].  The perimeter, major axis, and minor axis measurements were also used to 
calculate the tortuosity index, which is defined as:  
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where a and b are the major and minor axes, respectively, of the cell.  The tortuosity index 
indicates the cell’s smoothness, by comparing the measured perimeter to the computed perimeter 
of a perfect ellipse constructed with the cell’s measured major and minor axes.  Therefore a 
value for TI of 1 represents a cell whose perimeter is identical to a perfectly smooth ellipse and 
rises as the cell shape becomes more tortuous [188, 396, 632].   
3.2.4.2 Proliferation 
At the termination of each experiment described in Section 3.2.3.2, designated samples 
were fixed with 4% paraformaldehyde for 5 minutes and washed 3 times with PBS.  A 0.1% 
solution of Triton-X 100 (Sigma) in PBS was added for 30 minutes followed by 3 washes in PBS 
to permeabilize the cell membranes.  To stain the nuclei, DAPI (5mg/mL, Sigma) was added for 
1 minute followed by 5 washed in PBS.  The samples were photographed with a SPOT RT 
 108 
digital CCD camera (Diagnostic Instruments) at 200x on an epifluorescent microscope (E800, 
Nikon).  Total nuclear counts from ten random fields of view were used to quantify proliferation.  
The size of each field of view was determined with a 1 mm stage micrometer ruled to 0.01 mm 
(12-561-SM1, Fisher Scientific, Pittsburgh, PA).  This value and the averaged number of cells 
per field of view were used to compute the cell density reported as cells/cm2. 
3.2.4.3 Histology 
At the termination of each experiment described in Section 3.2.3.2, designated samples 
were fixed with 4% paraformaldehyde for 5 minutes and washed 3 times with PBS.  To 
determine possible osteogenic differentiation and adipogenic differentiation, selected samples 
were stained with Alizarin Red (3.2.1.1.1) or Oil Red O (3.2.1.1.2), respectively. 
3.2.4.4 Immunohistochemistry (IHC) 
3.2.4.4.1 General methods 
At the termination of each experiment described in Section 3.2.3.2, designated samples 
were fixed with 4% paraformaldehyde for 5 minutes and washed 3 times with PBS.  The samples 
were then incubated for 30 min with 0.1% solution of Triton-X 100 in PBS to permeabilize the 
cell membranes.  Non-specific binding of antibodies (listed in Section 3.2.4.4.2) was blocked by 
incubation for 45 minutes with 5% BSA (Fraction V, Sigma) in PBS followed by 5 washes with 
a solution of 0.5% BSA, 0.15% glycine (Sigma) in PBS (PBS/BSA/Gly).  Next, the samples 
were incubated with the primary antibody diluted in PBS/BSA/Gly for 60 min in a moist 
chamber to prevent drying of the samples. Unbound primary antibody was removed by 5 washes 
with PBS/BSA/Gly.  The samples were incubated with the secondary antibody (1:500) diluted in 
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PBS/BSA/Gly for 1 hour at room temperature in a moist chamber and then rinsed 3 times with 
PBS.  For nuclear visualization, cells were counterstained with DAPI (Invitrogen) for 1 minutes 
followed by 5 washes with PBS.  A negative control (primary delete) was prepared each time 
antibody staining occurred.  This sample was prepared in an identical manner to all other 
samples, but the primary antibody was left out of the 1 hour incubation in PBS/BSA/Gly.  All 
steps described for IHC staining occurred at room temperature (RT).   
3.2.4.4.2 Antibodies for IHC 
For all experiments, the samples were labeled with monoclonal antibodies against SMC, 
and EC markers (Table 3.2).  For markers of SMCs, SMA was used for a synthetic phenotype, 
and h1-calponin and SM-MHC were used for a full contractile phenotype.  For markers of ECs, 
flk-1 was used to denote EC potential, and vWF and PECAM were used as mature phenotypic 
markers.  All secondary antibodies for the antibodies listed in Table 3.2 were donkey anti-mouse 
conjugated with Alexa 488 fluorophore (Sigma).  All primary and secondary antibodies were 
provided by the University of Pittsburgh Center for Biological Imaging.   
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Table 3.2:  Antibodies and dilutions for IHC 
 
Classification Antibody Dilution Catalog Number Manufacturer 
SMC SMA 1:500 MAB1522 Chemicon, Temecula, CA 
SMC h1-calponin 1:400 M3556 Dako, Carpinteria, CA 
SMC SM-MHC 1:400 M3558 Dako 
EC Flk-1 1:200 Sc-6251 Santa Cruz Biotechnology, Santa Cruz, CA 
EC vWF 1:100 V1180 Biomeda, Foster City, CA 
EC PECAM 1:100 Mab1393 Santa Cruz 
 
3.2.4.4.3 Fluorescent microscopy 
Following antibody staining, the samples were mounted on glass microscope slides 
(Fisher) in gelvatol (10% polyvinyl-alcohol (Sigma), 21% glycerol (Sigma), and 0.1 M Tris (pH 
8.5, Sigma) in deionized water).  The samples were placed overnight at 4oC to cure the gelvatol 
before microscopy.  Fluorescent microscopy was performed at 200x on an epifluorescent 
microscope (E800, Nikon).  The primary delete sample was placed under the microscope under 
the FITC filter set to determine the background signal from the secondary antibody.  The 
exposure time on the camera (SPOT RT, National Diagnostics) was increased until non-specific 
staining from the secondary antibody was visible.  This exposure time was recorded and all 
subsequent images from the samples containing primary and secondary antibody was set below 
this level.  Three to five images were taken from different areas of the culture for each antibody.  
Representative images for each antibody are shown in Section 3.3.5. 
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3.2.4.5 RNA isolation and PCR 
3.2.4.5.1 RNA isolation 
At the termination of experiments outlined in Section 3.2.3.2, Section 4.2.1, and Section 
5.2.1, samples were processed for RNA isolation and purification (see Figure C.1 in Appendix 
C).  Protein was also extracted from experiments outlined in Section 3.2.3.2 using techniques 
outlined in Section 4.2.2.3, but was not of sufficient quantity to perform Western blotting.   
All steps outlined in the following subsections were carried out in RNAse-free conditions 
at RT unless otherwise noted.  As soon as each experiment was completed, samples were 
removed from the Mechanical Panel and rinsed in RNAse-free 4oC PBS.  The PBS was aspirated 
and followed by the addition of 1 mL of Trizol® (Invitrogen) for each BioFlex® well or 2mL of 
Trizol® for each CultureSlip®.  Trizol® is a proprietary cell lysis buffer containing monophasic 
solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA, DNA, and 
proteins [633]. Isolation procedures described here are based upon the single-step RNA isolation 
method developed by Chomczynski and Sacchi [634].  After 2 minutes, each sample within a 
given mechanical stimulus was scraped with a fresh, sterile cell scraper (Greiner Bio-one, 
Monroe, NC).  Each sample was rinsed 3 times with its Trizol® and then serially transferred, 
ending in a sterile RNAse-free polypropylene conical tube (Falcon) and frozen at -80oC for 
further processing to extract the intracellular components. 
3.2.4.5.2 RNA Purification 
After 24 total samples were collected in Trizol® (approximately 5-6 Mechanical Panel 
experiments), RNA purification was performed under RNAse-free conditions at RT unless 
otherwise noted.  First, the samples were defrosted at 30oC for 20 minutes in a heat block (Heat 
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Block 2 Model #049302, VWR, West Chester, PA) and vortexed (Vortex Genie 2, Model #6-
650, Scientific Industries, Bohemia, NY) every 5 minutes to ensure that the entire cell lysate was 
well-mixed.  Next, 0.2mL of chloroform (9180-33, J.T. Baker, Phillipsburg, NJ) was added to 
each tube using a sterile 5 mL glass pipette (Falcon).  Each tube was shaken by hand for 15 
seconds, vortexed, and placed at 30oC in the heat block for 10 minutes with vortex agitation 
every 5 minutes.  After the incubation, the samples were centrifuged (Legend RT, Sorvall, 
Newtown, CT) at 3500 x g for 30 minutes at 4oC.  The chloroform caused the separation of the 
aqueous and organic phases of the Trizol®-cell lysate mixture, with the RNA being held in the 
aqueous layer.  The aqueous layer was removed by transfer with a sterile polystyrene pipette 
(Falcon) for each sample and placed in a fresh, sterile, 50 mL conical polypropylene tube 
(Falcon).  The remaining organic layer was placed back at -80oC for subsequent processing of 
the DNA and protein content (see Section 4.2.2.3).   
The aqueous layer containing the RNA was then processed using a protocol modified 
from the Qiagen RNeasy Clean-up Kit (Qiagen, Valencia, CA) [635].  For each 100 µL of 
aqueous layer, 350 µL of RLT buffer (Qiagen) containing 0.1% β-mercaptoethanol (M-6250, 
Sigma) was added and mixed thoroughly by shaking.  Next 250 µL of 100% ethanol 
(111ACS200, Pharmco-AAper, Brookfield, CT) was added and mixed thoroughly by vortexing.  
Each RNA/RLT/ethanol mixture was loaded into an RNeasy column (Qiagen) arranged on a 
manifold (QiaVac 24 Plus, Qiagen) and pulled through under standard house vacuum.  These 
columns contain a proprietary packed-bed that selectively binds RNA under reducing conditions.  
Once the samples have been run into the columns, the vacuum was removed and 350 µL of 
buffer RW1 (Qiagen) was added to each column and drawn through with vacuum.  Following 
this wash, 80 µL of DNAse I solution (79254, Qiagen) was pipetted directly on top of the 
 113 
column and allowed to penetrate for 20 minutes at RT.  Following another 350 µL wash of 
buffer RW1 pulled through the column by vacuum, 750 µL of buffer RPE (Qiagen) was added to 
the column and pulled through under vacuum.   
The columns were removed from the manifold and placed into RNAse-free 2.0 mL 
round-bottomed collection tubes.  Another 250 µL of buffer RPE was added and the columns 
were centrifuged at 16,000 x g at RT (5415R, Eppendorf, New York City, NY) for 1 minute.  
The flow-through and collection tube were discarded, replaced with a fresh collection tube, and 
the columns re-centrifuged for 1 minute.  Again, the collection tube was discarded, and the 
columns placed in fresh 1.5 mL conical collection tubes (Qiagen).  The RNA bound to the 
columns was extracted in 30 µL of RNAse-free water (Qiagen) added directly to the top of each 
column.  The columns were centrifuged at 16,000 x g at RT for 1 minute, and the extracted RNA 
solution was pipetted back onto the top of the columns and then re-centrifuged for 1 minute to 
ensure that all available RNA was extracted from the column.   The final 30 µL RNA solution 
was transferred from the 1.5 mL conical collection tube to an RNAse-free 1.5 mL 
microcentrifuge tube (Ambion, Austin, TX) and stored at -80oC for analysis of RNA quantity 
and quality (Section 3.2.4.5.3) followed by conversion to cDNA by reverse transcriptase (Section 
3.2.4.5.4) and polymerase chain reaction (PCR) analysis of gene expression (Section 3.2.4.5.5).   
3.2.4.5.3 Analysis of RNA quality 
All collected RNA was analyzed for quality and quantity at the core genomics facilities 
of the University of Pittsburgh or the Gene Expression and Genotyping Facility (GEGF) at Case 
Western Reserve University.  Briefly, 1 µL of purified RNA (described in Section 3.2.4.5.2) was 
placed into a capillary electrophoresis chip (RNA 6000 Nano, Agilent, Santa Clara, CA) 
prepared according to manufacturer’s protocols and loaded into the Bioanalyzer (Model 2100, 
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Agilent).  The assay results were analyzed with the 2100 Expert software (v1.5, Agilent) to 
determine the concentration and RNA integrity number (RIN), which is a measure of RNA 
quality.  The concentration and RIN results were used to determine if the samples were viable for 
PCR analysis.  Concentrations greater than 10 ng/µL and RIN values greater than 8 were 
considered of high enough quality to perform PCR analysis.   
3.2.4.5.4 Reverse transcriptase reaction 
RNA samples determined to have high quality and sufficient concentration to perform 
PCR analysis were selected for reverse transcriptase (RT) conversion of the RNA to cDNA with 
the High-Capacity cDNA Reverse Transcription Kit (4374967, Applied Biosystems, Foster City, 
CA).  These techniques were also performed according to the manufacturer’s instructions by the 
core genomics facilities of the University of Pittsburgh or Case Western Reserve University.  
Briefly, 10 µL of 2X RT Master Mix (10x RT buffer, 10x random primers, 25x dNTP, 
MultiScribe™ reverse transcriptase, and RNAse inhibitor) was combined with 10 µL of purified 
RNA (as described in Section 3.2.4.5.2) and centrifuged briefly to remove any air bubbles and to 
bring all reactants together.  The combined RT Master Mix and RNA was placed on a thermal 
cycler (9700, Applied Biosystems) with settings according to Table 3.3.  The resulting cDNA 
was stored at -80oC prior to downstream analysis.   
 
Table 3.3: Thermal cycler protcol used for RT reaction. 
 
Step 1 Step 2 Step 3 Step 4  
Temperature (oC) 25 37 85 4 
Time 10 minutes 120 minutes 5 seconds ∞ 
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3.2.4.5.5 Real-time PCR analysis  
Real-time PCR (RT-PCR) analysis of the RT product described in Section 3.2.4.5.4 was 
performed using a custom-designed TaqMan® low density PCR array (TLDA, Applied 
Biosystems).  The gene names, phenotypic classifications, and Applied Biosystems catalog 
numbers for the custom-designed TLDA card are listed in Table 3.4.  The TLDA is a custom-
configured 384 well microfluidics microplate that contains pre-loaded TaqMan® gene expression 
assays.  It offers the ability to quickly assay 32 genes by quantitative PCR from 4 experimental 
samples in triplicate.  TaqMan® gene expression assays are built on 5’ nuclease chemistry, with 
each assay containing two unlabeled PCR primers and a FAM™-dye labeled minor groove 
binding TaqMan® PCR primer.  The TaqMan® primers for the TLDA are subject to the 
availability of the primer in stock; therefore no custom or low-demand primers were available.  
Working within these limits, primers were chosen to represent almost all possible phenotypic 
outcomes that could be associated with BMMSCs following stimulation via the Mechanical 
Panel. 
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Table 3.4: List of TaqMan® PCR primers, their classifications and catalog numbers for the first custom-designed 
TLDA 
 
Classification Gene Name Applied Biosystems Catalog #
Adipocyte PPAR gamma Rn00440945_m1 
Anti-Apoptosis BCL-2 Rn99999125_m1 
Apoptosis Caspase 3 Rn00563902_m1 
BMMSC CD59 Rn00563929_m1 
BMMSC CD90 Rn00562048_m1 
Cardiomyocyte Troponin Rn00437164_m1 
Chondrocyte Aggrecan I Rn00573424_m1 
Chondrocyte Collagen II Rn00563954_m1 
EC CD133/Prominin I Rn00572720_m1 
EC Endoglin Rn00568869_m1 
EC Flk-1 Rn00564986_m1 
EC iNOS Rn00561646_m1 
EC vWF Rn00788354_m1 
Endothelial cell adhesion 
molecule (ESAM) Rn-1531509_g1 EC 
Fibroblast Vimentin Rn00579738_m1 
Housekeeping Ribosomal protein 18 (18s) Rn02133666_u1 
ECM Collagen I Rn00584426_m1 
ECM Collagen III Rn01437683_m1 
ECM Collagen IV Rn01401018_m1 
ECM Elastin Rn01499782_m1 
Myocyte Desmin Rn00574732_m1 
Osteoblast Alkaline Phosphatase Rn00564931_m1 
Osteoblast Osteocalcin Rn00566386_g1 
Osteoblast RUNX2 Rn01512296_m1 
Secreted Peptides BMP2 Rn00567818_m1 
Secreted Peptides FGF2 Rn00570809_m1 
Secreted Peptides Rn00572010_m1 TGF-β 
Secreted Peptides VEGF Rn00582935_m1 
Secreted Peptides Rn00562055_m1 TNFα 
SMC Caldesmon Rn00565719_m1 
SMC Rn00580659_m1 SM22α 
SMC Calponin Rn00582058_m1 
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 3.2.4.5.5.1  PCR amplification and detection 
The PCR reaction was performed according to the manufacturer’s specifications by the 
core genomics facilities at the University of Pittsburgh and Case Western Reserve University.  
For the TLDAs, 50 µL of 2X PCR Master Mix (4304437, Applied Biosystems) and 
approximately 400ng of cDNA (from Section 3.2.4.5.4) diluted to a volume of 50 µL in RNAse-
free water were combined in a 1.5 mL microcentrifuge tube, mixed well, and centrifuged.  The 
PCR Master Mix/cDNA mixture was pipetted into two loading ports on the TLDA and 
centrifuged at 330 x g twice for 1 minute.  The individual reactions in the TLDA plate were then 
sealed using the Applied Biosystems sealing device which uses precision stylus assembly to seal 
the main fluid distribution channels in the TLDA.  The TLDA was then loaded into the 7900HT 
Fast Real-Time PCR System (Applied Biosystems) and run for 40 cycles.   
3.2.4.5.5.2 PCR data analysis 
All data generated by either the TLDA RT-PCR run was analyzed by the ΔΔCT method  
with SDS Software (Version 2.0, Applied Biosystems) [636].  The built-in automatic 
thresholding and outlier removal algorithms were used to determine the threshold cycle (CT) for 
each gene.  A relative quantitation (RQ) analysis was then performed using the CT of the 
endogenous to normalize each sample followed by normalization to the control sample for each 
gene assayed.  The resulting fold-changes in gene expression compared to controls were 
exported to Microsoft Excel, where a custom-built macro was used to arrange the data for export 
to the Experimental Database (see Section 3.2.5.1).  The RQ values for each experiment were 
averaged to provide the average change in gene expression compared to controls.    
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3.2.4.5.5.3 RT negative control 
Wherever possible, the primers chosen for the custom-designed TLDA spanned an exon, 
and were thus only capable of non-genomic amplification (designated by “m1” in the catalog 
number).  Inevitably, there were some primers which did not span an exon, and could potentially 
amplify genomic DNA.  Thus four RT-negative samples, derived from one Mechanical Panel 
experiment were handled as described in Section 3.2.4.5.4 but lacking the MultiScribe™ reverse 
transcriptase enzyme in the 2X RT Master Mix.  These samples were analyzed on a TLDA card 
to determine what genomic amplification, if any, was occurring in the primers chosen.  
Regardless of the outcome of the RT negative sample, no genomic amplification was anticipated 
in any of the experimental samples as a result of the DNAse treatment in the RNA purification 
protocol (Section 3.2.4.5.2). 
3.2.4.5.5.4 Determination of the dynamic range 
In order to determine the optimal RNA mass for efficient RT and detection of a majority 
of the genes in the TLDA, the following experiment was performed using the TLDA 
configuration in Table 3.4.  The dynamic range was determined by performing the RT reaction 
(see Section 3.2.4.5.4) on a starting mass of RNA that spans at least 4 logs.  The RNA used for 
this purpose was Universal Rat RNA (636658, Clontech, Mountain View, CA) to ensure that all 
genes queried would show detectable amplification within 40 cycles.  The RT reaction was 
initialized with 1, 10, 100, and 1000 ng of universal RNA, and analyzed (see Appendix H).  The 
results helped to determine the range for the loading amount of RNA (assuming 100% 
conversion to cDNA) for the TLDA and single reaction assays.   
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3.2.5 Data storage and statistical analysis 
3.2.5.1 Database design and utilization 
All data (including images, spreadsheets, PDFs, SDS files, etc.) were stored in a custom-
built Access (v2003, Microsoft Corporation, Redmond, WA) database for easy retrieval and 
export to statistical analysis software.  The database was designed as fourth normal form to 
eliminate redundant fields and provide a modular framework that has utility outside of this 
particular research project [637].  A detailed description and framework of the database is found 
in Appendix E. 
3.2.5.2 Statistical analysis from database contents 
All quantifiable data (e.g., morphologic measurements, PCR, etc.) stored in the 
experimental database (Section Appendix E3.2.5.1 and ) were exported to the statistical package 
(SPSS v.13, SPSS Inc., Chicago, IL) for subsequent analysis.   
3.2.5.2.1 Proliferation, morphology, and gene expression statistics 
The data exported from the experimental database were categorized along each stimulus 
(control, CS, CP, or LSS).  Paired t-tests were then used to make all comparisons between each 
stimulus and the control values with α=0.05.  Next the data was filtered to compare differences 
within the stimulus (CS, CP, or LSS) at each of the four different magnitudes and/or frequencies 
of stimulation.  The data were also explored using the Komolgorov-Smirnov test for normality as 
well as box plots for outlier and extreme value analyses.  Outliers were defined as points falling 
between 1.5 and 3 times the interquartile range from either the upper or lower quartile in the box 
plot.  Extreme values were defined as points falling greater than 3 times the interquartile range 
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from either the upper or lower quartile in the box plot [638].  Data points identified as outliers 
and extreme values were excluded from further analysis.  The Levene statistic was first used to 
test the homogeneity of variance.  For data with non-homogeneous variance, the Brown-Forsythe 
test was used to calculate the F-statistic for ANOVA.  Data with a homogenous variance was 
assessed with the standard F-statistic.  For post-hoc testing, assuming homogenous variance, the 
Fisher’s least significant difference (LSD) was used to compare between groups since all 
comparisons were proposed a priori.  Data with unequal variance was compared using the 
Games-Howell test because of its utility with small sample sizes (n<6) [639].  In addition to 
comparisons of means between magnitudes and frequencies of stimulation, the Spearman rank-
correlation was calculated to determine possible relationships between the measured values and 
the frequency and magnitudes of stimulation.  For comparisons between stimuli, the data were 
re-categorized along lines of similar magnitude (see Table 3.1), and analyzed with one-way 
ANOVA as described above.   
3.2.5.2.2 Analysis of Cellular Alignment 
Because the data from the measurement of cellular orientation was in degrees, circular 
statistics were determined to be the most appropriate measure of the distribution of the cellular 
orientation.  For such data, a uniform distribution around the circumference of a circle was 
assumed to be the true population distribution.  The probability density function described by 
this distribution is: 
 
πθπθ 20   ,21)( ≤≤=f (3.4) 
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and implies that the probability of being at any given angle is equal.  Thus, there is no preferred 
direction to the orientation of the cells, which is the expected outcome for cells growing 
randomly on any given surface.   
For each experiment, the measured angle for each cell was given by the unit polar 
coordinates (αi, r), where r equals 1.  These were converted into rectangular coordinates (xi, yi), 
where xi is given by:  
(3.5) )2cos( ii rx α=
 
and yi is given by: 
(3.6) )2sin( ii ry α=
 
Because the measured angle for each cell was only on the 0-180o plane, 2αi was used to 
normalize the data on a 360o circle [640]. 
Next, the average x-coordinate for each experiment was calculated by a simple arithmetic mean: 
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where n is the total number of cells for which the angle αi was measured.  Likewise, the average 
y-coordinate for each experiment was calculated by:  
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(3.8) 
 
The results of Equation (3.7) and Equation (3.8) were used to give the length of the resultant 
vector R for the coordinates (X, Y):  
 22 YXR += (3.9) 
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 The polar direction of R was assumed to be the circular mean direction for that experiment and 
was calculated as the common angle in the 0-180o quadrant satisfying both parts of the 
following: 
 ⎟⎠
⎞⎜⎝
⎛=⎟⎠
⎞⎜⎝
⎛= −−
R
Y
R
Xa 11 sin*5.0 cos*5.0 (3.10) 
 
Next, the average angle from each the experiment was used to compute the ranked second order 
(average of the average) X -coordinate:  
∑
=
=
n
k
kakX
1
)*2cos(* (3.11) 
 
where k is the rank of each average angle, āk, for each of the n experiments.  Likewise, the 
ranked second order Y -coordinate was computed from: 
∑
=
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(3.11) and (3.12) were used to compute the non-parametric Rayleigh’s R*: The results of 
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The probability that R*>r is given by:   
 ( )1122* )12()1(6 −− ++−= nnnRep (3.14) 
 
which tests the null hypothesis of uniform distribution on the ranked second order vectors  [640].   
For graphical purposes, a linear histogram was used, with the measured angle for each 
cell being placed in one of eighteen bins between 0o and 180o with a binwidth of 10o.  For data 
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that appeared to be bimodal at 0o and 180o, measured angles were transformed by 90o to bring 
potential peaks together as a unimodal distribution.  This was the case for tBMMSCs exposed to 
LSS where the measured angles were initiated along the direction of flow, resulting in potential 
bimodal peaks at 0o and 180o.   
3.3 
3.3.1 
RESULTS 
Multipotentiality of tBMMSC  
Positive Alizarin Red staining of tBMMSCs exposed to osteogenic media (recall Section 
3.2.1.1.1) and positive Oil Red O staining of tBMMSCs exposed to adipogenic media (recall 
Section 3.2.1.1.2) indicated a successful differentiation of the tBMMSCs into these two cellular 
phenotypes (Figure 3.5) and confirmed the multipotentiality of the cells in our hands.   
 
    
A) B) 
 
Figure 3.5:  (A) Alizarin Red staining of tBMMSCs following osteogenic induction under defined media conditions 
confirms matrix mineralization.  (B) Oil Red O staining of tBMMSCs following adipogenic induction under defined 
media conditions confirms lipid formation within the cells.  Taken together, these images demonstrate that the 
tBMMSCs are multipotent.  Represenative images taken at 100x.   
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3.3.2 Morphology 
Representative images of each stimulus (Figure 3.6) showing gross changes in cell size, shape, 
and alignment demonstrate that mechanical stimulation differentially altered the morphology of 
tBMMSCs.  These observations were confirmed through morphometric analysis of the area, 
major axis, perimeter, and angle data (see Section 3.2.4.1), which is detailed below.   
3.3.2.1 Area changes 
The mean cellular area and normalized cellular area (calculated by division of the area 
measurement by the control values) are presented as the average ± SEM in Figure 3.7.  Area 
measurements for tBMMSCs exposed to LSS-1 (9.6 ± 1.2 x103 μm2, n=4),  
LSS-5 (15.8 ± 1.3 x103 μm2, n=6), LSS-10 (10.3 ± 1.4 x103 μm2, n=6), and  
LSS-20 (10.3 ± 1.1 x103 μm2, n=5) were all significantly elevated (p<0.05) when compared to 
control.  Within LSS, the normalized area measurements for LSS-1 were significantly larger 
(p<0.05) than LSS-5, LSS-10, and LSS-20.  Correlation statistics demonstrate a dose-response to 
LSS, with increasing LSS leading to decreasing cellular area (ρ= -0.547, p<0.05).   
Under the cyclic pressure stimulus, there was a significant (p<0.05) decrease in cellular 
area for tBMMSCs exposed to CP-90HF (2.0 ± 0.5 x103 μm2, n=4), CP-90 (2.2 ± 7.6 x103 μm2, 
n=5), CP-120 (2.8 ± 3.5 x103 μm2, n=6), and CP-180 (1.9 ± 2.7 x103 μm2, n=6) when compared 
to controls.  Within CP, the normalized area measurements for CP-90HF were significantly 
larger (p<0.05) than CP-90 and CP-120, and nearly significantly larger (p=0.06) than CP-180.  
Correlative statistics did not indicate there was any type of dose-response to the magnitude or 
frequency of stimulation for tBMMSCs exposed to CP, but there was a statistically significant 
difference in area for tBMMSCs exposed to CS-1 vs. CS-1HF (p<0.05).   
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 LSS-20 CP-180 CS-10 
LSS-10 CP-120 CS-5 
LSS-5 CP-90 CS-1 
LSS-1 CP-90HF CS-1HF 
 
Figure 3.6: Representative images of coomassie brilliant blue stained tBMMSCs following 5 days of exposure to 
the Mechanical Panel.  All images taken at 100X.   
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No significant change in area was detected for tBMMSCs exposed to CS-1HF (4.3 ± 0.9 
x103 μm2, n=4), CS-5 (3.9 ± 0.6 x103 μm2, n=6), and CS-10 (5.9 ± 0.8 x103 μm2, n=6) compared 
to controls.  However, tBMMSCs did show a significant (p<0.05) decrease in cellular area 
compared to controls when exposed to CS-1 (2.5 ± 0.2 x103 μm2, n=4).  In fact, the measured 
cellular area for tBMMSCs exposed to CS-1 was very similar to those measured at all levels of 
CP.  Within CS, CS-1 was significantly (p<0.05) smaller than CS-1HF and CS-5.  When 
comparing CS across the same frequency, there was a threshold effect but no significant 
correlation as a dose-response.   
Comparisons across stimuli indicate that tBMMSCs exposed to CS or CP were 
significantly (p<0.05) smaller in size than LSS.  In addition CP-120 was significantly (p<0.05) 
smaller than CS-5.  The relationships within and across components of the Mechanical Panel are 
depicted in Figure 3.7B.   
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Figure 3.7 Surface area measurements for tBMMSCs exposed to 5 days of mechanical stimulation.  (A) Raw 
measurements for all experiments.  (B) Area measurements for each component of the Mechanical Panel normalized 
by division by the experimental control.  The dashed line represents control values.  All data presented as the 
average ± standard error of the mean (SEM).  * denotes p<0.05 compared to controls.  + denotes p<0.1 compared to 
controls.  † denotes p<0.01 for means within each stimulus.  (1), (2), (3) denote p<0.05 for means between stimuli of 
corresponding bar color where (1)=CS, (2)=CP, and (3)=LSS. 
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3.3.2.2 Major axis changes 
The measurement of changes in the major axis has previously been interpreted as a 
measure of cellular elongation [526, 641, 642].  The measured major axes and normalized major 
axes (calculated by division of the major axis measurement by the control values) are presented 
as the average ± SEM in Figure 3.8.  Similar to area measurements, major axis measurements 
were significantly (p<0.05) elevated for tBMMSCs exposed to LSS-1 (142.7 ± 5.4 μm, n=4), 
LSS-5 (187.0 ± 6.5 μm, n=6), LSS-10 (147.8 ± 10.7 μm, n=6), and LSS-20 (148.8 ± 8.4 μm, 
n=5) when compared to controls.  Within LSS, the normalized major axis for LSS-1 was 
significantly (p<0.05) more elongated than LSS-5 and LSS-10.  In addition, a moderate negative 
correlation was determined to a dose-response for tBMMSCs exposed to LSS (ρ= -0.641, 
p<0.05).  The data indicates that as the magnitude of shear increased, the length of the major axis 
decreased.   
For tBMMSCs exposed to CP, major axis measurements demonstrated significant 
(p<0.05) decreases at CP-90HF (67.0 ± 1.3 μm, n=4), CP-90 (72.4 ± 12.8 μm, n=5), CP-120 
(79.6 ± 4.9 μm, n=6), and CP-180 (65.0 ± 3.3 μm, n=6) when compared to controls.  Within CP 
experiments, there was a significant (p<0.05) decrease in the normalized major axis from CP-
90HF to CP-90, CP-120, and CP-180.  There was no dose-response correlation for the magnitude 
or frequency of CP stimulation.   
Major axis measurements in tBMMSCs exposed to CS showed only significant changes 
at the 1% stretch magnitude compared to controls.  The major axis was significantly (p<0.05) 
reduced for CS-1 (77.7 ± 3.5 μm, n=4) compared to controls in a similar fashion to the reduction 
found with CP exposure.  However, by increasing the frequency of the applied stretch, CS-1HF 
(97.5 ± 8.0 μm, n=4) demonstrated a significant (p<0.05) increase in major axis length compared 
 129 
to controls.  Although CS-5 (111.3 ± 5.9 μm, n=6) and CS-10 (128.8 ± 8.8 μm, n=6) 
demonstrated increases in the major axis length, only CS-5 was significantly (p<0.05) increased 
compared to controls. Within CS, normalized major axis measurements for CS-1 were 
significantly (p<0.05) shorter than CS-1HF, CS-5 and CS-10.  The major axis measurement was 
weakly correlated for a dose-response for CS (ρ= -0.488, p=0.055), and strongly correlated (ρ= -
0.873, p<0.01) to a frequency-response.   
Comparisons of the major axis lengths across stimuli yielded similar results to the 
comparisons for area across stimuli.  CS-1HF, CP-90HF, and LSS-1 were each significantly 
(p<0.05) different.  CS-1 and CP-90 were significantly (p<0.05) smaller than LSS-5, but were 
not different from each other.  CS-5, CP-120, and LSS-10 were each significantly (p<0.05) 
different and CP-180 was significantly (p<0.05) smaller than CS-10 and LSS-20.  The 
relationships within and across components of the Mechanical Panel are depicted in Figure 
3.8B.  
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Figure 3.8:  Major axis measurements for tBMMSCs exposed to 5 days of mechanical stimulation.  (A) Raw 
measurements for all experiments.  (B) Major axis measurements normalized by division by the experimental 
control for each of the components of the Mechanical Panel.  The dashed line represents control values.  All data 
presented as the average ± standard error of the mean (SEM).  * denotes p<0.05 compared to controls.  + denotes 
p<0.1 compared to controls.  † denotes p<0.01 for means within each stimulus.  (1), (2), (3) denote p<0.05 for 
means between stimuli of corresponding bar color where (1)=CS, (2)=CP, and (3)=LSS. 
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3.3.2.3 Shape index changes 
The calculated shape indices and normalized shape indices (calculated by subtraction of 
the control shape index from each calculated shape index) are presented as the average ± SEM in 
Figure 3.9.  With this normalization, negative differences relate to cells that are more spindle-
shaped than the controls, while positive differences relate to cells that are more round than the 
controls.  For tBMMSCs exposed to mechanical stimulation show significant changes depending 
on the type, magnitude, and frequency of applied stimulation.  Shape indices for LSS-1 (0.26 ± 
0.04, n=4) and LSS-5 (0.27 ± 03, n=6), and 10 dynes/cm2 (0.24 ± 0.02, n=6) were not 
significantly different from controls.  However, the shape index of LSS-20 dynes/cm2 (0.18 ± 
0.02) was significantly (p<0.05) smaller than the control, indicating that the tBMMSCs were 
becoming more spindle shaped at this higher shear stress.  Within the LSS stimulus, LSS-20 was 
significantly (p<0.05) more spindle-shaped than LSS-10, LSS-5, and LSS-1.  LSS demonstrated 
a strong dose-response (ρ= -0.792, p<0.001) with increasing shear stress leading to a decreased 
shape index, indicating a more spindle-shaped cell.   
The shape indices for CP-90HF (0.37 ± .02; n=4), CP-90 (0.37 ± 0.02, n=3), CP-120 
(0.33 ± 0.03, n=6), and CP-180 (0.36 ± 0.01, n=6) were significantly (p<0.05) greater compared 
to the controls, indicating that the application of CP leads to a more rounded phenotype. Within 
CP there was no difference at the various magnitudes or frequencies, and thus no correlation 
between the shape index and either the magnitude or frequency was detected.   
The shape indices for CS-5 (0.23 ± 0.02, n=5), and CS-10 (0.21 ± 0.01, n=7) were 
significantly (p<0.05) smaller compared to controls, indicating a more spindle shape.  However, 
the shape index for CS-1 (0.35 ± 0.01, n=4) was significantly (p<0.05) higher than controls, 
indicating that the tBMMSCs were more rounded.  In fact, the shape index for CS-1 was very 
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similar to all values calculated for CP.  The shape index for CS-1HF (0.25 ± 0.01, n=4) was not 
significantly different compared to controls.  Within CS, all values were significantly (p<0.05) 
different from each other, with the exception of CS-5 and CS-10, whose shape indices were 
nearly identical.  The normalized values for shape index for CS, which changed from a more 
rounded phenotype at CS-1 to a more spindle shaped phenotype for CS-5 and CS-10, had a fairly 
strong correlation (ρ= -0.639, p<0.01) to the magnitude of CS.  A strong frequency correlation 
(ρ= -0.873, p<0.01) also existed for CS, with increasing frequency leading to a more spindle 
shape. 
Comparisons across the stimuli demonstrate the strong changes in shape index between 
each stimulus.  With the exception of CS-1 and CP-90, which had similar changes in shape 
index, all comparisons between CP and the other stimuli demonstrated significant (p<0.05) 
changes in shape index.  The relationships within and across components of the Mechanical 
Panel are depicted in Figure 3.9B. 
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Figure 3.9:  Shape Index measurements based upon the area perimeter measurements for tBMMSCs exposed to 5 
days of mechanical stimulation.  (A) Raw shape index calculations. (B) Shaped indices normalized by subtraction of 
the experimental control for each of the components of the Mechanical Panel.  All data presented as the average ± 
SEM.  * denotes p<0.05 compared to controls.  + denotes p<0.1 compared to controls.  † denotes p<0.01 for means 
within each stimulus.  (1), (2), (3) denote p<0.05 for means between stimuli of corresponding bar color where 
(1)=CS, (2)=CP, and (3)=LSS. 
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3.3.2.4 Tortuosity index changes 
The calculated tortuosity indices and normalized tortuosity indices (calculated by 
subtraction of the control tortuosity index from each calculated tortuosity index) are presented as 
the average ± SEM in Figure 3.10.  With this normalization, negative differences relate to cells 
that are less tortuous than the controls, while positive differences relate to cells that are more 
tortuous than the controls.  tBMMSCs exposed to LSS-1 (1.5 ± 0.09, n=4), and LSS-5 (1.43 ± 
0.06, n=6) were not significantly different from the controls, but LSS-10 (1.53 ± 0.07, n=6) and 
LSS-20 (1.8 ± 0.08, n=5) were significantly (p<0.05) more tortuous compared to the controls.  
Within LSS, only LSS-20 was significantly (p<0.05) more tortuous than LSS-5.  LSS 
demonstrated a strong correlation (ρ=0.787, p<0.01) to the magnitude of applied LSS, with 
increasing shear stress leading to increased tortuosity.   
tBMMSCs exposed to CP-90HF (1.15 ± 0.02, n=4), CP-90 (1.13 ± 0.03, n=3), CP-120 
(1.23 ± 05.06, n=6) and CP-180 (1.18 ± 0.04, n=6) were significantly (p<0.05) less tortuous than 
the controls.  However, within CP, there were no differences amongst the magnitudes or 
frequencies.  There were no statistically significant correlations for magnitude or frequency 
dependent changes in tortuosity following exposure to CP.   
Similar to the tortuosity indices for CP, CS-1 (1.15 ± 0.03, n=4) was significantly 
(p<0.05) less tortuous than controls.  However, all other calculated tortuosity indices for CS-1HF 
(1.39 ± 0.09, n=4), CS-5 (1.32 ± 0.12, n=5), and CS-10 (1.45 ± 0.05, n=6) were not significantly 
different than the controls.  Within CS, only CS-1 was significantly (p<0.05) less tortuous than 
CS-10.  tBMMSCs exposed to CS demonstrated a slight correlation (ρ= -0.655, p=0.07) to 
increases in the frequency of stretch, but not to increases in the magnitude of stretch. 
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Comparisons across the stimuli demonstrated significant (p<0.05) differences between 
the change in tortuosity index for CS-1 and CP-90 when compared to LSS-5.  Additionally, there 
were significant (p<0.05) increases in the change in tortuosity indices from CS-10 to CP-180 and 
to LSS-20, and for CP-120 compared to LSS-10.  The relationships within and across 
components of the Mechanical Panel are depicted in Figure 3.10. 
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Figure 3.10:  Tortuosity Index calculated from the perimeter and major axis measurement of tBMMSCs exposed to 
5 days of mechanical stimulation.  (A) Raw tortuosity index calculations.  (B) Tortuosity indices normalized by 
subtraction of each component of the Mechanical Panel by their respective experimental control.  All data presented 
as the average ± SEM.  * denotes p<0.05 compared to controls.  + denotes p<0.1 compared to controls.  † denotes 
p<0.01 for means within each stimulus.  (1), (2), (3) denote p<0.05 for means between stimuli of corresponding bar 
color where (1)=CS, (2)=CP, and (3)=LSS. 
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3.3.2.5 Changes in angle of alignment 
Cellular alignment quantified with Scion Image is presented as average normalized 
incidence histograms in Figure 3.11 Figure 3.12, , and Figure 3.13.  Statistical analysis against a 
uniform distribution was carried out according to Equations (3.11), (3.12), (3.13), and (3.14).  
For tBMMSCs exposed to CP, the orientation of the cells was found to be random for CP-90HF 
(R*=0.952, p>0.10, n=4), CP-90 (R*=0.816, p>0.10, n=3), CP-120 (R*=0.965, p>0.10, n=5), 
and CP-180 (R*=0.619, p>0.10, n=5).  Exposure to LSS-1 (R*=0.954, p>0.10, n=4) and LSS-5 
(R*=0.722, p>0.10, n=5) demonstrated random orientation.  However, LSS-10 (R*=1.23, 
p<0.05, n=4) showed statistically significant orientation around the 90o (parallel to flow) and 
trended towards an orientation near 90o at LSS-20 (R*=1.039, p<0.10, n=5).  Application of CS-
1HF (R*=0.176, p>0.10, n=4) and CS-1 (R*=0.567, p>0.10, n=5), did not show any preferred 
orientation, but CS-5 (R*=1.30, p<0.05, n=5) and CS-10 (R*=1.29, p<0.05, n=5) resulted in 
statistically significant orientation at 90o (perpendicular to the direction of applied stretch). 
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Figure 3.11: Normalized histograms for cellular of orientation in CP experiments.  The error bars represent the 
standard error of the mean for the averaged normalized frequencies.  Non-parametric analysis against a uniform 
distribution resulted in no statistical significant differences with any of the cyclic pressure regimens, which is in 
agreement with the normalized histogram for the control. 
 139 
 Shear Stress
5 dynes/cm2
0
2
4
6
8
10
12
0° 45° 90° 125° 180°
Fr
eq
ue
nc
y
Shear Stress 
1 dyne/cm2
0
2
4
6
8
10
12
14
16
0° 45° 90° 125° 180°
Fr
eq
ue
nc
y
B) A) 
  
Shear Stress
10 dynes/cm2
0
2
4
6
8
10
12
14
0° 45° 90° 125° 180°
Fr
eq
ue
nc
y
 
Shear Stress
20 dynes/cm2
0
2
4
6
8
10
12
0° 45° 90° 125° 180°
Fr
eq
ue
nc
y
D) C) 
 
Control
0
2
4
6
8
0° 45° 90° 125° 180°
Fr
eq
ue
nc
y
E) 
 
Figure 3.12:  Normalized histograms for cellular orientation in tBMMSCs exposed to LSS.  The error bars represent 
the standard error of the mean for the averaged normalized frequencies.  Non-parametric analysis against a uniform 
distribution resulted in no statistical difference for 1 dyne/cm2 and 5 dynes/cm2.  However, at 10 dynes/cm2 and 20 
dynes/cm2, a preferred orientation begins to develop around 90o, which is in the direction of flow.  The histogram 
from control samples is provided to represent random orientation. 
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Figure 3.13:  Normalized histograms for cellular orientation in tBMMSCs exposed to CS.  The error bars represent 
the standard error of the mean for the averaged normalized frequencies.  Non-parametric analysis against a uniform 
distribution did not demonstrate any significant changes for 1% 2.75 Hz and 1% 1 Hz cyclic stretch.  However, 
higher magnitudes of stretch (5% 1 Hz and 10% 1 Hz) demonstrate a significant change from a uniform distribution 
centered on 90o, which is perpendicular to the direction of stretch.   
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3.3.3 Proliferation 
Changes in cellular proliferation following 5 days of stimulation for the Mechanical 
Panel settings outlined in Section 3.2.3.2 are depicted in Figure 3.14.  The cell density of 
tBMMSCs exposed to CS-1HF (7.24 ± 3.73 x103 cells/cm2, n=4), CS-5 (12.21 ± 3.36 x103 
cells/cm2, n=7) and CS-10 (4.95 ± 1.04 x103 cells/cm2, n=7) was unchanged when compared to 
the controls.  However, the cell density for CS-1 (16.57 ± 2.30 x103 cells/cm2) was significantly 
(p<0.05) increased from controls.  Although there appears to be possible dose- and frequency- 
responses for tBMMSCs exposed to CS, the Spearman correlations for magnitude and frequency 
were non-significant.   
Similarly to CS-1, the cell density for tBMMSCs exposed to CP-90 (41.21 ± 12.53 x103 
cells/cm2, n=5), CPO-120 (21.10 ± 2.71 x103 cells/cm2, n=7), and CP-180 (26.78 ± 4.40 x103 
cells/cm2, n=7) was significantly (p<0.05) increased compared to the controls.  The cell density 
for CP-90HF (28.17 ± 6.74 x103 cells/cm2, n=4) was elevated over controls, but not statistically 
significant (p=0.07).  There was also a weak, but statistically significant correlation (ρ= -0.483, 
p<0.05) for a dose-dependent decrease in cell density with increasing magnitudes of CP 
stimulation.  There was no correlation between cell density and the frequency of CP.   
Conversely, the cell density for tBMMSCs exposed to LSS at 5 dyens/cm2 (3.12 ± 1.69 
x103 cells/cm2, n=7), 10 dynes/cm2 (2.54 ± 0.50 x103 cells/cm2, n=6), and 20 dynes/cm2 (2.08 ± 
0.53 x103 cells/cm2, n=6) were significantly (p<0.05) decreased when compared to controls.  
Only cell density for LSS at 1 dyne/cm2 (2.87 ± 0.93 x103 cells/cm2, n=4) was not significantly 
different from the controls.  A weak, but statistically significant decrease (ρ= -0.469, p<0.05) in 
cell density was found for increasing magnitudes of LSS. 
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Comparisons made within as well as across each stimuli displayed an inconsistent 
homogeneity of variance.  As a result, most post-hoc comparisons were made with the Games-
Howell test.  The few statistically significant differences detected were for an increase in cell 
density for CS-1 compared to CS-5 (p<0.05), and for increases in cell density for CP-90HF 
compared to CS-1HF and LSS-1 (p<0.05), for CS-1 compared to LSS-5 (p<0.05), for CP-120 
compared to CS-5 and LSS-10 (p<0.05), as well as for CP-180 compared to LSS-20 (p<0.05). 
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Figure 3.14:  Cell density of tBMMSCs following 5 days of mechanical stimulation.  (A) Raw cell density 
measurements for each component of the Mechanical Panel  (B) Cell density for each component of the Mechanical 
Panel normalized by division by the experimental control.  The dashed line represents control values.  All data 
presented as the average ± SEM.  * denotes p<0.05 compared to controls.  + denotes p<0.1 compared to controls.  † 
denotes p<0.01 for means within each stimulus.  (1), (2), (3) denote p<0.05 for means between stimuli of 
corresponding bar color where (1)=CS, (2)=CP, and (3)=LSS. 
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 3.3.4 Histology 
The assessment of osteoblast or adipocyte differentiation by histological staining in 
tBMMSCs exposed to the Mechanical Panel at the magnitudes and frequencies listed in Table 
3.1 yielded no apparent differentiation towards osteoblast or adipocytes.  No staining was 
detected for Alizarin Red and Oil Red O, which stain mineralized calcium (osteoblast) and lipid 
accumulation (adipocytes), respectively.  Representative images from one 5 day Mechanical 
Panel experiment are presented in Figure 3.15.  These results were consistent regardless of the 
magnitude, frequency, or type of applied mechanical stimulation.  Figure 3.15 shows a few very 
small lipid pockets in the LSS-20 sample, but these can be contrasted with the positive staining 
for Oil Red O in Figure 3.5B to see that they are insignificant compared to the differentiation 
towards adipocytes using adipogenic medium.  The red hue in the CS-10 sample depicted in 
Figure 3.15 results from the Oil Red O staining the silicone grease that coats the bottom of the 
membrane for samples exposed to CS, not the cells themselves.   
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 Figure 3.15:  Representative histology images from a 5 day Mechanical Panel experiment stained for Alizarin Red 
and Oil Red O  All images taken at 100x.   
 146 
 3.3.5 Immunohistochemistry 
Representative images of each protein endpoint described in Section 3.2.4.4 are shown in 
Figure 3.16, Figure 3.17, Figure 3.18, Figure 3.19, Figure 3.20 Figure 3.21, and .   
tBMMSCs exposed to CS, regardless of the magnitude or frequency, induced the 
expression of SMA (Figure 3.16).  The expression of SMA at CS-1 did appear to be weaker than 
that induced by CS-10 and CS-5, but this cannot be conclusively determined by IHC.  CS-1HF 
demonstrated what appeared to be a stronger intensity signal for SMA, but the expression was 
restricted to smaller pockets within the field of view, as opposed to the general staining found for 
the other CS samples at 1 Hz.  No SMA expression was detected for tBMMSCs exposed to any 
level of CP or LSS.  In addition, SMA expression was not detected in control samples, and the 
IgG negative control was also negative, demonstrating a lack of non-specific binding of the 
secondary antibody. 
Figure 3.17Calponin expression, shown in , demonstrated a dose-dependent threshold of 
staining for tBMMSCs exposed to cyclic stretch.  CS-1 did not show positive staining, whereas 
CS-10 and CS-5 demonstrated positive staining for calponin.  Positive calponin staining for CS-
1HF may be indicative of a frequency response.  Similar to the SMA staining at CS-1HF, only 
pockets of positive staining were visible within each field of view, which contrasts with the 
general staining shown for CS-10 and CS-5.  This suggests that the higher frequency produces 
effects in a sub-population of the tBMMSCs.  Control, CP, and LSS samples showed little or no 
staining for calponin, and IgG control samples were also negative. 
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Figure 3.16:  Representative immunohistochemistry images for smooth muscle α-actin.  Arrows indicate the 
direction of applied stimulation, if applicable.  All images  taken at 200x.   
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 Figure 3.17:  Representative immunohistochemistry images for calponin.  Arrows indicate the direction of applied 
stimulation, if applicable.  All images  taken at 200x.   
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Myosin heavy chain expression, shown in Figure 3.18, also demonstrated a threshold of 
expression based upon the magnitude of cyclic stretch.  CS-10 was weakly positive for myosin 
heavy chain in three out of four experiments, while CS-5 and CS-1 was negative for myosin 
heavy chain.  The staining pattern was fairly diffuse, unlike the expected filamentous pattern 
which was evident in the calponin staining (recall Figure 3.17).  Like SMA and calponin, CS-
1HF did demonstrate localized staining in all experiments, again suggesting that higher 
frequency stimulation was similar to the higher magnitude stimulation.  CP and LSS stimulation 
did not induce the expression of myosin heavy chain.  Control and IgG negative samples were 
also negative for myosin heavy chain.   
Flk-1 (VEGFRII) expression, shown in Figure 3.19, was constitutively expressed in 
tBMMSCs as evidenced by positive staining control samples.  Flk-1 expression was maintained 
under all levels of CS.  Like SMA, calponin, and MHC, flk-1 expression in the CS-1HF cyclic 
stretch samples appears to be heterogeneous in intensity.  The higher intensity staining was 
centered on the similar core, swirl pattern seen in the SMA, calponin, and MHC samples.  In 
addition, although not quantitative, the staining intensity for the 1 Hz CS stimuli did not appear 
to vary in any manner similar to the variance in intensity seen with SMA.  Flk-1 expression was 
also maintained under cyclic pressure at CP-180, but was lost at CP-120, CP-90 and CP-90HF.  
A similar response to that found with CP was noted for tBMMSCs exposed to LSS.  The higher 
magnitudes of shear, including LSS-20 and LSS-10 maintained expression of flk-1.  Lower 
magnitudes, including LSS-5 and LSS-1 lost the expression of flk-1.  It should be noted that the 
staining intensity for the positive samples was much lower in the tBMMSCs exposed to cyclic 
pressure and laminar shear stress relative to control and cyclic stretch samples from the same 
group.  Although IHC is not quantitative, this may indicate that despite the presence of positive 
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staining there was likely a modulation of the expression to levels lower than that seen in the 
control and cyclic stretch.   
The more mature marker for ECs, PECAM (shown in Figure 3.20) was negative for the 
controls as well as all levels of CS, CP, and LSS.  The other mature EC marker tested, vWF 
(shown in Figure 3.21), was also negative for the controls as well as all levels of CS, CP, and 
LSS.   
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Figure 3.18:  Representative immunohistochemistry images for myosin heavy chain.  Arrows indicate the direction 
of applied stimulation, if applicable.  All images  taken at 200x.   
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Figure 3.19:  Representative immunohistochemistry images for flk-1.  Arrows indicate the direction of applied 
stimulation, if applicable.  All images  taken at 200x.    
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Figure 3.20: Representative immunohistochemistry images for PECAM.  Arrows indicate the direction of applied 
stimulation, if applicable.  All images  taken at 200x.   
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Figure 3.21:  Representative immunohistochemistry images for vWF.  Arrows indicate the direction of applied 
stimulation, if applicable.  All images  taken at 200x.   
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 3.3.6 Gene expression 
All gene targets (see Table 3.4) analyzed in the RT-negative experiments failed to produce 
sufficient signal to determine a CT value, demonstrating that no genomic amplification occurred.  
The amplification plot for an RT-negative sample, shown in Figure 3.22A, is contrasted with a 
normal RT-PCR run, shown in Figure 3.22B.  
For all PCR endpoints, the results are presented as the average fold-change from control 
values ± standard deviation (SD) with associated sample numbers achieving a positive 
interrogation.  Samples failing to register any detectable transcripts were not used to tabulate the 
average gene expression for that endpoint.  Because the sample numbers reaching positive 
interrogation were relatively low for many of the genes in question (limiting our ability to 
perform statistical analysis), results with potential biological significance (i.e., greater than ± 1.3 
fold changes in gene expression) are highlighted in green and red to indicate potential up- and 
down-regulation, respectively.  This value has previously been used in the literature as a guide 
for further investigation when analysis is limited by sample size [643, 644].  Genes were grouped 
according to their classifications found in Table 3.4 to help detect trends in related endpoints.   
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A) 
 
 B) 
 
Figure 3.22:  RT-PCR reaction products curves.  (A) Osteocalcin reaction products for RT-negative samples do not 
show an exponential increase, demonstrating no genomic amplification.  (B) Osteocalcin reaction products for 
experimental samples show the appropriate exponential increase indicating proper amplification. 
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 3.3.6.1 Muscle-related genes 
The average RQ values ± SD for muscle-related genes are depicted in Table 3.5.  
Although relatively few endpoints reached biological and statistical significance because of a 
failure to interrogate, enough samples were detected at greater than ± 1.3 fold changes in gene 
expression to postulate that some effect is being produced by mechanical stimulation.  SMC 
genes, which include caldesmon, calponin, and SM22α, tended to be upregulated by mechanical 
stimulation in general, regardless of type, magnitude or frequency.  However, for caldesmon 
expression, CS did not appear to have the same effect as CP and LSS, failing to create much of 
any change in gene expression over the range of magnitudes and frequencies tested.  Other 
muscle-related genes more specific to cardiac muscle (cardiac troponin) tended to be strongly 
downregulated by LSS (p<0.05 for all magnitudes), and were highly variable under CS and CP.  
Desmin, another muscle-related gene more often associated with skeletal muscle, also was highly 
variable but on average tended to be upregulated by mechanical stimulation, regardless of the 
type, magnitude, frequency. 
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Table 3.5:  Fold changes in muscle-related gene expression relative to control for each component of the 
Mechanical Panel as analyzed by the low density qPCR.  Green and red highlights indicate an average fold change 
greater than 1.3 or less than 0.7 (considered biologically relevant), respectively.  Data are presented as the mean ± 
SD with sample numbers.  + p<0.10, *p<0.05, and ND=No detectable transcripts.   
 
Stimulus Caldesmon Calponin Cardiac Troponin
CP-90HF 1.41 +/- 0.78, n=4 0.96 +/- 0.57, n=4 7.89 +/- 14.13, n=4
CP-90 1.14 +/- 0.31, n=3 2.93 +/- 2.45, n=2 0.32 +/- 0.32, n=2
CP-120 1.71 +/- 0.4, n=3 + 1.62 +/- 0.55, n=3 4.8 +/- 6.57, n=3
CP-180 1.59 +/- 0.85, n=4 0.74 +/- 0.66, n=4 1.18 +/- 1.06, n=3
CS-1HF 1.21 +/- 0.39, n=4 2.17 +/- 1.27, n=4 3.78 +/- 5.3, n=4
CS-1 1.11 +/- 0.32, n=5 9.03 +/- 9.68, n=2 1.68 +/- 2.04, n=5
CS-5 1.09 +/- 0.26, n=4 2.34 +/- 1.18, n=4 6.31 +/- 11.42, n=4
CS-10 0.8 +/- 0.29, n=3 1.28 +/- 0.73, n=3 0.3 +/- 0.22, n=2
LSS-1 1.39 +/- 0.13, n=4 * 3.93 +/- 1.72, n=4 * 0.06 +/- 0.09, n=3 * 
LSS-5 0.81 +/- 0.45, n=3 0.93 +/- 0.73, n=3 0.01 +/- 0.01, n=2 * 
LSS-10 1.85 +/- 0.87, n=4 2.38 +/- 2.39, n=4 0.07 +/- 0.1, n=3 * 
LSS-20 1.2 +/- 0.23, n=5 16.6 +/- 23.44, n=2 0.19 +/- 0.16, n=4 * 
Muscle
 
Stimulus Desmin SM22α
CP-90HF 4.18 +/- 6.77, n=4 1.62 +/- 0.84, n=4
CP-90 0.2 +/- 0, n=1 0.92 +/- 0.36, n=3
CP-120 1.18 +/- 0.58, n=2 1.96 +/- 0.06, n=3 * 
CP-180 1.9 +/- 1.1, n=3 1.91 +/- 0.93, n=4
CS-1HF 4.21 +/- 6.26, n=4 1.88 +/- 1.07, n=4
CS-1 1.43 +/- 0.94, n=3 1.05 +/- 0.16, n=5
CS-5 2.75 +/- 1.68, n=3 2.08 +/- 0.74, n=4 + 
CS-10 9.6 +/- 14.02, n=3 1.17 +/- 0.46, n=3
LSS-1 4.48 +/- 6.7, n=4 5.95 +/- 0.96, n=4 * 
LSS-5 0.37 +/- 0.04, n=2 * 2.29 +/- 0.7, n=3 + 
LSS-10 1.54 +/- 0.56, n=3 6.49 +/- 2.85, n=4 * 
LSS-20 3.29 +/- 5.31, n=4 2.92 +/- 1.95, n=5 + 
Muscle
 
 159 
 3.3.6.2 Endothelial-related genes 
The average RQ values ± SD for endothelial-related genes are depicted in Table 3.6.  
Like the muscle-related genes, most endothelial-related genes failed to show any statistically 
significant changes from control levels.  LSS had the most profound affect, statistically 
downregulating most of the interrogated endothelial-related genes, particularly flk-1 and vWF.  
vWF was significantly downregulated for LSS-1 (p<0.10) and LSS-5 (p<0.05), but LSS-10 and 
LSS-20 showed no change in the expression of vWF.  CP tended to increase several of the 
endothelial related-genes including endoglin, CD133 and vWF, although none were statistically 
significant.  The effect of CP on flk-1 appears to have a threshold around CP-120, with steady to 
increased expression at CP-120 and CP-180, respectively, but undetectable expression and 
downregulated expression at CP-90 and CP-90HF.  Conversely, CS demonstrated some ability to 
increase the expression of flk-1, which the exception at CS-10, which may downregulate flk-1 
expression.  Looking across CS-10, it would appear that this high level of stretch strongly 
inhibited any endothelial gene expression, with downregulation or non-detection at all other 
endothelial-genes.  iNOS failed to show detectable expression in most samples.   
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Table 3.6:  Fold changes in endothelial-related gene expression relative to control for each component of the 
Mechanical Panel as analyzed by the low density qPCR.  Green and red highlights indicate an average fold change 
greater than 1.3 or less than 0.7 (considered biologically relevant), respectively.  Data are presented as the mean ± 
SD with sample numbers.  + p<0.10, *p<0.05, compared to controls, and ND=No detectable transcripts. 
 
Stimulus CD133 Endoglin ESAM
CP-90HF 18.08 +/- 21.79, n=2 1.45 +/- 0.61, n=3 0.07 +/- 0, n=1
CP-90 2.16 +/- 0, n=1 18.09 +/- 19.08, n=3 ND
CP-120 40.88 +/- 0, n=1 20.91 +/- 28.13, n=3 ND
CP-180 137.47 +/- 0, n=1 1.68 +/- 1.25, n=4 0.04 +/- 0, n=1
CS-1HF 2.92 +/- 0, n=1 7.16 +/- 13.52, n=4 18.02 +/- 20.43, n=3
CS-1 1.51 +/- 0.52, n=3 0.85 +/- 0.05, n=3 * ND
CS-5 ND 0.72 +/- 0.6, n=4 15.34 +/- 0, n=1
CS-10 ND 0.17 +/- 0, n=2 * ND
LSS-1 0.06 +/- 0, n=1 0.54 +/- 0.28, n=3 7.75 +/- 8.28, n=3
LSS-5 ND 5.26 +/- 9.11, n=3 ND
LSS-10 48.28 +/- 0, n=1 0.58 +/- 0.69, n=4 7.83 +/- 11.04, n=2
LSS-20 0.12 +/- 0.03, n=3 * 0.15 +/- 0.15, n=3 * ND
Endothelial
 
Stimulus iNOS Flk-1 vWF
CP-90HF ND 0.46 +/- 0.76, n=3 1.48 +/- 0.93, n=4
CP-90 0.05 +/- 0, n=1 0.21 +/- 0, n=1 1.23 +/- 0.43, n=3
CP-120 ND 1.03 +/- 1.43, n=2 1.57 +/- 0.57, n=3
CP-180 ND 2.91 +/- 3.02, n=3 1.73 +/- 1.04, n=4
CS-1HF ND 1.78 +/- 1.62, n=3 1.13 +/- 0.41, n=4
CS-1 0.56 +/- 0.55, n=2 11.31 +/- 19.08, n=4 1.2 +/- 0.41, n=5
CS-5 ND 10.46 +/- 18.35, n=4 0.86 +/- 0.14, n=4
CS-10 ND 0.45 +/- 0.19, n=2 0.59 +/- 0.26, n=3
LSS-1 ND 0.02 +/- 0.03, n=3 * 0.62 +/- 0.32, n=4 + 
LSS-5 ND 0.01 +/- 0, n=2 * 0.39 +/- 0.11, n=3 * 
LSS-10 ND 0.06 +/- 0.09, n=3 * 0.95 +/- 0.53, n=4
LSS-20 0.75 +/- 0.81, n=2 0.11 +/- 0.13, n=3 * 0.89 +/- 0.5, n=5
Endothelial
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 3.3.6.3 Soluble factor- and apoptosis-related gene expression 
The average RQ values ± SD for soluble factor and apoptosis-related genes are depicted 
in Table 3.7.  The most striking trend was the general increase in expression for FGF2 and TGF-
β exposed to LSS, much of it with some statistical significance.  FGF-2 was also generally 
increased by CS, although none to any statistical levels.  VEGF-A expression was seemingly 
unaffected by mechanical stimulation, maintaining near-baseline levels for almost all conditions 
except LSS-20, which was significantly increased (p<0.05) and LSS-5, which was significantly 
decreased (p<0.05).  On average, soluble factor expression was increased for all three for the 
higher magnitudes of LSS.     
Gene expression for Bcl-2 (anti-apoptotic) and caspase 3 (pro-apoptotic) did not appear 
to definitively show any propensity for or against apoptosis.  In general, both genes followed 
each other in terms of up- or down-regulation.  TNFα did not demonstrate any detectable 
expression for any condition.   
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Table 3.7:  Fold changes in soluble factor and apoptosis-related gene expression relative to control for each 
component of the Mechanical Panel as analyzed by the low density qPCR.  Green and red highlights indicate an 
average fold change greater than 1.3 or less than 0.7 (considered biologically relevant), respectively.  Data are 
presented as the mean ± SD with sample numbers.  + p<0.10, *p<0.05 compared to controls, and ND=No detectable 
transcripts. 
 
Stimulus FGF2 TGF-β VEGF-A
CP-90HF 0.85 +/- 0.48, n=4 1.09 +/- 0.37, n=4 0.89 +/- 0.37, n=4
CP-90 0.8 +/- 0.48, n=3 1.09 +/- 0.37, n=3 0.81 +/- 0.15, n=3
CP-120 1.28 +/- 0.57, n=3 1.45 +/- 0.54, n=3 1.04 +/- 0.42, n=3
CP-180 1.57 +/- 1.79, n=4 1.74 +/- 1.17, n=4 1.41 +/- 1.27, n=4
CS-1HF 1.53 +/- 0.79, n=4 1.32 +/- 0.53, n=4 1.17 +/- 0.37, n=4
CS-1 0.89 +/- 0.13, n=5 0.98 +/- 0.19, n=5 1.07 +/- 0.13, n=5
CS-5 1.38 +/- 0.63, n=4 1.2 +/- 0.4, n=4 0.89 +/- 0.3, n=4
CS-10 1.31 +/- 0.72, n=3 0.83 +/- 0.35, n=3 0.73 +/- 0.27, n=3
LSS-1 4.06 +/- 0.68, n=4 * 2.46 +/- 0.5, n=4 * 1.18 +/- 0.31, n=4
LSS-5 1.84 +/- 1.02, n=3 1.62 +/- 0.84, n=3 0.64 +/- 0.12, n=3 * 
LSS-10 6.51 +/- 3.8, n=4 + 4.69 +/- 2.26, n=4 * 1.92 +/- 1.2, n=4
LSS-20 4.38 +/- 0.91, n=5 * 3.56 +/- 0.69, n=5 * 1.9 +/- 0.63, n=5 * 
Soluble Factor
 
Stimulus Bcl2 Caspase 3 TNF-α
CP-90HF 6.9 +/- 6.27, n=4 1.21 +/- 0.76, n=4 ND
CP-90 ND 1.14 +/- 0.18, n=2 ND
CP-120 4.34 +/- 4.47, n=3 1.33 +/- 0.48, n=3 ND
CP-180 1.39 +/- 1.15, n=4 1.55 +/- 0.92, n=4 ND
CS-1HF 2.18 +/- 1.67, n=3 1.25 +/- 0.28, n=4 ND
CS-1 10.87 +/- 0, n=1 1.34 +/- 0.28, n=2 ND
CS-5 1.1 +/- 0.8, n=4 0.99 +/- 0.25, n=4 ND
CS-10 6.56 +/- 10.6, n=3 0.76 +/- 0.36, n=3 ND
LSS-1 3.38 +/- 3.28, n=3 1.4 +/- 0.56, n=4 ND
LSS-5 0.53 +/- 0.08, n=2 + 0.79 +/- 0.42, n=3 ND
LSS-10 0.75 +/- 0.53, n=4 1.97 +/- 0.99, n=4 ND
LSS-20 ND 1.75 +/- 0.55, n=2 ND
Apoptosis
 
 
 
3.3.6.4 Extracellular matrix-related gene expression 
The average RQ values ± SD for matrix-related genes are depicted in Table 3.8.  The 
most striking effects on matrix gene expression came from LSS, which had some statistical 
significance to upregulating collagen I, while downregulating elastin gene expression.  Other 
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potentially strong changes occurred under CP, which seems to upregulate collagen I and III as 
well as elastin gene expression.  CS did not seem to affect matrix gene expression except for 
increasing elastin gene expression at CS-1 and CS-5 before downregulating it at CS-10.  
Collagen IV gene expression was inconsistent, often failing to detect any transcripts.   
 
Table 3.8:  Fold changes in extracellular matrix-related gene expression relative to control for each component of 
the Mechanical Panel as analyzed by the low density qPCR.  Green and red highlights indicate an average fold 
change greater than 1.3 or less than 0.7 (considered biologically relevant), respectively.  Data are presented as the 
mean ± SD with sample numbers.  + p<0.10, *p<0.05, compared to controls, and ND=No detectable transcripts. 
 
Stimulus Collagen I Collagen III Collagen IV Elastin
CP-90HF 1.38 +/- 0.66, n=4 1.76 +/- 1.01, n=4 14.84 +/- 0, n=1 5.4 +/- 6.21, n=4
CP-90 1.11 +/- 0.42, n=3 1.37 +/- 0.18, n=3 + 0.03 +/- 0, n=1 11.88 +/- 14.7, n=3
CP-120 1.51 +/- 0.27, n=3 + 2.53 +/- 1.61, n=3 0.04 +/- 0, n=1 3.79 +/- 0.95, n=3 * 
CP-180 1.58 +/- 0.8, n=4 2.29 +/- 0.91, n=4 + 0.15 +/- 0, n=1 4.56 +/- 2.36, n=4 + 
CS-1HF 1.32 +/- 0.44, n=4 1.07 +/- 0.37, n=4 ND 1.05 +/- 0.97, n=4
CS-1 1.12 +/- 0.35, n=5 1.04 +/- 0.11, n=5 2.6 +/- 1.19, n=3 3.11 +/- 4.39, n=5
CS-5 1.26 +/- 0.27, n=4 1.07 +/- 0.2, n=4 1.01 +/- 0, n=1 1.56 +/- 1.22, n=4
CS-10 0.74 +/- 0.34, n=3 0.76 +/- 0.41, n=3 1.24 +/- 0, n=1 0.33 +/- 0.41, n=3
LSS-1 2.95 +/- 1.94, n=4 1.18 +/- 0.58, n=4 ND 0.73 +/- 0.85, n=4
LSS-5 2.41 +/- 0.63, n=3 + 0.94 +/- 0.67, n=3 0.04 +/- 0, n=1 0.18 +/- 0.17, n=3 * 
LSS-10 4 +/- 2.06, n=4 + 1.38 +/- 0.06, n=4 * 0.1 +/- 0, n=1 0.53 +/- 0.52, n=4
LSS-20 6.49 +/- 3.04, n=5 * 1.21 +/- 0.39, n=5 0.24 +/- 0.35, n=3 + 0.23 +/- 0.21, n=4 * 
Matrix
 
 
3.3.6.5 Stem-cell related gene expression 
The average RQ values ± SD for stem cell-related genes are depicted in Table 3.9.  CD59 
and CD90, which are reported to be expressed in tBMMSCs were most affected by LSS, which 
significantly downregulated CD90, and showed some moderate increases in CD59.  CP tended to 
behave in an almost opposing fashion, with borderline downregulation of CD59, and some 
upregulation of CD90, although none were statistically significant.  Vimentin expression was 
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relatively unchanged with some increases under higher CP (CP-120 and CP-180) and some 
decreases under CS-10 and LSS-5.  However, no particular patterns seemed to develop.   
 
 
 
Table 3.9:  Fold changes in stem cell-related gene expression relative to control for each component of the 
Mechanical Panel as analyzed by the low density qPCR.  Green and red highlights indicate an average fold change 
greater than 1.3 or less than 0.7 (considered biologically relevant), respectively.  Data are presented as the mean ± 
SD with sample numbers.  + p<0.10, *p<0.05, compared to controls. 
 
Stimulus CD59 CD90 Vimentin
CP-90HF 0.76 +/- 0.3, n=4 1.28 +/- 0.74, n=4 1.08 +/- 0.52, n=4
CP-90 0.51 +/- 0.25, n=3 + 1 +/- 0.2, n=3 0.84 +/- 0.34, n=3
CP-120 0.76 +/- 0.47, n=3 1.39 +/- 0.29, n=3 1.26 +/- 0.41, n=3
CP-180 1.03 +/- 0.48, n=4 1.51 +/- 0.77, n=4 1.62 +/- 0.97, n=4
CS-1HF 1.71 +/- 1.02, n=4 1.22 +/- 0.43, n=4 1.12 +/- 0.25, n=4
CS-1 0.91 +/- 0.17, n=5 1.11 +/- 0.13, n=5 1.13 +/- 0.22, n=5
CS-5 1.77 +/- 0.67, n=4 0.98 +/- 0.07, n=4 1.03 +/- 0.21, n=4
CS-10 0.98 +/- 0.27, n=3 0.56 +/- 0.24, n=3 + 0.62 +/- 0.27, n=3
LSS-1 3.45 +/- 1.55, n=4 + 0.37 +/- 0.18, n=4 * 0.94 +/- 0.2, n=4
LSS-5 0.83 +/- 0.27, n=3 0.19 +/- 0.08, n=3 * 0.47 +/- 0.16, n=3 * 
LSS-10 4.99 +/- 4.73, n=4 0.46 +/- 0.17, n=4 * 1.27 +/- 0.65, n=4
LSS-20 1.94 +/- 1.12, n=5 0.33 +/- 0.05, n=5 * 0.95 +/- 0.1, n=5
Stem Cell
 
 
3.3.6.6 Osteoblast-related gene expression 
The average RQ values ± SD for osteoblast-related genes are depicted in Table 3.10.  
The most consistent result from this gene subset was either non-expression or downregulation, 
especially with respect to Runx2 and osteocalcin.  Alkaline phosphatase expression was 
inconsistent, and BMP2 expression was relatively unchanged.   
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Table 3.10:  Fold changes in osteoblast-related gene expression relative to control for each component of the 
Mechanical Panel as analyzed by the low density qPCR.  Green and red highlights indicate an average fold change 
greater than 1.3 or less than 0.7 (considered biologically relevant), respectively.  Data are presented as the mean ± 
SD with sample numbers.  + p<0.10, *p<0.05 compared to controls, and ND=No detectable transcripts. 
 
Stimulus Alkaline Phosphatase BMP2 Osteocalcin Runx2
CP-90HF 19.93 +/- 22.47, n=3 0.83 +/- 0.58, n=4 0.36 +/- 0.48, n=2 ND
CP-90 0.92 +/- 0, n=1 0.52 +/- 0.25, n=3 + 0.85 +/- 0, n=1 ND
CP-120 ND 0.94 +/- 0.39, n=3 35.69 +/- 50.39, n=2 ND
CP-180 25.96 +/- 0, n=1 1.44 +/- 1.23, n=4 0.83 +/- 0, n=1 0.02 +/- 0, n=1
CS-1HF 0.02 +/- 0, n=1 1.31 +/- 0.43, n=4 0.89 +/- 0.41, n=2 ND
CS-1 1.19 +/- 0.41, n=3 1.13 +/- 0.55, n=5 0.81 +/- 0.24, n=3 ND
CS-5 23.57 +/- 9.89, n=2 1.26 +/- 0.46, n=4 0.52 +/- 0.68, n=2 0.02 +/- 0, n=1
CS-10 ND 0.98 +/- 0.47, n=3 ND ND
LSS-1 31.59 +/- 31.4, n=3 0.75 +/- 0.23, n=4 0.03 +/- 0.02, n=2 * ND
LSS-5 25.52 +/- 0, n=1 0.4 +/- 0.03, n=3 * ND ND
LSS-10 16.68 +/- 0, n=1 1.96 +/- 1.34, n=4 0 +/- 0, n=1 0.01 +/- 0, n=1
LSS-20 2.4 +/- 1.2, n=3 1.87 +/- 0.54, n=5 * 0.64 +/- 0.41, n=3 ND
Osteoblast
 
 
3.3.6.7 Chondrocyte- and adipocyte-related gene expression 
The average RQ values ± SD for chondrocyte- and adipocyte-related genes are depicted 
in Table 3.11.  With respect to chondrocyte-related genes, only aggrecan demonstrated 
consistently detectable expression.  Aggrecan expression was strongly downregulated with 
statistical power for LSS-5, LSS-10, and LSS-20.  Conversely, CS-1HF, CS-1, and CS-5 and CP 
in general tended to upregulate aggrecan expression.  Collagen II expression was detected only 
occasionally under LSS.  However, when it was detected, it was strongly upregulated, usually 
greater than 20-fold.  With respect to adipocyte-related gene expression, PPAR-γ expression was 
strongly downregulated by LSS, and only moderately increased under CP.   
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Table 3.11:  Fold changes in chondrocyte and adipocyte-related gene expression relative to control for each 
component of the Mechanical Panel as analyzed by the low density qPCR.  Green and red highlights indicate an 
average fold change greater than 1.3 or less than 0.7 (considered biologically relevant), respectively.  Data are 
presented as the mean ± SD with sample numbers.  + p<0.10, *p<0.05 compared to controls, and ND=No detectable 
transcripts. 
 
Adipocyte
Stimulus Aggrecan Collagen II PPAR-γ
CP-90HF 3.53 +/- 5.39, n=4 ND 1.23 +/- 0.59, n=4
CP-90 1 +/- 0.64, n=3 17.77 +/- 0, n=1 0.9 +/- 0.29, n=3
CP-120 1.4 +/- 0.62, n=3 ND 1.48 +/- 0.26, n=3 + 
CP-180 1.22 +/- 0.24, n=4 ND 1.54 +/- 0.94, n=4
CS-1HF 1.7 +/- 0.69, n=4 ND 0.97 +/- 0.4, n=4
CS-1 1.18 +/- 0.39, n=5 ND 1.03 +/- 0.14, n=5
CS-5 1.55 +/- 0.36, n=4 + ND 0.98 +/- 0.24, n=4
CS-10 0.81 +/- 0.31, n=3 ND 0.72 +/- 0.16, n=3 + 
LSS-1 0.98 +/- 0.33, n=4 34.94 +/- 24.13, n=3 0.18 +/- 0.01, n=4 * 
LSS-5 0.38 +/- 0.29, n=3 + ND 0.1 +/- 0.04, n=3 * 
LSS-10 0.56 +/- 0.2, n=4 * 22.07 +/- 0, n=1 0.18 +/- 0.06, n=4 * 
LSS-20 0.33 +/- 0.09, n=5 * 194.33 +/- 0, n=1 0.17 +/- 0.04, n=5 * 
Chondrocyte
 
3.4 
3.4.1 
DISCUSSION 
Differential morphology and proliferation changes 
The use of our novel Mechanical Panel experimental design allowed for the differential analysis 
of how mechanical stimulation impacts stem cell morphology, growth, and differentiation.  Our 
morphology and proliferation results, summarized in Table 3.12, demonstrate that after 5 days of 
mechanical stimulation – including cyclic stretch, cyclic hydrostatic pressure, and laminar shear 
stress – we detected significant changes in the morphology, alignment, and proliferation of 
tBMMSCs.  In many cases, these changes were dependent upon the type, magnitude, and 
frequency of stimulation as evidenced by statistically significant correlation coefficients.   
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Table 3.12: Summary of the morphology and proliferation results for the 5 day Mechanical Panel experiments.  
Double arrows indicate a significant increase or decrease (p<0.05) in the measured parameter from control values.  
Single arrows denote a moderate (p<0.10) change in the measured parameter.  ⊥ and || indicate significant 
perpendicular and parallel alignment (p<0.05), respectively.  
 
Shape 
Index 
Tortuosity 
Index Stimulus Area Length Alignment Proliferation 
CP-90HF ↓↓ ↓↓ ↑↑ ↓↓ - ↑ 
CP-90 ↓↓ ↓↓ ↑↑ ↓↓ - ↑↑ 
CP-120 ↓↓ ↓↓ ↑↑ ↓↓ - ↑↑ 
CP-180 ↓↓ ↓↓ ↑↑ ↓↓ - ↑↑ 
CS-1HF - ↑↑ - - - - 
CS-1 ↓↓ ↓↓ ↑↑ ↓↓ - ↑↑ 
CS-5 - ↑↑ ↓↓ - -  ⊥
CS-10 - - ↓↓ - -  ⊥
LSS-1 ↑↑ ↑↑ - - - - 
LSS-5 ↑↑ ↑↑ - - - ↓↓ 
LSS-10 ↑↑ ↑↑ ↓ ↑↑ || ↓↓ 
LSS-20 ↑↑ ↑↑ ↓↓ ↑↑ || ↓↓ 
 
Overall, our results demonstrate that cyclic pressure leads to a significantly smaller, and 
more rounded cell with fewer pseudopods (as measured by the tortuosity index).  Previous 
reports on ECs under pressure have demonstrated an increase in tortuosity concurrent with 
cellular elongation [396].  It is unclear, however, whether BMMSCs should behave in manner 
similar to aortic ECs.  Cyclic pressure not only affected BMMSC size and shape, but it also 
caused a dramatic increase in proliferation that had statistically significant negative correlation 
(ρ= -0.483, p<0.05) to the magnitude of stimulation.  This increase in proliferation as a result of 
cyclic pressure has been demonstrated in other cell types including SMCs [225, 228, 645] and 
ECs [386, 646] as well as in Dexter cultured BMMSCS [1].   
Cyclic stretch had varying effects on tBMMSCs depending upon the magnitude and 
frequency of stimulation.  Higher frequency stretching at low magnitude (CS-1HF) caused the 
cells to behave more similarly to the higher magnitudes of stimulation at 1 Hz.  However, low 
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magnitude 1 Hz (CS-1) stimulation caused the cells to behave similar to the tBMMSCs exposed 
to cyclic pressure, leading to a smaller, more rounded morphology, and increased proliferation.  
The higher magnitudes of cyclic stretch (5% and 10% stretch) caused a more elongated, spindle 
shaped cell and resulted in a perpendicular alignment to the direction of stretch.  These changes 
are in agreement with previously published data in other stem cells [526, 647].  The changes in 
alignment are characteristic of stress-shielding and occur in any cell type that is free to move in 
two dimensions [199, 527, 647, 648].  Unlike previously published research [526], CS did not 
seem to have a negative impact on proliferation despite the increase in staining for SMC-related 
proteins.  This observation contradicts earlier theories of mutually exclusive proliferation and 
differentiation.  One potential reason for this may have been the high serum content (20% FBS) 
used for the culture of these cells which was maintained throughout the Mechanical Panel 
experiments.  We maintained the same serum content during the experiments to prevent any 
changes in cell behavior as a result of chemical changes not associated with mechanical 
stimulation.  
Laminar shear stress induced a dramatic increase in cell size that diminished slightly with 
increasing shear stress.  Cellular alignment and elongation began to occur at 10 dynes/cm2.  In 
addition, increasing shear stress was associated with a decrease in cell number.  It is uncertain 
whether this decrease in cell number was related to an inhibition of proliferation, or positive 
selection of non-proliferating cells caused by washing away cells attempting to divide.  We do 
have some evidence (Appendix F) based upon preliminary Ki67 staining that shows a 
diminished proliferation index following exposure to LSS-5, which supports either a global 
inhibition of proliferation or the positive selection of non-proliferating cells.  There is also 
evidence in the literature that supports a decrease in proliferation by shear stresses greater than 5 
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dynes/cm2 in mature ECs [193, 405, 649].  Perhaps this is a conserved mechanism regardless of 
cell phenotype.   
When looking at the overall trends in the morphology and proliferation data, a pattern 
begins to appear.  Based upon our data, there appears to be a correlation between cell size and 
shape, and proliferation.  This is most apparent when comparing the cyclic pressure and CS-1 
samples with the shear stress samples.  The larger, more elongated cells tend to proliferate much 
less than the smaller, more rounded cells.  This is confirmed by correlation testing that shows a 
strong, positive correlation for shape and proliferation (ρ=0.729, p<0.001) and a weaker, 
negative correlation between area and proliferation (ρ= -0.435, p<0.001).  This positive 
correlation between shape and proliferation indicates that as shape index increases (i.e., the cells 
become more rounded), proliferation increases.  Likewise, as the cells size (area) increases, 
proliferation tends to decrease, albeit in a weaker fashion.  Additionally, shape index has a weak 
negative correlation (ρ= -0.367, p<0.001) with area, meaning that as the cell shape index 
increases (becomes more rounded), the area tends to decrease.  A linear regression model (Table 
3.13) of proliferation with area and shape index (SI) as independent variables is given by:  
 
(3.15) 
 
( ) ( )23242 22 1094.61003.913.1)/( cmcellsxSIcmcellsxAreamcmcellscmcellsDensity −+⎟⎟⎠⎞⎜⎜⎝⎛−= μ
and had an R2 of 0.665 (p=0.00), which indicates that area and shape index can account for more 
than 66% of the variance in the data (Figure 3.23).   
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Table 3.13:  Linear regression output from SPSS for proliferation regressed against area and shape index.  Despite 
the weak correlation between shape index and area, they do not exhibit colinearity, and are therefore suitably 
compatible in the linear regression model.   
 
Coefficientsa
-6.94E+003 3.56E+003 -1.952 .055
-1.13E+000 1.89E-001 -.417 -5.977 .000 .894 1.119
9.03E+004 1.09E+004 .578 8.296 .000 .894 1.119
(Constant)
Area
Shape
B Std. Error
Unstandardized
Coefficients
Beta
Standardized
Coefficients
t Sig. Tolerance VIF
Collinearity Statistics
Dependent Variable: Cell Densitya. 
 
 
  
Figure 3.23:  Non-normalized regression model fit for cell density with cellular area and shape index as 
independent variables.  Observed values for cell density (cell/cm2) are plotted against values predicted by the model 
in Equation 813H813H814H814H(3.15). 
R2=0.665 
p=0.00 
 3.4.2 Differential protein expression 
One of the main objectives of the work presented in this chapter was to determine what role, if 
any, each of the three mechanical stimuli that comprise the Mechanical Panel have on the 
differentiation of stem cells.  Our results are summarized in Table 3.14.   
 
Table 3.14:  Summary of IHC results for Mechanical Panel experiments.  ++ indicates strong homogenous staining 
intensity.  + indicates a moderate to weak homogeneous staining intensity.  +/- indicates heterogenous staining. 
– indicates no staining was evident. 
 
Stimulus SMA Calponin MHC Flk-1 PECAM vWF 
- - - - - - CP-90HF 
- - - - - - CP-90 
- - - - - - CP-120 
- - - + - - CP-180 
+/- +/- +/- ++ - - CS-1HF 
+ - - ++ - - CS-1 
++ ++ - ++ - - CS-5 
++ ++ + ++ - - CS-10 
- - - - - - LSS-1 
- - - - - - LSS-5 
- - - + - - LSS-10 
- - - + - - LSS-20 
- - - ++ - - Control 
 
We have found an apparent CS-dose-dependent expression of SMC protein markers. CS-1 
caused the tBMMSCs to express SMA (Figure 3.16); CS-5 led to the expression of both SMA 
and calponin (Figure 3.17); and CS-10 stimulated expression of both of these, in addition to the 
highly selective contractile protein, SMMHC (Figure 3.18). CS-1HF also resulted in expression 
of all three markers, but not to the extent seen for CS-5 and CS-10 in terms of the relative 
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numbers of positive cells within a field of view.  Exposure of BMMSCs to CP, LSS, or control 
conditions did not induce the expression of any of these SMC-related proteins.  These stretch-
dependent changes in SMC protein expression are consistent with previously published data on 
stem cells obtained from different sources, but only exposed to a single loading regimen [526, 
527, 650].  However, to our knowledge, these are the first studies to comprehensively study the 
magnitude and frequency effects of cyclic stretch in BMMSCs.   
In addition to the SMC protein expression changes that result from cyclic stretch, we 
have also discovered that these cells constitutively express flk-1 (see Figure 3.19), or VEGFRII, 
the active signaling receptor for VEGF (see Section 1.3.1.1).   Although we did not see any other 
markers of EC differentiation, the presence of flk-1 still allows the potential for these cells to 
differentiate to ECs since flk-1 expression is necessary for any EC differentiation during 
development and has been used as a sorting marker for ESCs with EC potential [567, 651, 652].  
The expression of flk-1 was maintained by the cells under all levels of CS (Figure 3.19), 
regardless of the expression of SMC markers. Although it would appear contradictory for stem 
cells to express EC-related markers as well as SMC-related markers that have traditionally been 
viewed as terminal differentiation, this type of phenomenon has also been reported in SMC-
precursors derived from the blood [262].  The expression of flk-1 was also maintained under CP-
180 and LSS-10 and LSS-20, but CP and LSS magnitudes below these resulted in a loss of flk-1 
expression. No expression of EC-related proteins (PECAM and vWF), or positive staining for 
alizarin red (osteoblasts) or oil red (adipocytes) was detected, thus strongly suggesting a 
specificity of differentiation for this particular set of stimuli.  
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3.4.3 Differential gene expression 
In addition to the immunohistochemistry data, we have some evidence, although as yet 
inconclusive, that mechanical stimulation modulates gene expression for targets associated with 
SMCs, cardiomyocytes, ECs, adipocytes, osteoblasts, and chondrocytes (Table 3.5-Table 3.10).  
The increases in SMC gene expression are in agreement with other published gene expression 
data on BMMSCs from another source [527l, 653].  Unlike the protein expression, the increase 
in several SMC genes was not restricted to cyclic stretch, as our results suggest that LSS and CP 
may increase SMC-related gene expression.  This is in accordance with other published studies 
of stem cells exposed to pressure with shear stress [530, 569].  However, we did not detect 
concomitant protein expression under the regimens tested.  This may be a result of post-
translational modification or knock-down of the transcribed genes through other mechanisms 
that we have not yet investigated.  One such possibility might be a potential increase in PDGF 
expression.  Decreases in SMA protein levels as a result of PDGF-BB stimulation have 
previously been shown to derive from post-translational destabilization of the SMA mRNA [129] 
even though SMA transcription may still occur at high levels [128].  PDGF has a similar effect 
on myosin production in SMCs, causing more than a 35% decrease in SM-1 protein but doubling 
non-muscle myosin protein [130].  In addition to the potential post-transcriptional modifications, 
there is evidence for transcriptional regulation of SMC genes by PDGF-BB through several 
mechanisms, including increases in the myocardin-related transcription repressors kruppel-like 
factor 4 (KLF4) [654]  and megakaryoblastic leukemia-1 (MKL-1) [655] as well as the 
displacement of myocardin from serum response factor (SRF) through phosphorylation of Elk-1 
[656].  These molecules are all potential targets for future studies into the mechanisms of how 
mechanical stimulation modulates gene expression in stem cells.   
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Concurrent with our analysis of SMC-related genes, we have obtained some evidence 
that EC-related genes can be modulated in stem cells by mechanical stimulation.  Flk-1 gene 
expression was downregulated under LSS and in the lower magnitudes of CP, which is 
consistent with our observations of flk-1 protein expression by immunohistochemistry.  
Although we did not detect any vWF expression in our tBMMSCs exposed to mechanical 
stimulation, our gene expression results indicate that vWF may be expressed under CP.  This 
again raises the question of post-translational modification.  Additionally, this apparent 
disconnect between gene and protein expression may be a result of timing and/or concentration.  
It is possible that these genes are just being turned on by the fifth day of stimulation, and no 
detectable protein has been produced yet.  Future studies centered on these specific endpoints 
may help to identify the appropriate processes driving this phenomenon.  The downregulation of 
other EC-related genes by LSS seems to contradict the literature for other stem cell types, 
particularly embryonic stem cells [567, 568, 651].  However, we do have evidence that LSS 
downregulates flk-1, which was found to be necessary for EC gene expression in embryonic 
stem cells exposed to shear stress [567].   
The lack of gene expression for osteoblast, chondrocyte, and adipocyte-related genes 
seems to fit our data demonstrating a no late-stage osteoblast and adipocyte differentiation using 
Alizarin Red and Oil Red O assays.  The increase in soluble factor expression, particularly FGF-
2 and TGβ, by LSS may be related to the convection of the large volume of media required to 
operate the Streamer® apparatus.  The shear stress device contained over 400 mL of cell culture 
media, which was over an order of magnitude greater than the cyclic pressure, control, and cyclic 
stretch cultures.  The constant movement of this media over the cells in the shear stress system 
could potentially eliminate local microenvironments driving autocrine and paracrine signaling by 
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washing away secreted factors, leading the cells to continually secrete these biomolecules.  This 
potentially constant production of growth factors and the lack of signaling may drive the increase 
in cell size and decreased proliferation seen under LSS.  Although a linear regression 
demonstrates that cell size and shape were able to account for more than 66% of the variability in 
proliferation (Table 3.13 and Figure 3.23), this does not imply a causal relationship. 
3.4.4 Limitations 
As with any in vitro study, there are experimental limitations that may have an impact on the 
results obtained.  As a primary isolation, the tBMMSCs were invariably heterogenous.  Although 
the Mechanical Panel was designed to minimize the effects of heterogeneity between stimuli, our 
interpretation of the data must include the potential that the applied mechanical stimuli were 
selecting for a subpopulation of cells within the original heterogenous mix.  Selection need not 
occur through apoptotic mechanisms, but may be a result of a selective increase or inhibition of 
proliferation in a particular sub population.   
Another important limitation to the current study was the use of profoundly subconfluent 
cultures (200 cells/cm2 starting density) to initiate the Mechanical Panel.  In addition to being the 
standard culture conditions published for the tBMMSCs [613], subconfluent cultures were used 
to potentially identify the individual response of the cells to each of the Mechanical Panel 
components through morphologic and proliferation changes that were relatively unaffected by 
neighboring cells.  While this aided in the ease of analysis and may allow for a heterogeneous 
cell population to be interrogated with relative certainty that each cell is behaving independently, 
cells do not exist in a subconfluent state in vivo.  At no time during their development and 
subsequent life are cells without some form of cell-cell contact.  This isolation may have a 
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profound effect on the way the cells responded to the mechanical stimulation, and confluent 
cultures, which would be required to generate enough cellular material for tissue engineering 
applications, may have a completely different outcome.  Nonetheless, having subconfluent 
cultures did allow for us to identify potentially useful stimulations regimens, such as cyclic 
pressure, that may be used to expand cells quickly for tissue engineering applications as well as 
further determine the role of cyclic stretch on differentiation of these BMMSCs towards SMCs.   
In addition to the potential implications for altering cell behavior, subconfluent cultures 
imposed a serious limitation on the available biologic material for assays such as RT-PCR and 
Western blotting.  As a result of low protein yields, no Western blotting could be performed to 
corroborate the IHC or RT-PCR data that was generated.  Even the RT-PCR analysis was 
somewhat limited in that only one TLDA could be run with the available RNA and we believe 
that several TLDAs were under loaded as a result of low RNA yields.  This resulted in the failure 
to successfully interrogate several genes and resulted in empty data sets with essentially no 
reserve materials to repeat the assay, further hampering our statistical analysis of the gene 
expression results.   
Another limitation which may have had a significant impact on the RT-PCR results was 
the use of 18s as the endogenous control gene.  The use of 18s has recently been reported to be 
insufficient as an endogenous control gene because of its extremely high abundance relative to 
target mRNA transcripts [657].  This can result inadequate normalization for vastly different 
transcriptomes.  We have evidence, found in Appendix G, which demonstrates that not only is 
18s expressed at significantly higher levels than target mRNA, but it has a variance in expression 
that is not related to the target mRNA.  In retrospect, an investigation of all of the potential 
endogenous control genes should have been performed to identify a gene or set of genes (as is 
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currently suggested in the literature [657, 658]) that would achieve their CT near the threshold of 
the genes of interest as well as remain stable under the various mechanical stimuli used in this 
study.  This test of endogenous controls was performed for subsequent experiments on the 
temporal change in gene expression as a result of mechanical stimulation (see Chapter 4.0).   
Although we have demonstrated that cyclic stretch induces differentiation towards an 
SMC phenotype, including the highly differentiated contractile protein SMMHC, we have not 
provided evidence that these differentiated cells are functionally equivalent to adult SMCs.  The 
use of contractile agents, such as carbachol, to initiate and visualize cellular contraction [659] 
has been impeded by our ability to image the BioFlex® culture plates at the end of a CS 
experiment.  In order to ensure that the membrane experiences uniform stretch, silicone grease is 
applied to the underside to help it glide over the loading post.  This effectively prevents an 
inverted microscope from being able to view the cells following an experiment without cutting 
the membrane out and cleaning it with harsh scraping techniques that disturb unfixed cells.  
Furthermore, the membrane itself was permanently deformed by the cyclic stretching process 
and did not present a uniform focal plane on which to image the cells following an experiment.   
Another limitation, which was mentioned previously, was the high volume of media 
needed to operate the shear stress system.  This essentially presented the cells with an infinitely 
fresh media supply relative to their counterparts in the other apparatuses in the Mechanical 
Panel.  To mitigate this effect over time, no media changes were performed during the 5 day 
experiments for shear stress, while media changes were performed every 48 hours in accordance 
with the standard culture protocol for the tBMMSCs in the control, cyclic stretch, and cyclic 
pressure systems.  In addition, the shear stress system operated in the absence of any form of 
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pulsatile flow, unlike the other components of the Mechanical Panel, which is not physiologic for 
the vascular system that was being modeled for our studies.   
3.5 CONCLUSION 
We have demonstrated that mechanical stimulation has differential effects on the morphology, 
proliferation, protein, and gene expression in BMMSCs.  Our results have confirmed previous 
observations that cyclic stretch can drive stem cell differentiation towards an SMC phenotype 
and have extended our understanding of the role cyclic stretch plays in differentiation by the use 
of multiple magnitudes and frequencies of stimulation.  We have demonstrated that cyclic 
pressure accelerates proliferation, and that a correlation exists between cell size, shape, and 
proliferation.  To our knowledge, this work is the first comprehensive study examining multiple 
types of mechanical stimulation in parallel across a broad range of magnitudes and multiple 
frequencies and has future applications in bioreactor design and tissue engineering research. 
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4.0 TEMPORAL RESPONSE TO MECHANICAL STIMULATION 
4.1 INTRODUCTION 
Based upon the successful identification of the differential response of BMMSCs to three 
mechanical stimuli using our Mechanical Panel, the next step was to investigate the time-
dependent evolution of this response.  Previous work using both embryonic stem cells and bone 
marrow derived stem cells has demonstrated temporal changes in gene expression in response to 
mechanical stimuli.  Park et al. [527] demonstrated that SM22α and SMA gene transcription 
were both transiently increased in BMMSCs exposed to 10% cyclic uniaxial stretch for 1-3 days.  
Similarly, Yamamoto et al. [567] found that flk-1+ embryonic stem cells exposed to shear stress 
had increased RNA levels for SM22α and SMA within 24 hours, but that these genes fell back 
towards control levels at 48 and 72 hours.  However, EC-related genes including flk-1 and 
PECAM experienced sustained increases in RNA levels with shear stress.  Similar sustained, 
shear-induced increases in EC markers have also been demonstrated in C3H10T1/2 embryonic 
stem cells [568].  To further characterize the mechanobiology of tBMMSCs, we investigated 
their response to 1 and 3 days of stimulation in the Mechanical Panel.  In addition, we attempted 
to address some of the limitations identified in Section 3.4.4.  In these experiments, we used 
confluent cultures to model more physiologic microenvironments as well as improve our yield of 
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biological material for PCR and Western blotting.  Furthermore, we performed the necessary 
tests to determine a more suitable gene to be used as an endogenous control for PCR endpoints. 
4.2 
4.2.1 
METHODS 
Experimental design 
4.2.1.1 Time points 
Experiments performed to address Specific Aim 3 were designed to determine the time-
dependent response of tBMMSCs to a specific magnitude and frequency of each mechanical 
force stimulus from the Mechanical Panel (see Section 3.1.1).  Because the overall goal of this 
study is to determine how gene and protein expression changes in tBMMSCs, time points of 24 
hours and 3 days were chosen to potentially capture the maximal gene and protein changes 
associated with the Mechanical Panel based upon other research conducted in stem cell 
differentiation [527, 558, 567].  Each of these studies has shown significant changes in gene 
expression for some of the endpoints listed in Table 4.2 within 24 hours of mechanical 
stimulation.  Furthermore, 3 days of continued stimulation was sufficient time to determine 
whether the changes in gene expression were transient, and whether there was an associated 
change in protein expression. 
4.2.1.2 Cell source 
For each experiment, tBMMSCs were obtained as described in Section 3.2.1 and seeded 
at confluence (21,000 cells/cm2) on collagen I coated BioFlex™ (Flexcell) deformable substrates 
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for stretch and control conditions, or Culture Slips™ (Flexcell) for shear and pressure conditions.  
Forty-eight hours after seeding, the tBMMSCs were loaded into each of the systems described in 
Section 3.2.2 while control samples were placed in static incubator conditions.   
4.2.1.3 Mechanical panel parameters 
The regimens employed in these experiments are listed in Table 4.1.  These regimens 
were chosen based upon the response of the tBMMSCs during the 5 day experiments.  CS-10 
was chosen because it exhibited the maximal changes in phenotype, namely SMMHC, calponin, 
and SMA expression determined by IHC (see Figure 3.16 Figure 3.17 Figure 3.18, , and ), and 
also displayed an elongated, spindle shaped morphology (see Figure 3.8 and Figure 3.9) which 
is characteristic of SMCs [59, 213].  Because the tBMMSC response to cyclic pressure did not 
appear to be affected by the magnitude or frequency of stimulation, we chose to use CP-120 
because it was the most physiologically relevant as a vascular pressure.  In addition, research 
using other cell types, including ECs and SMCs, has shown higher magnitudes of pressure (>150 
mmHg) to be deleterious to the cells, leading to abnormal phenotypes and increased rates of 
apoptosis [229, 384-390].  Furthermore, although CP-120 demonstrated a decrease in flk-1 
staining from the constitutive expression (Figure 3.19), the flk-1 gene expression was not 
different than the control (Table 3.6).  LSS-20 was chosen because it was the maximum 
magnitude tested at the 5 day time point and exhibited the greatest changes in cell morphology; 
namely, elongation and markedly spindle shaped (see Figure 3.8 Figure 3.9and ) and decreased 
proliferation (Figure 3.14).  These changes in morphology are consistent with ECs under shear 
stress [188].  Furthermore, EC differentiation in an embryonic mesenchymal progenitor cell line 
(10T1/2 cells) has been demonstrated using 15 dynes/cm2 shear stress [568].   
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Table 4.1: Stimulation regimens used for Mechanical Panel experiments to determine the temporal response of 
tBMMSCs to mechanical stimulation.  tBMMSCs were exposed to these conditions for 24 hours or 3 days. 
 
Control Cyclic Stretch Cyclic Pressure Shear Stress  
20 dynes/cm2 Static incubator 
conditions 
10%, 1 Hz 120/80 mmHg, 1 Hz Regimen (CS-10) (CP-120) (LSS-20) 
 
4.2.2 Endpoints 
After 24 hours or 3 days of stimulation in the Mechanical Panel, the samples were removed and 
processed for RNA extraction and purification  (see Section 3.2.4.5) followed by RT-PCR (see 
Section 4.2.2.1).  In addition, protein extraction and Western blotting (see Section 4.2.2.3) were 
performed to identify changes in the protein targets of some of the RT-PCR endpoints.   
4.2.2.1 RNA isolation and qualitative assessment 
Cell lysis and RNA isolation was performed with TrizolTM immediately following the 
withdrawal of each stimulus using techniques described in Section 3.2.4.5.1.  The isolated RNA 
was purified using the RNeasy Kit (Qiagen) according to protocols described in Section 
3.2.4.5.2.  Following purification, RNA quality and quantity were assessed by the GEGF at Case 
Western Reserve University.  RNA concentration was assayed using a NanoDrop 
Spectrophotometer (ND-1000, NanoDrop Technologies, Wilmington, DE), and RNA quality was 
assessed with a BioAnalyzer (Model 2100, Agilent Technologies) using techniques described in 
Section 3.2.4.5.3.  RNA samples attaining an RIN value of greater than 8 were selected for RT-
PCR.   
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4.2.2.2 TaqMan® RT-PCR Low Density Array 
RNA samples suitable for RT-PCR analysis were converted to cDNA through reverse 
transcriptase reactions (see Section 3.2.4.5.4).  The converted cDNA was then loaded into a 
custom TaqMan® Low Density Array (TLDA, Applied Biosystems).  The gene names, catalog 
numbers, and classifications for the primers loaded into the TLDAs used for these experiments 
are listed in Table 4.2.  Because new primers are continually added to the available inventory for 
TLDA design, we chose to eliminate several gene targets whose expression was extremely low 
or never detected (e.g., Runx2 and TNFα) in favor of other gene targets, (e.g., PECAM and 
cyclin B1) that had recently become available for use on the custom TLDAs.  In addition, testing 
was performed to identify a more appropriate endogenous control gene for use on the TLDAs 
which was also used in the new custom TLDAs (see Section 4.2.2.2.1).  RT-PCR was performed 
by the technicians at the GEGF according to protocols described in Section 3.2.4.5.5.1.   
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 Table 4.2:  List of TaqMan® PCR primers, classifications, and catalog numbers for the second custom-designed 
TLDA card.  Many of the genes listed in the first card (see Table 3.4) that are not found on the second card were 
removed because of their lack of expression, or were moved to single assays because we wished to examine the 
primer in conjunction with a  non-inventoried primer that could not be placed on a TLDA.   
 
Applied 
Biosystems 
Catalog # 
Classification Gene Name 
Adipocyte PPAR γ Rn00440945_m1 
BMMSC CD59 Rn00563929_m1 
BMMSC CD90 Rn00562048_m1 
Cardiomyocyte Troponin Rn00437164_m1 
Chondrocyte Aggrecan I Rn00573424_m1 
Chondrocyte Collagen II Rn00563954_m1 
EC CD133/Prominin I Rn00572720_m1 
EC Endoglin Rn00568869_m1 
EC Flk-1 Rn00564986_m1 
EC iNOS Rn00561646_m1 
EC vWF Rn00788354_m1 
EC CD31 Rn01467262_m1 
EC E-Selectin Rn00594072_m1 
Fibroblast Vimentin Rn00579738_m1 
Housekeeping Gusb Rn00566655_m1 
ECM Collagen I Rn00584426_m1 
ECM Collagen III Rn01437683_m1 
ECM Collagen IV Rn01401018_m1 
ECM Elastin Rn01499782_m1 
Myocyte Desmin Rn00574732_m1 
Osteoblast Alkaline Phosphatase Rn00564931_m1 
Osteoblast Osteocalcin Rn00566386_g1 
Osteoblast Osteopontin/SPP1 Rn01449972_m1 
Proliferation Cyclin B1 Rn00596848_m1 
Secreted Peptides BMP2 Rn00567818_m1 
Secreted Peptides FGF2 Rn00570809_m1 
Secreted Peptides Rn00572010_m1 TGF-α 
Secreted Peptides VEGF Rn00582935_m1 
SMC Caldesmon Rn00565719_m1 
SMC Rn00580659_m1 SM22α 
SMC Myocardin Rn01786178_m1 
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4.2.2.2.1 Determination of endogenous control gene 
Table 3.4Following the initial results with the first custom-designed TLDA ( ), it became 
apparent that the endogenous control supplied by Applied Biosystems in the TLDA card may not 
have been appropriate for our cell type and/or experimental conditions (see Appendix F).  
Therefore, alternative endogenous control genes were investigated.  Equal masses (200ng) of 16 
cDNA samples encompassing a wide range of magnitudes, stimuli, frequencies, time points, and 
states of confluence (see Table 4.3) were chosen for analysis in 2 Endogenous Control TLDAs 
(Applied Biosystems) which contained TaqMan® gene expression assays for 16 common 
endogenous control genes (Table 4.4) in quadruplicate.  The Endogenous Control TLDAs were 
analyzed by RT-PCR according to techniques outlined in Section 3.2.4.5.5.  
The output from the RT-PCR reaction was processed using SDS software to determine 
the raw CT values for each of the 16 endogenous control genes for the 16 experimental samples.  
These raw CT values were imported into GeNorm, an Excel-based applet created by 
Vandesompele et al.[657] that calculates an expression stability parameter M for each gene as the 
average pair-wise variation V for that gene compared to all other genes in the data set.  The 
software computes the stability parameter for each gene, then removes the gene with the largest 
M value, and recalculates the stability parameter for each of the remaining genes.  The process is 
repeated until two genes remain, at which point no further ranking can be determined.  To make 
the choice between the two most stable genes from the GeNorm output, the variance in the CT 
was compared and the gene with the lower variance was chosen as the endogenous control gene 
for the second set of custom-designed TLDAs (Table 4.2).  As per Applied Biosystems' quality 
control policy, the 18S gene was still required to be on the TLDA although it would no longer be 
used to normalize the RT-PCR results. 
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 Table 4.3:  Sample list analyzed by the endogenous control TLDA.  The samples were chosen to represent each 
component of the Mechanical Panel at different magnitudes, frequencies, times of exposure, and confluence.   
 
Stimulus Magnitude Frequency Exposure Time Starting Density
200 cells/cm2 Control 0 0 5 days 
200 cells/cm2 CS 1% 2.75 Hz 5 days 
1 dyne/cm2 200 cells/cm2 LSS N/A 5 days 
200 cells/cm2 CP 90/70 mmHg 2.75 Hz 5 days 
200 cells/cm2 Control 0 0 5 days 
200 cells/cm2 CS 5% 1 Hz 5 days 
10 dynes/cm2 200 cells/cm2 LSS N/A 5 days 
200 cells/cm2 CP 180/140 mmHg 1 Hz 5 days 
21,000 cells/cm2 Control 0 0 24 hours 
21,000 cells/cm2 CS 10% 1 Hz 24 hours 
20 dynes/cm2 21,000 cells/cm2 LSS N/A 24 hours 
21,000 cells/cm2 CP 120/80 mmHg 1 Hz 24 hours 
21,000 cells/cm2 Control 0 0 3 days 
21,000 cells/cm2 CS 10% 1 Hz 3 days 
20 dynes/cm2 21,000 cells/cm2 LSS N/A 3 days 
21,000 cells/cm2 CP 120/80 mmHg 1 Hz 3 days 
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Table 4.4:  List of the endogenous control genes used in the Endogenous Control TLDA.  Each of these endogenous 
control genes have been commonly employed in research involving gene expression. 
 
Gene Name Protein 
18s 18s Ribosomal RNA 
Actb β-actin 
Arbp Acidic ribosomal phosphoprotein P0 
B2m β2 microglobulin 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
Gusb Glucuronidase, β 
Hmbs Hydroxymethylbilane synthase 
Hprt Hypoxanthine guanine phosphoribosyl transferase 
Pgk1 Phosphoglycerate kinase 1 
Ppia Peptidylprolyl isomerase A 
Ppib Peptidylprolyl isomerase B 
Rplp2 Ribosomal protein, large P2 
Tbp TATA box binding protein 
Tfrc Transferrin receptor 
Ubc Ubiquitin C 
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide Ywhaz 
 
4.2.2.3 Protein isolation and quantification  
The remaining organic phase from the Trizol™ preparation (see Section 3.2.4.5.1) was 
processed further to obtain the total cellular protein (see Figure C.1 in Appendix C) for 
application in Western blotting (Section 4.2.2.4).  The general methods for protein extraction, 
purification, and quantification are described in the following sections.  
4.2.2.3.1 Protein extraction 
For each milliliter of Trizol™ in the original extraction, 0.3 mL of 100% ethanol 
(Pharmco-AACP) was added and mixed by gentle inversion to precipitate the DNA remaining in 
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the organic layer.  The Trizol™/chloroform/ethanol mixture was incubated for 3 minutes at RT 
before centrifugation at 2000 x g for 5 minutes at 4oC.  The supernatant was removed with a 
glass pipette and held on ice for protein extraction while the DNA pellet was frozen at -80oC for 
possible future analysis of total DNA content. 
To precipitate the protein from the remaining Trizol™/chloroform/ethanol mixture, 1.5 
mL of 100% isopropanol (PX1835-14, EMD, San Diego, CA) per milliliter of original Trizol™ 
volume was added and vortexed to ensure proper mixing.  The 
Trizol™/chloroform/ethanol/isopropanol mixture was incubated at RT for 10 minutes before 
centrifugation at 11,500 x g for 30 minutes at 4oC to pellet the dissolved protein.  The 
supernatant was discarded, and the remaining protein pellet was further processed to eliminate 
potential organic contaminants.   
4.2.2.3.2 Protein Purification 
To purify the extracted protein, the initial pellet was washed with 2mL of wash solution 
(2.9% guanidine hydrochloride (5010, EMD) in 95% ethanol (Pharmco-AACP)) per milliliter of 
original Trizol™ volume.  The wash solution was mixed thoroughly with the protein pellet by 
vortexing, and incubated for 20 minutes at RT.  The sample was then centrifuged at 11,500 x g 
for 5 minutes at 4oC.  The supernatant was discarded, and the process repeated 3 times to 
eliminate organic contaminants from the protein pellet.  After the final wash, the protein pellet 
was mixed with 2mL of 100% ethanol (Pharmco-AACP) and incubated for 20 minutes at RT.  
The sample was then centrifuged at 11,500 x g for 5 minutes at 4oC.  After centrifugation, the 
supernatant was discarded and the sample placed in a desiccating jar under vacuum for 5 minutes 
to remove any further traces of ethanol.  The dehydrated protein was then resuspended in 50 mM 
Tris HCl (pH 8.0, T-3038, Sigma) and 0.1% sodium dodecyl sulfate (SDS, BP166, Fisher 
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Scientific) containing HALT® anti-proteinase (Pierce) by tituration and incubation at 50oC.  The 
resuspended protein was centrifuged at 16,000 x g to pellet any insoluble material and 
transferred to a fresh 1.5mL tube and stored at -80oC. 
4.2.2.3.3 Total protein quantification 
The amount of total resuspended protein from Section 4.2.2.3.2 was quantified using a 
Bradford colorimetric assay (BCA, Pierce) according to the manufacturer’s specifications.  
Briefly, 196 µL of Reagent A, 4 µL of Reagent B, and a 10 µL dilution of the protein sample 
were mixed in a 96-well plate and incubated for 30 minutes at 37oC.  The optical density of the 
final reaction was measured at 570 nm using a microplate reader (Model 680, Bio-Rad, Hercules, 
CA).  A standard curve using known concentrations of BSA was generated in triplicate and used 
calculate the concentration of the unknown protein samples.  The protein concentration and total 
yield of sample were recorded in the experimental database (see Section 3.2.5.1). 
4.2.2.4 Western blotting 
Relative changes in protein expression for the experiments outlined in Section 4.2.1 were 
quantified by Western blotting.  The general methods for the Western blotting are described in 
the following sections. 
4.2.2.4.1 Protein electrophoresis and transfer     
Purified protein (as described in Section 4.2.2.3.2) was separated by electrophoresis 
under reducing conditions.  Approximately 20-40 µg of protein (as determined from the BCA 
assay described in Section 4.2.2.3.3) was mixed 1:5 (v/v) with 6X sample buffer (50 mM Tris 
(pH 6.8, Sigma), 26% glycerol (G5516, Sigma), 6.5mmol DTT (43815, Sigma), 0.06% 
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Bromphenol Blue (161-0404, Bio-Rad), 0.4% SDS) and heated to 95oC for 3 minutes before 
being loaded in a 4-15% Tris-HCL gradient gel (161-1158, Bio-Rad).  The gel was run at 200 V 
for 30 minutes in Tris-SDS-Glycine buffer (161-0772, Bio-Rad) prior to being transferred to a 
nitrocellulose (Immobilon-NC, Millipore, Billerica, MA) or PVDF (Bio-Rad) membrane.  
Separate transfer protocols and solutions were used depending on the protein of interest and are 
outlined in Table 4.5.   
 
Table 4.5:  Transfer solutions and settings for each protein endpoint interrogated by Western blotting. 
 
Endpoint Transfer Solution Transfer Settings Membrane 
25 mM Tris HCl pH 8.0, 190 mM Glycine,  
20% methanol 40 V for 90 minutes PVDF SMA 
25 mM Tris, 190 mM Glycine, Calponin 100 V, 2 hours Nitrocellulose 20% methanol 
50 mM Tris, 30 V, 16 hours 
followed by SM-MHC Nitrocellulose 380 mM Glycine, 0.1% SDS, 
20% methanol 100 V, 1 hour 
50 mM Tris, 30 V, 16 hours 
followed by Flk-1 Nitrocellulose 380 mM Glycine, 0.1% SDS, 
20% methanol 100 V, 1 hour 
50 mM Tris, 30 V, 16 hours 
followed by PECAM 380 mM Glycine, 0.1% SDS, Nitrocellulose 
20% methanol 100 V, 3 hours 
 
4.2.2.4.2 Immunoblotting 
Following protein transfer, the nitrocellulose membrane was blocked for 1 hour and 
incubated with the primary antibody diluted in the blocking agent for 1 hour at RT.  A list of the 
blocking solutions and primary antibody dilutions is found in Table 4.6.  The membrane was 
washed four times for 5 minutes to remove any unbound primary antibody, and incubated with 
the horseradish peroxidase (HRP) conjugated secondary antibody (Pierce) in the blocking agent 
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for 1 hour at RT.  After four 5 minutes washes in buffer, the membrane was developed with 
enhanced chemiluminescence (SuperSignal West Femto, Pierce) according to the manufacturer’s 
instructions.  The developed membrane was imaged on a Kodak Image Station (Model 2100, 
Eastman Kodak, Rochester, NY).  For endpoints whose molecular weight was less than 60 kDa, 
the membrane was stripped using Blot Rejuvenate® (Chemicon) and reprobed with GAPDH.  For 
endpoints greater than 60 kDa, the membrane was cut and GAPDH staining performed 
separately. 
 
Table 4.6: Reagent details for each of the endpoints interrogated by Western blotting. 
Positive 
Control 
(µg/lane) 
Endpoint 
(molecular weight) 
Primary 
Dilution 
Secondary Ab 
(Source) Blocking Buffers 
1:20,000 Goat 
anti-mouse 
(Pierce) 
A-10  
(25μg) 
1:180,000  
(45o C) 
SMA  
(42 kDa) Superblock 
1:20,000 Goat 
anti-mouse 
(Pierce) 
A-10  
(50μg) 
50mM Tris, pH 7.5; 200mM NaCl; 0.1%  
Tween 20; 1% dry milk Calponin (32 kDa) 1:500 
1:20,000 Goat 
anti-mouse 
(Pierce) 
A-10  
(50μg) 
MHC  
(200 kDa) 
50mM Tris, pH 7.5; 200mM NaCl; 0.1%  
Tween 20; 1% dry milk 1:500 
1:20,000 Goat 
anti-mouse 
(Pierce) 
ECV304 
 (50μg) 
Flk-1  
(150-200 kDa) TBS; 0.5% Tween 20; 5% non-fat dry milk 1:1000 
1:20,000 Goat 
anti-mouse 
(Pierce) 
Jurkat 
 (50μg) 
PECAM 
(130-140 kDa) 
15mM Tris buffer, pH 8.0; 140mM NaCl;  
0.05% Tween 20; 5% non-fat dry milk 1:5000 
1:2,000 Mouse 
anti-goat 
(Pierce) 
GAPDH 
 (37 kDa) N/A PBS, 0.1% Tween, 5% non-fat dry milk 1:1000 
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4.2.2.4.3 Antibodies 
For SMC protein detection, SMA (MAB1522, Chemicon), calponin (M3556, Dako) and 
MHC (M3558, Dako) were used.  A-10 (a rat aortic SMC line) cell lysates (sc-3806, Santa Cruz) 
were used as a positive control for all SMC proteins.  For EC protein detection, flk-1 (cs-6251, 
Santa Cruz) and PECAM (MAB1393, Chemicon) were used.  ECV304 (a transformed EC cell 
line) cell lysate (sc-2269, Santa Cruz) was used as a positive control for flk-1, and Jurkat cell 
lysate (sc-2204, Santa Cruz) was used as a positive control for PECAM.  GAPDH (sc-20357, 
Santa Cruz) was used as an internal loading control. 
4.2.2.4.4 Image analysis 
Images of the Western blots were imported into Scion Image (Scion Corp) for 
densitometry analysis.  Each protein band at the correct molecular weight for each antibody was 
highlighted and the integrated optical density was measured.  The integrated optical density for 
each lane was normalized to its respective GAPDH loading control, and then divided by the 
normalized control sample for each experiment to provide a fold-change in protein expression.   
4.2.3 Statistical analysis 
The RQ values for each RT-PCR run and fold-changes in protein expression as determined from 
the Western blots were stored in the Experimental Database (see Section 3.2.5) and exported to 
SPSS software for statistical analysis.  For comparisons to the control, a one-sample t-test was 
performed against μ=1 with α=0.05.  For comparisons between stimuli and time points, one-way 
ANOVA with post-hoc LSD testing at α=0.05 was used to detect significant differences. 
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4.3 
4.3.1 
RESULTS 
Determination of endogenous control gene 
In light of the earlier RT-PCR results (see Section 3.3.6 and Appendix F), 16 endogenous 
control genes were evaluated using samples found in Table 4.3.  The resulting expression levels 
were evaluated using the stability index calculated by GeNorm software [657].  The results are 
displayed in Figure 4.1 and demonstrate that the two most stable genes for our experimental 
conditions are GAPDH and Gusb.  The calculated stability index for these genes was 0.10, which 
is below the recommended value of 0.15 [657].  By this stability index, either gene would 
therefore be suitable as the endogenous control for our experimental system.  To help make a 
definitive decision between these two genes, we also examined the average CT and CT variance 
for the endogenous control genes (Table 4.7).  Gusb had the lowest computed variance (0.0953 
cycles) and had an average CT (25.96 cycles), which was most similar to the CT values for the 
target genes in our TLDAs.  Based upon the independent confirmation by GeNorm analysis and 
our computed variance of Gusb as the most stable gene, we chose Gusb as the endogenous 
control gene for all of our subsequent RT-PCR.   
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Figure 4.1:  Plot of the stability index calculated from the variance in gene expression as a function of the stepwise 
removal of each of the genes listed on the X-axis.   
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Table 4.7:  Table depicting the average and variance of the CT for each of the potential endogenous control genes. 
 
Detector 
Average 
Detector 
Variance Detector 
18S 12.21 13.3260 
Ppia 22.47 8.1199 
Tbp 29.74 6.4745 
Tfrc 27.86 4.0181 
Rplp2 22.42 3.4542 
Ppib 22.32 3.0567 
Ywhaz 23.33 2.3627 
Pgk1 22.10 0.8304 
B2m 19.96 0.5312 
Gapdh 19.57 0.5005 
Arbp 21.32 0.4463 
Hprt 23.01 0.3862 
Actb 17.18 0.2729 
Hmbs 25.44 0.1546 
Ubc 21.81 0.1341 
Gusb 25.96 0.0953 
 
4.3.2 Gene Expression 
4.3.2.1 Muscle related genes 
The average RQ values ± SD for muscle-related genes are depicted in Table 4.8.  Similar 
to the previous 5 day data, caldesmon did not seem to be affected by mechanical stimulation, 
maintaining expression levels near controls.  The lone exception was a statistically significant 
(p<0.05, but not biologically relevant) decrease in caldesmon under LSS at 3 days, which was 
also significantly lower than the 24 hour expression (p<0.05).  The expression of cardiac 
troponin significantly decreased (p<0.05) for CP and LSS at both 24 hours and 3 days.  
However, under CS, the expression is unchanged at 24 hours and 3 days.  Desmin expression 
was significantly decreased (p<0.05) for LSS at both 24 hours and 3 days, and unchanged for 
CP.  Desmin expression was not affected by CS at 24 hours, but increased nearly 2-fold (p<0.05) 
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at 3 days.  SM22α expression changes under CS were not statistically significant, but the data 
seems to trend towards a transient downregulation at 24 hours followed by a return towards 
control values at 3 days.  On average, there appears to be some biologically relevant increase in 
expression in SM22α for CP and LSS at 3 days, but the expression patterns were highly variable 
as demonstrated by the high standard deviation.  Myocardin (recently available on the TLDA), 
which has been reported as a selectively expressed master transcription factor for SMC genes 
[62, 103-106, 656], was significantly downregulated (p<0.05) at 24 hours by CP and LSS, and 
remained downregulated for LSS (although not statistically significant).  No change was evident 
for CS at 24 hours, but a trend towards upregulation (p<0.05) was developing by 3 days.   
 
Table 4.8:  Fold changes in muscle-related gene expression relative to control for each component of the 
Mechanical Panel.  Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 
(considered biologically relevant), respectively.  Data are presented as the mean ± SD with sample numbers.  + 
p<0.10, *p<0.05, vs. controls.   
 
Time Stimulus Caldesmon Cardiac Troponin Desmin
CP-120 1.04 +/- 0.27, n=6 0.29 +/- 0.06, n=6 * 0.78 +/- 0.14, n=6 * 
CS-10 1.01 +/- 0.17, n=6 0.87 +/- 0.29, n=6 1.21 +/- 0.95, n=6
LSS-20 1.4 +/- 0.26, n=6 * 0.18 +/- 0.07, n=6 * 0.41 +/- 0.12, n=6 * 
CP-120 1.04 +/- 0.21, n=5 0.47 +/- 0.12, n=5 * 0.76 +/- 0.22, n=5 + 
CS-10 0.93 +/- 0.11, n=8 1.33 +/- 0.33, n=8 * 1.82 +/- 0.51, n=8 * 
LSS-20 0.84 +/- 0.06, n=6 * 0.27 +/- 0.18, n=6 * 0.34 +/- 0.17, n=6 * 
24
 
H
ou
rs
3 
D
ay
s
Muscle
 
Time Stimulus Myocardin SM22α
CP-120 0.71 +/- 0.13, n=6 * 1.63 +/- 0.61, n=6 + 
CS-10 0.99 +/- 0.1, n=6 0.47 +/- 0.4, n=6 * 
LSS-20 0.69 +/- 0.15, n=6 * 1.34 +/- 0.56, n=6
CP-120 0.96 +/- 0.25, n=5 1.5 +/- 0.97, n=5
CS-10 1.24 +/- 0.17, n=8 * 0.9 +/- 0.15, n=8
LSS-20 0.78 +/- 0.38, n=6 1.18 +/- 0.76, n=6
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4.3.2.2 Endothelial Related Genes 
The average RQ values ± SD for endothelial-related genes are depicted in Table 4.9.  
CD133 was downregulated by all three mechanical stimuli at 24 hours, and had variable 
expression at 3 days, showing some an average trend towards upregulation in CP and LSS.  
Endoglin, which is the TGF-β receptor reported to be highly expressed in ECs [321, 660], was 
significantly downregulated (p<0.05) by both CS and LSS at 24 hours and 3 days.  Conversely, 
endoglin expression was unchanged at 24 hours and trending towards and increase in expression 
for CP at 3 days.  E-selectin, which was another new addition to the TLDAs, appears to be 
highly variable.  However, this is a result of the failure of the control sample to register a CT 
value for one experiment, which caused the CT for the remaining samples to be calculated 
against an assumed CT of 40 cycles, resulting in extremely large RQ values.  The individual fold-
changes for E-selectin under LSS were always more than two-fold (range 2.4 - 54 fold) greater 
than controls and can therefore be considered a biologically relevant increase in expression.  
Similarly, vWF gene expression was significantly increased for LSS at 24 hours (p<0.05) and 3 
days (p<0.05).  iNOS expression, which had never registered any transcripts in any sample at 5 
days (see Table 3.6), was significantly elevated (p<0.10) under LSS at both 24 hours and 3 days.  
Similarly to E-selectin, the relative changes in iNOS to control samples were highly variable 
because of the failure to register transcript values under several control samples.  For LSS, 
changes in iNOS expression ranged from 1 to 84-fold over controls.  PECAM (CD31) was 
another new assay to the TLDA, and exhibited biologically and statistically relevant (p<0.10) 
increases under CP and LSS at 24 hours and 3 days.  No changes were found for CS from the 
controls at either time point.  Flk-1 expression was significantly downregulated under LSS at 24 
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hours (p<0.05) and 3 days (p<0.05) as well as CP at 3 days (p<0.05).  Conversely, flk-1 was 
significantly upregulated (p<0.05) under CS-10 at 3 days. 
 
Table 4.9: Fold changes in endothelial-related gene expression relative to control for each component of the 
Mechanical Panel.  Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 
(considered biologically relevant), respectively.  Data are presented as the mean ± SD with sample numbers.   
+ p<0.10, *p<0.05 vs. controls.   
 
Time Stimulus CD133 Endoglin E-Selectin vWF
CP-120 1.28 +/- 0.98, n=6 1.29 +/- 0.74, n=6 4.16 +/- 7.74, n=5 1.06 +/- 0.33, n=6
CS-10 0.84 +/- 0.64, n=6 0.38 +/- 0.14, n=6 * 6.48 +/- 8.72, n=6 1.09 +/- 0.17, n=6
LSS-20 0.83 +/- 0.55, n=6 0.19 +/- 0.1, n=6 * 25.87 +/- 27.98, n=6 + 1.76 +/- 0.34, n=6 * 
CP-120 2.5 +/- 1.52, n=5 + 1.17 +/- 0.54, n=5 18.5 +/- 30.25, n=3 0.93 +/- 0.16, n=5
CS-10 0.88 +/- 0.77, n=8 0.56 +/- 0.13, n=8 * 10.86 +/- 16.1, n=6 1.09 +/- 0.1, n=8 * 
LSS-20 1.78 +/- 2.12, n=6 0.29 +/- 0.16, n=6 * 55.43 +/- 72.11, n=6 1.3 +/- 0.14, n=6 * 
Endothelial
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Time Stimulus iNOS PECAM Flk-1
CP-120 81.91 +/- 64.8, n=5 * 12.32 +/- 25.03, n=6 0.86 +/- 0.53, n=6
CS-10 9.19 +/- 7.88, n=3 1.22 +/- 1.26, n=5 1.27 +/- 1.09, n=6
LSS-20 27.4 +/- 21.47, n=5 + 4.8 +/- 3.96, n=5 + 0.28 +/- 0.16, n=6 * 
CP-120 78.45 +/- 47.31, n=2 1.8 +/- 0.7, n=5 + 0.44 +/- 0.24, n=4 * 
CS-10 19.77 +/- 21.97, n=3 0.98 +/- 0.86, n=8 1.84 +/- 0.5, n=7 * 
LSS-20 82.19 +/- 64.54, n=4 + 2.81 +/- 1.84, n=6 + 0.32 +/- 0.3, n=5 * 
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4.3.2.3 Soluble factor-related genes 
The average RQ values ± SD for soluble factor-related genes are depicted in Table 4.10.  
In a similar fashion to the 5 day data (see Table 3.7), LSS significantly upregulated FGF2, TGF-
β, and VEGF-A at 24 hours (p<0.05) and 3 days (p<0.05).  CP at 24 hours and CS-10 at 3 days 
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were the only other stimuli showing statistically significant (p<0.05), but not quite biologically 
relevant, changes in VEGF-A.   
 
Table 4.10:  Fold changes in soluble factor-related gene expression relative to control for each component of the 
Mechanical Panel.  Green highlights indicate an average fold change greater than 1.3 (considered biologically 
relevant), respectively.  Data are presented as the mean ± SD with sample numbers.  + p<0.10, *p<0.05 vs. controls. 
 
Time Stimulus FGF2 TGF-β VEGF-A
CP-120 1.3 +/- 0.36, n=6 + 1.11 +/- 0.16, n=6 1.28 +/- 0.22, n=6 * 
CS-10 0.9 +/- 0.72, n=6 0.72 +/- 0.57, n=6 0.96 +/- 0.16, n=6
LSS-20 4.84 +/- 1.81, n=6 * 4.35 +/- 1.51, n=6 * 3.43 +/- 1, n=6 * 
CP-120 1.42 +/- 0.51, n=5 1.07 +/- 0.28, n=5 1.13 +/- 0.34, n=5
CS-10 1.22 +/- 0.27, n=8 + 0.95 +/- 0.1, n=8 0.83 +/- 0.2, n=8 * 
LSS-20 3.51 +/- 1.82, n=6 * 3 +/- 0.73, n=6 * 2.76 +/- 0.95, n=6 * 
Soluble Factor
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4.3.2.4 Extracellular matrix-related gene expression 
The average RQ values ± SD for matrix-related genes are depicted in Table 4.11.  In 
general, LSS demonstrated increased expression for all ECM genes with the exception of 
collagen IV, there was no detectable signal at 24 hours and 3 days.  Collagen I showed similar 
increases in expression under LSS at 24 hours (p<0.05) and 3 days (p<0.05) compared with the 5 
days data (Table 3.8).  Elastin and collagen III expression were also increased under LSS, which 
is contrary to the previous data at 5 days.  CS showed a significant upregulation of collagen III at 
24 hours and 3 days, while significantly downregulating elastin at 24 hours and returning to 
baseline values at 3 days.  CS also showed a statistically significant (p<0.05, but not biologically 
relevant) transient decrease in collagen I expression at 24 hours, followed by a return to baseline 
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values at 3 days.  Collagen IV expression in general was highly variable across the samples, with 
a greater tendency towards strong downregulation (p<0.05) under CS and LSS at 24 hours.   
 
Table 4.11:  Fold changes in ECM-related gene expression relative to the control for each component of the 
Mechanical Panel.  Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 
(considered biologically relevant), respectively.  Data are presented as the mean ± SD with sample numbers.  
+ p<0.10, *p<0.05 vs. controls. 
 
Time Stimulus Collagen I Collagen III Collagen IV Elastin
CP-120 1.43 +/- 0.5, n=6 + 1.09 +/- 0.34, n=6 3.1 +/- 3.25, n=6 3.03 +/- 2.49, n=6
CS-10 0.82 +/- 0.13, n=6 * 1.38 +/- 0.08, n=6 * 0.35 +/- 0.19, n=6 * 0.5 +/- 0.12, n=6 * 
LSS-20 3.96 +/- 1.7, n=6 * 2.4 +/- 0.97, n=6 * 0.25 +/- 0.29, n=6 * 5.71 +/- 3.78, n=6 * 
CP-120 1.08 +/- 0.55, n=5 1.03 +/- 0.28, n=5 0.42 +/- 0.49, n=2 3.25 +/- 1.76, n=5 * 
CS-10 0.93 +/- 0.21, n=8 1.26 +/- 0.15, n=8 * 12.28 +/- 23.49, n=4 0.76 +/- 0.59, n=8
LSS-20 3.18 +/- 0.75, n=6 * 1.46 +/- 0.32, n=6 * 0.12 +/- 0.13, n=2 + 26.79 +/- 20.16, n=6 * 
Matrix
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4.3.2.5 Stem cell-related gene expression 
Table 4.12The average RQ values ± SD for stem cell-related genes are depicted in .  CP 
showed statistically significant (p<0.05), transient decreases in CD90 and vimentin staining at 24 
hour followed by a return to baseline at 3 days.  CD90 was also significantly downregulated by 
LSS at 24 hours and 3 days (p<0.05), while vimentin levels (which is highly expressed in 
immature cells and fibroblasts [661]) were significantly elevated at 24 hours (p<0.1) before 
returning to baseline at 3 days.  CS showed a statistically significant (p<0.05, but not 
biologically significant) decrease in CD59 followed by a return to baseline levels.  Only LSS at 
24 hours appears to have upregulated CD59 (p<0.05) and on average retained this increase 
(although not statistically significant).   
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Table 4.12:  Fold changes in stem cell-related gene expression relative to control for each component of the 
Mechanical Panel.  Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 
(considered biologically relevant), respectively.  Data are presented as the mean ± SD with sample numbers.   
+ p<0.10, *p<0.05 vs. controls. 
 
Time Stimulus CD59 CD90 Vimentin
CP-120 1.04 +/- 0.29, n=6 0.79 +/- 0.09, n=6 * 0.75 +/- 0.08, n=6 * 
CS-10 0.82 +/- 0.15, n=6 * 1 +/- 0.14, n=6 1.33 +/- 0.22, n=6 * 
LSS-20 1.7 +/- 0.6, n=6 * 0.6 +/- 0.16, n=6 * 1.76 +/- 0.35, n=6 * 
CP-120 1.19 +/- 0.54, n=5 0.9 +/- 0.17, n=5 0.9 +/- 0.13, n=5
CS-10 0.92 +/- 0.2, n=8 1.05 +/- 0.15, n=8 1.22 +/- 0.15, n=8 * 
LSS-20 1.32 +/- 0.39, n=6 0.38 +/- 0.03, n=6 * 1.02 +/- 0.19, n=6
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4.3.2.6 Osteoblast-related gene expression 
The average RQ values ± SD for osteoblast-related genes are depicted in 885H885H886H886HTable 4.13.  Alkaline 
phosphatase expression tended to be increased by mechanical stimulation, with the exception of 
CS at 24 hours, which has a significant downregulation (p<0.05).  The osteo-inductor BMP2 was 
significantly upregulated for CS at 24 hours (p<0.05) and 3 days (p<0.05).  LSS showed some 
increased expression (p<0.10) early on at 24 hours for all osteoblast-related genes except 
osteocalcin, which was significantly downregulated (p<0.05) at 24 hours and 3 days.  Alkaline 
phosphatase and osteopontin were increased (p<0.10) and decreased (p<0.10), respectively, by 
CP at 24 hours.  Although osteopontin expression was increased for CS at 24 hours (p<0.05) and 
3 days (biologically, but not statistically), the late osteoblast marker, osteocalcin showed no 
change at either time point.   
 
 
 
  
Table 4.13:  Fold changes in osteoblast-related gene expression relative to control for each component of the 
Mechanical Panel.  Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 
(considered biologically relevant), respectively.  Data are presented as the mean ± SD with sample numbers.   
+ p<0.10, *p<0.05 vs. controls. 
 
Time Stimulus Alkaline Phosphatase BMP2 Osteocalcin Osteopontin
CP-120 2.45 +/- 1.51, n=6 + 1.06 +/- 0.26, n=6 0.88 +/- 0.29, n=6 0.68 +/- 0.39, n=6 + 
CS-10 0.63 +/- 0.11, n=6 * 2.16 +/- 0.79, n=6 * 0.87 +/- 0.33, n=6 1.68 +/- 0.53, n=6 * 
LSS-20 2.73 +/- 1.05, n=6 * 2.19 +/- 1, n=6 * 0.49 +/- 0.35, n=6 * 2.21 +/- 1.36, n=6 + 
CP-120 3.28 +/- 3.1, n=5 1.26 +/- 0.57, n=5 0.87 +/- 0.12, n=5 + 1.51 +/- 0.65, n=5
CS-10 1.39 +/- 0.7, n=8 1.56 +/- 0.63, n=8 * 0.95 +/- 0.26, n=8 1.36 +/- 0.8, n=8
LSS-20 7.58 +/- 8.78, n=6 1.43 +/- 0.86, n=6 0.31 +/- 0.14, n=6 * 1.06 +/- 0.99, n=6
Osteoblast
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4.3.2.7 Chondrocyte-related gene expression 
The average RQ values ± SD for chondrocyte-related genes are depicted in Table 4.14.  
LSS was the only stimulus that showed statistically significant downregulation of aggrecan at 
both 24 hours (p<0.10) and 3 days (p<0.05).  These results are consistent with the 5 days data for 
LSS-20 (see Table 3.11).  The expression of collagen II, on the other hand, was extremely 
variable, due to the fact that no control sample ever registered a CT value and several of the 
Mechanical Panel samples also failed achieve adequate signal for a CT value (note n=1 or 2 
although at least y6 experiments were interrogated).  Only CP and CS at 24 hours showed 
statistically significant (p<0.05) for the 3 samples that registered transcripts.     
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Table 4.14:  Fold changes in chondrocyte-related gene expression relative to control for each component of the 
Mechanical Panel.  Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 
(considered biologically relevant), respectively.  Data are presented as the mean ± SD with sample numbers.   
+ p<0.10, *p<0.05 vs. controls. 
 
Time Stimulus Aggrecan Collagen II
CP-120 1.04 +/- 0.14, n=6 7.7 +/- 0.51, n=3 * 
CS-10 0.67 +/- 0.54, n=6 14.91 +/- 4, n=3 * 
LSS-20 0.8 +/- 0.18, n=6 * 38.33 +/- 15.64, n=2
CP-120 1.08 +/- 0.2, n=5 143.02 +/- 196.32, n=2
CS-10 1.05 +/- 0.25, n=8 32.17 +/- 0, n=1
LSS-20 0.52 +/- 0.24, n=6 * 72.5 +/- 91.86, n=3
Chondrocyte
24
 
H
ou
rs
3 
D
ay
s
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4.3.2.8 Adipocyte-related gene expression 
The average RQ values ± SD for the adipocyte-related gene PPAR-γ are depicted in 
Table 4.15.  No statistically significant changes in PPAR-γ were detected, although on average, 
RQ values tended to increase 3 days under LSS.   
 
Table 4.15:  Fold changes in PPAR-γ expression relative to control for each component of the Mechanical Panel.  
Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 (considered biologically 
relevant), respectively.  Data are presented as the mean ± SD with sample numbers.  No significant differences were 
found compared to controls. 
 
Adipocyte
Time Stimulus PPAR-γ
CP-120 0.94 +/- 0.25, n=6
CS-10 0.97 +/- 0.36, n=6
LSS-20 0.97 +/- 0.74, n=6
CP-120 1.18 +/- 0.44, n=5
CS-10 1.09 +/- 0.22, n=8
LSS-20 1.33 +/- 0.68, n=6
24
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4.3.2.9 Proliferation-related gene expression 
The average RQ values ± SD for the proliferation-related gene cyclin B1 are depicted in 
Table 4.16.  Cyclin B1, which is part of the control mechanism for the G2/M transition in the 
cell cycle [662], was a newly added gene to the TLDA to assess cell cycle regulation changes 
that may have been occurring under mechanical stimulation.  At 24 hours, both CP and LSS 
demonstrated a statistically significant (p<0.05) downregulation of cyclin B1.  The drop was 
most severe under LSS (p<0.01 compared CP) and persisted through 3 days, while CP returned 
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to baseline values.  CS showed no change at 24 hours, and a statistically significant (p<0.05) 
increase in cyclin B1 expression at 3 days.   
 
Table 4.16: Fold changes in cyclin B1-related gene expression relative to control for each component of the 
Mechanical Panel.  Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 
(considered biologically relevant), respectively.  Data are presented as the mean ± SD with sample numbers.   
+ p<0.10, *p<0.05 vs. controls. 
 
Proliferation
Time Stimulus CyclinB1
CP-120 0.55 +/- 0.13, n=6 * 
CS-10 0.89 +/- 0.7, n=6
LSS-20 0.04 +/- 0.03, n=6 * 
CP-120 0.94 +/- 0.4, n=5
CS-10 1.58 +/- 0.41, n=8 * 
LSS-20 0.04 +/- 0.03, n=6 * 
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4.3.3 Protein expression 
The following section describes our results with the calponin, which was the only antibody we 
were able to successfully detect by Western blot, despite several attempts and troubleshooting 
procedures for the other endpoints.  Representative images and descriptions for our attempts at 
detecting SMA, SMMHC, flk-1 and PECAM are found in Appendix J. 
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4.3.3.1 Calponin 
Calponin expression in the 24 hour and 3 day Mechanical Panel experiments was 
confirmed by Western blotting as shown in Figure 4.2.  Following successful probing, the 
membrane was stripped and reprobed for GAPDH as an endogenous loading control.  GAPDH 
was deemed suitable as a protein loading control based upon our PCR endogenous control study 
(see Section 4.3.1).  Each band was measured by densitometry, and the integrated optical density 
for calponin was normalized by the integrated optical density for GAPDH in that lane followed 
by normalization to the control sample for that experiment.  The average fold-change ± SD for 
calponin at 24 hours and 3 days is depicted in Figure 4.3.  Although the high variability in the 
data limited our ability to detect statistical differences, there was a significant decreased (p<0.05) 
for LSS at 3 days compared to controls and CS at 3 days.   
 
32kDa 
Calponin 
37 kDa 
GAPDH 
 
Figure 4.2:  Western blot stained for calponin (upper band) with 40μg of the A-10 cell lysate serving as a positive 
control.  The membrane was stripped and reprobed for GAPDH (lower band) to serve as an endogenous loading 
control.   
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Figure 4.3:  Time-dependent changes in calponin expression in tBMMSCs following mechanical stimulation.  Data 
are presented as the mean ± SD.  † p<0.05 compared to CS and *p<0.05 compared to controls. 
4.4 
4.4.1 
DISCUSSION 
The importance of choosing an appropriate endogenous control gene 
The results of our endogenous control gene test using experimental samples confirmed our 
earlier concern over the gene expression results from our initial Mechanical Panel experiments.  
We were able to definitively prove that 18s, which we had previously used as the endogenous 
control, was the2nd least stable gene by the GeNorm analysis (Figure 4.1), and had the highest 
computed variance in addition to having an average CT (Table 4.7) which was more than 10 
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cycles below our the CT values for the other target genes in our TLDAs.  Based upon the current 
opinion in the literature [657, 658, 663], our erroneous utilization of 18s as the endogenous 
control gene likely diminished our ability to distinguish with any certainty the relative change in 
expression for the 5 day experiments (see Section 3.3.6).  For example, looking at one 
experiment using either 18s or Gusb as the endogenous control alters the RQ value between -
27% and 88% (see Error! Reference source not found.), which could completely alter the 
interpretation of the data.  In order to rectify this to provide a more meaningful representation of 
the gene expression changes in the 5 day experiments, individual RT-PCR reactions with 18s and 
Gusb on the any remaining samples of cDNA from the experiments performed in Chapter 3.0 
should be performed.  By performing these single reactions, we hypothesize a correction factor 
equivalent to average CT value of Gusb for the previous TLDAs can be computed according to: 
 
*
?
sin
sin 1818
TLDA
TLDA
gle
gle
Gusb
s
Gusb
s ≅ (4.1) 
 
where 18ssingle and Gusbsingle are the average CT values from the single RT-PCR reactions, 
18sTLDA is the CT value from the TLDA, and Gusb*TLDA is the hypothetical CT value for Gusb on 
the same TLDA as 18sTLDA.   
We will validate this hypothesis by performing the calculation in Equation (4.1) using 
the current TLDA configuration, which has both 18s and Gusb as target genes, and additional 
single reactions with 18s and Gusb on the same cDNA loaded into the TLDA.  If we can 
correctly reproduce the TLDA results using this technique, we should be able to more accurately 
re-analyze the results from our initial TLDA assays.   
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4.4.2 Temporal changes in gene expression 
Expanding upon our 5 day data, we have demonstrated that that mechanical stimulation can alter 
the phenotypic gene expression of BMMSCs in a time-dependent manner.  A summary of our 
results, broken down by gene group, is found in Table 4.17.   
 
Table 4.17:  Summary of the changes in gene expression for phenotypic groups by mechanical stimulation.  To give 
some global sense to the data, a change index (CI) was calculated by averaging a score of 0 for no change, +/- 1 for 
a biological or statistical (p<0.1) trend, and +/- 2 for a biologically relevant and statistically significant change for 
each of the genes in that category.  ↑↑ and ↓↓ indicate a majority increase or decrease (CI>0.75) in the overall gene 
expression for that group from control values.  Single arrows denote a moderate change (0.25≤CI≤0.75) in the 
majority of the genes for a particular phenotype, and ↔ indicates no change (CI<0.25). 
 
Cyclic Pressure Shear Stress Cyclic Stretch Gene Group 24 hours 3 days 24 hours 3 days 24 hours 3 days 
Muscle ↓ ↓ ↓ ↓↓ ↓ ↑↑ 
Endothelial ↑ ↑ ↑ ↑ ↓ ↔ 
Bone ↔ ↑ ↑↑ ↔ ↑ ↑↑ 
Cartilage ↑↑ ↑ ↔ ↓ ↑ ↑ 
Fat ↔ ↔ ↔ ↑ ↔ ↔ 
Growth Factor ↑↑ ↔ ↑↑ ↑↑ ↔ ↔ 
ECM ↑↑ ↔ ↑↑ ↑ ↓ ↑ 
Stem Cell ↓ ↔ ↑ ↓ ↑ ↑ 
Proliferation ↓↓ ↔ ↓↓ ↓↓ ↔ ↑↑ 
 
In general, LSS and CP seemed to downregulate muscle-related genes.  These results are contrast 
to other results reported by Kobayashi et al.[530] who found that shear stress and pressure-
dominated shear stress increased the protein expression of SMA and SMMHC.  We were not 
able to assay for these particular genes in our TLDA format, but based upon the decreased 
expression of myocardin, which is necessary for nearly all SMC proteins, including SM22α, 
SMA, caldesmon, calponin, and SM-MHC [62, 105-107], we can hypothesize that that these 
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genes and/or proteins would also be diminished by LSS and CP.  Furthermore, our gene results 
in these studies are in agreement with our 5 day stimulation data in that LSS and CP failed to 
demonstrate staining for SMA, calponin, or SMMHC by IHC (see Figure 3.16 Figure 3.17, , and 
Figure 3.18).  The expression of two muscle-related genes, myocardin and desmin, was initially 
unchanged by CS at 24 hours, and then upregulated (p<0.1 and p<0.05) at 3 days.  Similarly, 
gene expression for SM22α following the application of CS also trends downward (although not 
statistically significant) in the first 24 hours and then returns to control levels at 3 days.  These 
trends are somewhat in contrast to previously reported data from Park et al.[527] who reported a 
transient increase in SM22α for BMMSCs on collagen exposed to 10% CS at 24 hours followed 
by a return to baseline levels.  The authors attributed this decrease in muscle gene expression to 
the migration of the BMMSCs to a perpendicular position, effectively shielding them from the 
uniaxial stretch.  Subsequent studies forcing the alignment of BMMSCs in the direction of 
stretch showed that calponin expression could be maintained at a higher level than BMMSCs 
allowed to re-orient perpendicular to the direction of stretch.  However, despite the re-
orientation, calponin was significantly increased over the controls [558].  Our laboratory also has 
evidence to support this, showing that SMA and calponin expression are induced by static stress 
and cyclic stretch in tBMMSCs aligned parallel to the direction of stress and stretch in a 3-
dimensional fibrin construct [557].  In addition we also have published data showing that despite 
perpendicular alignment, expression of SMA and calponin are maintained after 7 days [526] of 
cyclic stretch.  Our current data at these early time points indicates a trend of decreased muscle-
related gene expression in the 24 hour period followed by a return to baseline levels in CS.  The 
return of SM22α to baseline levels may be a result of the increasing levels of myocardin, which 
should precede changes in expression of the other SMC proteins that under the same promotional 
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control [62].  However, caldesmon expression was not affected by mechanical stimulation in a 
similar manner as myocardin and SM22α, which is inconsistent with its transcriptional control 
by myocardin. 
Overall changes in endothelial-related gene expression tended to be increased by both CP 
and LSS at 24 hours and 3 days.  Conversely, CS stimulation started with a trend towards 
downregulation at 24 hours and then increased to control levels at 3 days.  CP and LSS 
demonstrated expression of both E-selectin and iNOS, two genes which typically have had little 
or no detectable expression under control and CS conditions, leading us to hypothesize that the 
BMMSCs are becoming more endothelial-like.  This is supported by our evidence that two of the 
most consistently upregulated genes by LSS and CP were vWF and PECAM, which are 
associated with more mature ECs.  However, we have thus far been unable to detect either of 
these proteins by IHC in the 5 day experiments (see Figure 3.20 Figure 3.21 and ), and have not 
been able to detect PECAM by Western blot (see Appendix J).  Furthermore, gene expression 
for vWF, which was also investigated at 5 days, was upregulated under CP but strongly 
downregulated under LSS (see Table 3.6).  We hypothesize that this change in the LSS from the 
5 day experiments to the 24 hour and 3 day experiments may be a result of the state of 
confluence of the cells since CP at 5 days were confluent (see Coomassie Blue images in Figure 
3.6), and had increased vWF gene expression (see Table 3.6).  Likewise, for these temporal 
changes in gene expression, the experiments were begun at confluence, and we subsequently 
detected increases in vWF and PECAM gene expression under both CP and LSS.  Our 
endothelial-related gene expression results are in agreement with other work by Yamamoto et al. 
[567] and Wang et al. [568] who found similar increases in endothelial gene expression for 
embryonic stem cells.  However, flk-1 expression did not follow these trends for our BMMSCs.  
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Like the previous 5 day data, flk-1 gene expression was decreased for both CP and LSS at 3 
days, which is in contrast to the shear stress studies for the embryonic stem cells [567, 568].   
The expression of growth factors, including VEGF-A, was consistently upregulated by 
LSS at 24 hours and 3 days in a manner similar to our previous 5 day data.  Similar results for 
the regulation of VEGF have been shown for embryonic stem cells [568] and vascular 
endothelial cells [308] exposed to shear stresses similar in magnitude to that used in our study.  
However, under lower shear stress (5 dynes/cm2), Yamamoto et al. [567] found no changes in 
VEGF expression, which is similar to our 5 day data (see Table 3.6).  Despite the increases in 
both TGF-β and VEGF-A under LSS, their receptors (endoglin and flk-1) were downregulated 
under shear stress.  Given that a positive-feedback loops have been shown to exist between 
TGF-β and endoglin [664-666], the downregulation of endoglin in conjunction with the 
upregulation of TGF-β in our LSS studies may be indicating that although the BMMSCs are 
increasing their expression of the growth factor, they are not receiving any signaling from their 
receptors as a result of the convection and dilution of these factors away from the cells.   
The expression of ECM genes under mechanical stimulation at 24 hours and 3 days 
provided some departure from the expression levels detected in the subconfluent cultures at 5 
days.  Most striking was the increase in expression of elastin under LSS, which we had 
previously found downregulated at 5 days (see Table 3.8).  This too may be a function of the 
presence of a confluent monolayer of cells.  In the developing artery, elastin mRNA expression 
has been spatially correlated to the presence of TGF-β [667].  The increased TGF-β gene 
expression also seen under LSS seems to support this type of mechanism, but the concurrent 
decrease in endoglin expression seems to point to a lack of TGF-β signaling in the cells.  
However, without evidence of localized TGF-β protein or increased downstream messengers 
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such as the SMAD complexes [668, 669], we can only speculate about the mechanisms involved.  
LSS continued to upregulate expression of other ECM genes, including collagen I and III.  CS 
also increased collagen III expression at 24 hours and 3 days, and downregulated elastin 
production at 24 hours.  The increase in collagen III gene expression is contrary to that reported 
by Park et al. [527] who found no change in collagen III expression from CS, but the decrease in 
elastin expression was similar to what we found for CS-10 at 5 days of stimulation.  Other 
research examining the response of BMMSCs to mechanical loading has found increased 
collagen III similar to that found with mechanical stimulation of heart valve interstitial cells 
[561] and tissue-engineered ligaments [507]. 
The expression of bone- and chondrocyte-related genes by BMMSCs under mechanical 
stimulation was relatively inconclusive.  Alkaline phosphatase gene expression seemed to be 
increased by mechanical stimulation in general, but there was a significant downregulation by 
CS at 24 hours.  Alkaline phosphatase, which is expressed in high levels by BMMSCs, has been 
reported to diminish with differentiation [551].  Other osteoblast genes, including osteocalcin 
and osteopontin, have previously been reported to increase in stromal cells under extremely low 
levels of shear stress (0.27 – 2.5 dynes/cm2) [572, 573], but under our 20 dyens/cm2 shear, we 
found them to be significantly downregulated at 3 days, and our 5 day data seems to indicate a 
decrease in osteoblast gene expression at all levels of LSS tested (1-20 dynes/cm2).  Osteopontin 
gene expression by BMMSCs under CS was significantly elevated at 24 hours and remained 
elevated, but not statistically significant, at 3 days.  Although previous reports on gene 
expression in BMMSCs have indicated that no transcripts for osteopontin should be detected in 
non-osteoblast differentiated BMMSCs [551], osteopontin mRNA has been detected in a variety 
of other cells including vascular SMCs and ECs, with implications for atherosclerosis [670-672].  
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The presence of osteopontin in other cell types has also been attributed to its potential role in cell 
adhesion because it contains the Arg-Gly-Asp-Ser adhesion molecule which is capable of 
binding fibronectin [673, 674].   
Because our time course experiments were conducted at confluence, our previous 
methods of assessing proliferation were not feasible.  Therefore, we added cyclin B1 to the 
TLDA to detect changes in proliferation as a result of mechanical stimulation.  Cyclin B1 has 
been used for this purpose previously [662, 675], and more recently the similar study by 
Kurpinski et al.[558], where they demonstrated an increase in cyclin B1 expression as a result of 
CS.  Our data also indicate a significant increase in cyclin B1 expression following exposure to 
CS at 3 days.  In agreement with our nuclear counting data at 5 days, LSS was a strong 
downregulator of cyclin B1 expression, effectively arresting the cell in the G2/M phase of the 
cell cycle.  Similar results have been shown for ECs under laminar shear stress [649, 676, 677].  
Cyclin B1 was also transiently decreased at 24 hours by CP before returning to baseline levels at 
3 days.  This was surprising given our previous 5 day data indicating that CP induced large 
increases (>2.5 fold; see Figure 3.14) in cell number.  There is other evidence in the literature 
that CP increases proliferation in bone marrow derived cells as well as ECs, SMCs, and 
chondrocytes [1, 225, 228, 386, 394, 577, 645].  More recently, mechanisms involving VEGF 
[394] and the PI3k/Akt pathway [645] have been proposed as potential mediators for increased 
proliferation.  Our results may suggest that contact inhibition of the BMMSCs played a more 
dominant role in their cell cycle progression, which is in contrast to the effect of pressure on 
aortic ECs that lose their contact inhibition in the presence of pressure [396].  It is possible that 
the arrest at the G2/M phase of the cell cycle may be a result of other paracrine signals 
previously unavailable to the BMMSC, which were only just reaching confluence in the 5 day 
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experiments.  Further studies utilizing other markers of proliferation should be undertaken to 
obtain a more accurate proliferation profile of these cells.   
4.4.3 Temporal changes in calponin expression 
Our results for the Western blotting of calponin demonstrate that calponin is expressed in 
confluent cultures of tBMMSCs on collagen.  On average calponin expression in the controls 
was approximately 7.5 fold less than fully differentiated stem cells.  And only LSS at 3 days 
showed significant decreases compared to controls and CS.  The calponin expression as 
measured by densitometry was highly variable; sometimes being upregulated by mechanical 
stimulation, and other times downregulated.  In one instance, the control sample measured 1.5-
fold more calponin than the positive control.  These results are highly perplexing given our 
previous IHC results (see Figure 3.17 and previous studies [526, 557]).  However, Western blot 
results from other cells types including platelets and fibroblasts have shown positive staining for 
calponin [81].  In addition, groups studying the effects of stretch have demonstrated that calponin 
is expressed in control cultures of stem cells [558, 647], and IHC data on BMMSCs has shown 
calponin staining in a diffuse pattern which does not coincide with its role as an actin binding 
protein [678].  It has also been well-documented that BMMSCs tend to acquire SMC-like 
cytoskeletal proteins in long-term culture, which typically involves growth to confluence and 
beyond [528, 552, 679].  Therefore, in our cultures starting at confluence on a collagen surface, it 
is not inconceivable that calponin expression developed in the 3-5 days of experiment time.  In 
addition to the sometimes high level of expression of calponin in the control samples, the lack of 
change in calponin expression following CS was troubling in light of our previous results (see 
[526] and Figure 3.17).  However, the change in SMC protein expression in response to 
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mechanical stimulation has been reported both as increased [526, 527, 530, 557, 558, 569, 650] 
and decreased [527, 647] depending upon cell source and type of stretch (uniaxial vs. equiaxial).  
Yet, despite occasional results that seem to contradict each other, the majority of research 
continues to point to the increase in SMC protein expression in stem cells as a result of cyclic 
stretch. 
4.4.4 Limitations 
Although the use of confluent cultures in our Mechanical Panel system provided a more 
physiologically relevant milleu for paracrine and cell-cell signaling, and generated more 
available RNA for our gene expression studies, our ability to detect subsequent protein 
expression by Western blot continued to be hampered by low yields.  Several experiments could 
not be analyzed by Western blotting because one or more samples with high RNA content 
yielded less than 50μg of protein.  These issues may be a result of the use of Trizol™ to extract 
the RNA and protein from our experiments.  As part of the extraction process, proteins are 
precipitated by alcohol, washed several times in a high-alcohol solution, and finally dried.  This 
dried protein pellet required extensive work at >50oC with our protein resuspension buffer.  
Often, one or more samples within an experimental group did not fully resuspend, suggesting the 
possibility that we may in effect have left out many of the highly hydrophobic membrane 
proteins such as PECAM and flk-1, as well as other intracellular high molecular weight proteins 
including myosin heavy chain.  Future studies may have to rely on separate extraction 
techniques, one for protein and one for RNA, or increase the amount of detergent to 1% or 
higher.  Other possibilities may be that these membrane-bound proteins make up a very small 
fraction of the total protein, potentially requiring immunoprecipitation for successful Western 
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blotting, or that our transfer protocols are inefficient for the high molecular weight proteins (e.g., 
SMMHC; see Appendix J.2). 
Another limitation in the interpretation of this data was the high variability in the Western 
blotting results for calponin.  There was an inconsistent level of expression of calponin in the 
control cultures, despite utilizing cells from the same lot that were within a 3-4 passages of each 
other and culturing the cells in the same lot of FBS.  Furthermore, there were no distinguishing 
signs throughout the culture periods leading up to the experiments that may have indicated the 
tBMMSCs were abnormal in any way.  One possible explanation again points to the protein 
extraction technique, which had variable success in solubilizing the dehydrated protein from the 
TrizolTM extraction.  This could have effectively limited our ability to determine real changes in 
protein expression between the 4 arms of the Mechanical Panel. 
4.5 CONCLUSION 
We have continued our exploration of the response of BMMSCs to mechanical stimulation using 
our unique Mechanical Panel approach to follow the temporal changes in gene and protein 
expression.  Using confluent cultures of BMMSCs in an attempt to create a more physiologic 
signaling environment as well as enable us to obtain enough biologic material for RNA and 
protein analysis, we have determined that LSS and CP tend to upregulate the expression of 
several EC-related genes at 24 hours and 3 days.  This is the first indication we have that our 
BMMSCs are capable of EC differentiation.  Unfortunately, we were unable to detect subsequent 
protein expression for flk-1 and PECAM by Western blotting but are encouraged enough by the 
gene expression data to continue these studies.  Our data for CS at 24 hours seems to indicate a 
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decrease in muscle-related protein expression, but by 3 days, several genes including cardiac 
troponin, desmin, and myocardin were becoming more prominent, suggesting that the cells are 
potentially entering a myofibroblast phenotype.  Perhaps given further cues including 
biochemical stimulation such as TGF-β [647, 650], BMMSCs under mechanical stimulation may 
continue down the path towards functional SMCs and ECs, which would provide important steps 
forward for vascular tissue engineering. 
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5.0 LINEAGE COMMITMENT FOLLOWING MECHANICAL STIMULATION 
5.1 INTRODUCTION 
Another important issue with stem cell research is the lineage commitment of the cells following 
their initial differentiation.  It has been well documented that SMCs, which exist in a highly 
mechanically dynamic environment, alter the expression of genes and proteins associated with 
their mature phenotype upon static culture in vitro [189, 196-198].  This type of phenotypic 
alteration raises the question of whether stem cells, once differentiated into a particular lineage 
by chemical or mechanical means, can maintain their commitment to that lineage should they 
experience withdrawal of those stimuli.  This is of particular importance in cell therapy 
applications where these tissue-committed cells may find their way into an unintended tissue 
bed.  Experiments performed to address Specific Aim 4 were designed to test whether tBMMSCs 
exposed to cyclic stretch could maintain their differentiated state following withdrawal of the 
stimulus, or if they would return to their baseline levels of gene and protein expression.   
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5.2 
5.2.1 
5.3 
5.3.1 
METHODS 
Experimental Design 
For each experiment, tBMMSCs were obtained as described in Section 3.2.1 and seeded at 
confluence (21,000 cells/cm2) onto 3 collagen I coated BioFlex™ (Flexcell) deformable 
substrates.  After 48 hours of pre-culture, two BioFlex™ plates were exposed to 10% cyclic 
stretch at 1 Hz (CS-10) and one to static control conditions for 3 days.  After 3 days, the control 
and one of the cyclically stretched BioFlex™ plates were removed and processed for RNA and 
protein endpoints (see Section 4.2.2).  The second plate of the cyclically stretched tBMMSCs 
was placed back in static culture for an additional 3 days (DeDiff) before being processed for 
RNA and protein endpoints as described in Section 4.2.2.   
RESULTS 
Gene expression 
5.3.1.1 Muscle related genes 
The average RQ values ± SD for muscle-related genes are depicted in Table 5.1.  No 
statistically significant differences from control values were detected, with only a trend (p<0.1) 
towards decreased expression present for caldesmon under CS-10 that may not be biologically 
relevant.  Although the high variance, particularly with the DeDiff samples, precludes statistical 
significance, cardiac troponin was increased on average in both CS-10 and DeDiff samples.  
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Gene expression for caldesmon in the DeDiff samples was significantly (p<0.05) higher than 
CS-10 as a result of the extended static culture time.  However, caldesmon expression for DeDiff 
samples was not different from the 3 day control values.   
 
Table 5.1:  Fold changes in muscle-related gene expression relative to control for CS or DeDiff samples.  Green 
highlights indicate an average fold change greater than 1.3 (considered biologically relevant).  Data are presented as 
the mean ± SD with sample numbers.  +p<0.10, vs. controls.   
 
Stimulus Caldesmon Cardiac Troponin Desmin
CS-10 0.88 +/- 0.06, n=3 + 1.37 +/- 0.27, n=3 1.82 +/- 0.61, n=3
DeDiff 1.19 +/- 0.13, n=3 1.66 +/- 1.06, n=3 1.27 +/- 0.36, n=3
Muscle
 
Stimulus Myocardin SM22α
CS-10 1.24 +/- 0.2, n=3 0.91 +/- 0.22, n=3
DeDiff 0.92 +/- 0.26, n=3 1.04 +/- 0.24, n=3
Muscle
 
 
5.3.1.2 Endothelial Related Genes 
The average RQ values ± SD for endothelial-related genes are depicted in Table 5.2.  
Compared to controls, only endoglin and flk-1 showed any statistically relevant change with 
downregulation of endoglin (p<0.05) and upregulation of flk-1 (p<0.1) in CS-10.  Other EC-
related genes showing biologically relevant changes included CD133, E-selectin, and iNOS, each 
appearing to be increased on average.  As evident from the SD values, there was large variability 
in both E-selectin and iNOS, which was a result of the failure of one of the control samples to 
register a detectable signal.  The other two samples which did have corresponding controls that 
 222 
registered showed a downregulation for CS-10 (RQ=0.44 ± 0.47) and no change for DeDiff 
(RQ=0.89 ± 1.17) compared to the controls.  Comparisons between CS-10 and DeDiff did, 
however, reveal a significant decrease in flk-1 (p<0.05) with the extended static culture time.   
 
Table 5.2: Fold changes in endothelial-related gene expression relative to control for CS and DeDiff samples.  
Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 (considered biologically 
relevant), respectively.  Data are presented as the mean ± SD with sample numbers.  + p<0.10, *p<0.05 vs. controls.   
 
Stimulus CD133 Endoglin E-Selectin vWF
CS-10 1.39 +/- 0.86, n=3 0.57 +/- 0.11, n=3 * 12.76 +/- 21.34, n=3 1.14 +/- 0.13, n=3
DeDiff 2.03 +/- 1.7, n=3 0.87 +/- 0.76, n=3 4.8 +/- 6.82, n=3 1.07 +/- 0.2, n=3
Endothelial
 
Stimulus iNOS PECAM Flk-1
CS-10 7.61 +/- 8.89, n=2 1.28 +/- 1.15, n=3 2.13 +/- 0.61, n=3 + 
DeDiff 42.32 +/- 56.75, n=2 1.23 +/- 0.79, n=3 0.79 +/- 0.59, n=3
Endothelial
 
 
5.3.1.3 Soluble factor -related genes 
The average RQ values ± SD for soluble factor-related genes are depicted in Table 5.3.  
No statistical differences were evident for any of the 3 genes interrogated compared to the 
controls.  On average, DeDiff was slightly elevated compared to controls for FGF-2 and TGF-β, 
and did show statistically a significant increase in TGF-β (p<0.05) compared to CS-10.   
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Table 5.3:  Fold changes in soluble factor-related gene expression relative to control for CS and DeDiff samples.  
Green highlights indicate an average fold change greater than 1.3 (considered biologically relevant).  Data are 
presented as the mean ± SD with sample numbers.  No statistically significant differences were found  for CS-10 or 
DeDiff when compared to controls.   
 
Stimulus FGF2 TGF-β VEGF-A
CS-10 1.05 +/- 0.07, n=3 0.94 +/- 0.06, n=3 0.89 +/- 0.13, n=3
DeDiff 1.95 +/- 1.05, n=3 1.39 +/- 0.31, n=3 1.02 +/- 0.34, n=3
Soluble Factor
 
 
5.3.1.4 Extracellular matrix-related gene expression 
The average RQ values ± SD for ECM-related genes are depicted in Table 5.4.  No 
statistically significant differences were detected compared to controls.  As in previous samples 
(see Table 3.8 and Table 4.11), collagen IV was highly variable as a result of only one control 
sample registering a detectable signal.  In that single instance, collagen IV was strongly 
downregulated by CS-10 (RQ=0.24) and even further downregulated by DeDiff (RQ=0.02).  
Comparisons between CS-10 and DeDiff did not reveal any significant changes with the added 
static culture time.   
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Table 5.4:  Fold changes in extracellular matrix-related gene expression relative to control for CS and DeDiff 
samples.  Green and red highlights indicate an average fold change greater than 1.3 or less than 0.7 (considered 
biologically relevant), respectively.  Data are presented as the mean ± SD with sample numbers. No statistically 
significant differences were found  for CS-10 or DeDiff when compared to controls.   
 
Stimulus Collagen I Collagen III Collagen IV Elastin
CS-10 0.93 +/- 0.4, n=3 1.16 +/- 0.11, n=3 23.87 +/- 33.42, n=2 1.07 +/- 0.96, n=3
DeDiff 1.24 +/- 0.56, n=3 1.41 +/- 0.4, n=3 8.68 +/- 12.25, n=2 0.67 +/- 0.49, n=3
Matrix
 
 
5.3.1.5 Stem-cell related gene expression 
The average RQ values ± SD for stem cell-related genes are depicted in Table 5.5.  
CS-10 showed the only statistically significant change (p<0.05) in stem cell markers by slightly 
upregulating vimentin expression compared to controls, but vimentin expression was not 
statistically different between CS-10 and DeDiff. 
 
Table 5.5:  Fold changes in stem cell-related gene expression relative to control for CS and DeDiff samples.  Green 
highlights indicate an average fold change greater than 1.3 (considered biologically relevant).  Data are presented as 
the mean ± SD with sample numbers. *p<0.05 vs. controls. 
 
Stimulus CD59 CD90 Vimentin
CS-10 0.95 +/- 0.31, n=3 1.04 +/- 0.25, n=3 1.26 +/- 0.09, n=3 * 
DeDiff 0.93 +/- 0.4, n=3 1.01 +/- 0.25, n=3 1.37 +/- 0.22, n=3
Stem Cell
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5.3.1.6 Osteoblast-related gene expression 
The average RQ values ± SD for osteoblast-related genes are depicted in Table 5.6.  Of 
the genes assayed, only BMP2 showed a statistically significant increase under CS-10.  There 
were no differences between CS-10 and DeDiff.  Overall osteoblast gene expression tended to be 
increased for both samples compared to controls, but the variability was almost equal to or 
higher than the average change in most instances. 
 
Table 5.6:  Fold changes in osteoblast-related gene expression relative to control for CS and DeDiff samples.  Green 
highlights indicate an average fold change greater than 1.3 (considered biologically relevant).  Data are presented as 
the mean ± SD with sample numbers.  *p<0.05 vs. controls. 
 
Stimulus Alkaline Phosphatase BMP2 Osteocalcin Osteopontin
CS-10 1.55 +/- 1.23, n=3 1.26 +/- 0.09, n=3 * 0.93 +/- 0.24, n=3 1.83 +/- 1.19, n=3
DeDiff 2.33 +/- 3.23, n=3 1.87 +/- 1.78, n=3 1.39 +/- 0.73, n=3 4.27 +/- 3.93, n=3
Osteoblast
 
 
5.3.1.7 Chondrocyte-related gene expression 
The average RQ values ± SD for chondrocyte -related genes are depicted in Table 5.7.  
Similar to previous results, collagen II failed to interrogate in all the control samples and was 
only able to successfully be interrogated in separate experiments with CS-10 and DeDiff.  No 
other statistically significant changes were evident, although a slight trend towards upregulation 
may be seen in aggrecan gene expression by the DeDiff sample.   
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Table 5.7:  Fold changes in chondrocyte-related gene expression relative to control for CS and DeDiff samples.  
Green indicate an average fold change greater than 1.3 (considered biologically relevant).  Data are presented as the 
mean ± SD with sample numbers.  No statistically significant differences were found  for CS-10 or DeDiff when 
compared to controls. 
 
Stimulus Aggrecan Collagen II
CS-10 1.2 +/- 0.38, n=3 32.17 +/- 0, n=1
DeDiff 1.56 +/- 0.56, n=3 37.35 +/- 0, n=1
Chondrocyte
 
 
5.3.1.8 Adipocyte-related gene expression 
The average RQ values ± SD for the adipocyte -related gene PPAR-γ are depicted in 
Table 5.8.  No statistically significant changes in PPAR-γ were detected for either CS or DeDiff 
samples.  However, there was a trend towards a downregulation of PPAR-γ by the extra time in 
control culture following CS (p<0.1).   
 
Table 5.8:  Fold changes in PPAR-γ expression relative to control for CS and DeDiff samples.  Data are presented 
as the mean ± SD.  No biologically relevant (±1.3 fold change) or statistically significant changes were found for 
CS-10 or DeDiff compared to controls. 
 
Adipocyte
Stimulus PPAR-γ
CS-10 1.23 +/- 0.2, n=3
DeDiff 0.73 +/- 0.4, n=3  
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5.3.1.9 Proliferation-related gene expression 
The average RQ values ± SD for cyclin B1 are depicted in Table 5.9.  Similar to the 
previous 3 day data, there was a trend towards upregulation by CS-10, but the variability in 
DeDiff samples was much higher, with one DeDiff experiment showing a fairly strong 
upregulation (RQ=3.26) , and one experiment strongly downregulated (RQ=0.26).  As a result, 
there was no difference between CS-10 and DeDiff samples.   
 
Table 5.9: Fold changes in cyclin B1-related gene expression relative to control for CS and DeDiff samples.  Green 
highlights indicate an average fold change greater than 1.3 (considered biologically relevant).  Data are presented as 
the mean ± SD.  No statistically significant differences were found  for CS-10 or DeDiff when compared to controls. 
 
Proliferation
Stimulus CyclinB1
CS-10 1.34 +/- 0.32, n=3
DeDiff 1.58 +/- 1.55, n=3  
 
5.3.2 Protein expression 
As a result of the previously-mentioned difficulties in performing Western blots on the higher 
molecular weigh proteins (PECAM, flk-1, SMMHC) and SMA (see Section 4.3.3), we were only 
able to obtain results for the stability of calponin expression following withdrawal of mechanical 
stimulation.  Our results were again plagued by high variability for reasons alluded to in Section 
4.4.4, and we did not find any statistically significant change in expression for any group.  The 
average ± SD for normalized calponin expression is presented in Figure 5.1.  Two Western blots 
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for calponin and GADPH blots are provided in Figure 5.2 to highlight the general variability in 
calponin expression between experiments.   
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Figure 5.1:  Changes in normalized calponin expression as determined by Western blot.  Data are presented as the 
mean ± SD. 
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32 kDa Calponin 
36 kDa 
GAPDH 
 
Figure 5.2:  Representative Western blot for calponin (top) and GAPDH (bottom) for two experiments 
(separated by dashed line).  A-10 cell lysates were used as a positive control. 
 
5.4 DISCUSSION 
Because one of the central questions in stem cell biology is whether these multipotential cells 
can maintain their phenotypic state following removal of the particular stimulus driving their 
differentiation, we investigated the changes in gene and protein expression that occurred from 3 
days of static culture following 3 days of cyclic stretch.  Using highly sensitive RT-PCR 
techniques that can examine multiple gene targets, we found just 3 of 30 target genes were 
altered by the cessation of mechanical stimulation in the tBMMSCs (summarized in Table 5.10).  
Although the removal of stretch appears to increase caldesmon gene expression compared to the 
cyclically stretched sample, the level of expression is in fact becoming closer control values; 
perhaps indicating that whatever changes were occurring in the tBMMSCs as a result of being 
cyclically stretched were being reversed.  The reversal of increases in SMC-related protein 
expression following cyclic stretch has also been demonstrated in ECs [83].   
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The increases in caldesmon and TGF-β gene expression following mechanical 
stimulation may be linked together as TGF-β has consistently been linked to the increased 
expression of SMC proteins in other cell types including ECs [77, 78, 680] and various stem cell 
populations [149, 161, 647, 661].  This raises the possibility that with this potential TGF-β 
stimulation, caldesmon expression may continue to climb.  Although our experimental variability 
precluded any statistical significance, this may be supported by the slight trend of increasing 
calponin expression starting with the control samples, and increasing through the DeDiff 
samples.  Here, too, may be preliminary indications that TGF-β is playing a role in this post-
stimulation time period to further drive the BMMSCs towards a myogenic lineage.  Another 
possible role of TGF-β in this post-stimulation time frame may have been to modulate the flk-1 
expression, which was previously elevated by CS-10.  Similar to our finding of increased TGF-β 
and decreased flk-1 expression in the DeDiff samples, increases in TGF-β have been shown to 
lead to decreases in VEGF-A and flk-1 during developmental [681] and angiogenic [682, 683] 
processes.   
 
Table 5.10:  Summary of the statistically significant changes in gene expression following removal of the cyclic 
stretch stimulation in the tBMMSCs. 
 
Change following removal of 
stimulation Gene Name (classification)
Caldesmon (SMC) ↑ 
Flk-1 (EC) ↓ 
↑ TGF-β (Growth factor) 
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5.4.1 
5.5 
Limitations 
Like the experiments discussed in Chapter 4.0, our investigation into the effects of 
stimulus withdrawal on the differentiation of tBMMSCs was impacted by our inability to 
completely solubilize the protein following TrizolTM extraction of the RNA.  As result, we were 
unable to investigate the higher molecular weight proteins that were of relevance to our study, 
namely SMMHC, PECAM, and flk-1.  Furthermore, the protein data that we were able to 
generate was highly variable, making interpretations difficult.  Concerning our experimental 
setup, while stopping the control and one CS sample at 3 days and placing a second CS sample 
back into static culture seemed like an ideal way to test the ability of the tBMMSCs to maintain 
their phenotype following mechanical stimulation, these experiments may have benefited from a 
second set samples that were in either CS or control conditions for the entire 6 days (plus 2 day 
pre-incubation) period of the experiment.  This may have been able to shed more light on the 
eventual fate of the BMMSCs.  Although some correlations to the 5 day data may be inferred, 
the starting cell density between the experiments was much too different to make any meaningful 
inferences.  Additional methodologies which might better test the commitment of tBMMSCs 
would be additional subculture with the use of inductive media for adipogenic and osteogenic 
phenotype following the 3 days of rest after mechanical stimulation.   
CONCLUSION 
By examining the ability of the tBMMSC to maintain their gene and protein expression 
phenotype following the withdrawal of mechanical stimulation, we have attempted to provide 
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insight into one of the fundamental questions in stem cell biology, namely whether these cells, 
once guided towards a particular phenotype, will remain committed or have the ability to return 
towards their original stem cell state.  Our results seem to indicate that removal of cyclic stretch 
did not alter gene expression in BMMSCs, as many of the gene endpoints did not show a 
significant change between CS and DeDiff cultures.  However, the three genes that did show 
changes (see Table 5.10) seem to indicate progression towards myogenic differentiation in light 
of studies linking TGF-β expression to increases in SMC and decreases in EC gene expression, 
as well as the observed trend for increasing calponin protein expression (see Figure 5.1) in our 
experiments.  Without statistical support, we can only hypothesize that myogenic differentiation 
is continuing following the removal of CS.  Further tests will be necessary to confirm this 
observation.   
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6.0 DISCUSSION 
6.1 
6.1.1 
SUMMARY OF RESULTS 
We have developed a unique approach to investigating the role of mechanical stimulation for 
differentiation of stem cells through the Mechanical Panel.  By utilizing simultaneous 
mechanical stimuli, we were able to effectively study the differential response to each stimulus 
while attempting to limit the effects of heterogeneity that exist in primary mesenchymal stem 
cells.  A brief summary of each specific aim will be presented followed by comments on the 
general advantages and disadvantages of these studies.  Finally, areas of future work will be 
discussed as they relate to our study findings.   
Specific aim 1 
In order for the proposed work utilizing the Mechanical Panel to move forward, we needed to 
develop a bioreactor capable of long-term application of cyclic hydrostatic pressure.  We 
designed and built a versatile, compact bioreactor and used a constant pressure source with a 
simple oscillating valve on a variable timing circuit to create various magnitudes and frequencies 
of cyclic hydrostatic pressure.  CFD analysis of a 2D model of our bioreactor demonstrated our 
system was completely hydrostatic, with no unanticipated shear stresses from the impinging air 
stream.  A major problem limiting the use of cyclic pressure bioreactors for long-term cell 
 234 
culture is caused by the need to cycle air into and out of the system, which disrupts the vapor 
pressure equilibrium over the culture media and drives evaporation.  To address this, we utilized 
a heated passover humidifier to raise the water vapor content of the incoming air to the 
bioreactor to and limit the disruption in vapor pressure equilibrium in the bioreactor itself.  The 
time-averaged vapor density of our system, which was calculated by measuring the mass of air 
and water consumed throughout the course of an experimental run, demonstrated our ability to 
maintain a properly humidified environment with a vapor density exceeding 45 g/L.  We 
biologically validated our pressure bioreactor by demonstrating cell viability under cyclic 
hydrostatic pressure for up to 7 days with no increase in cell necrosis.  In addition, we 
demonstrated that cyclic hydrostatic pressure can alter the morphology, proliferation, and 
differentiation of BMMSCs. 
6.1.2 Specific Aim 2 
The goal of specific aim 2 was to address our hypothesis that physiologically relevant applied 
mechanical stimulation can drive the differentiation of stem cells to specific phenotypes.  We 
utilized our Mechanical Panel setup to differentially expose BMMSCs to three separate 
mechanical stimuli relevant to the vasculature.  We varied the magnitudes and frequencies of 
these stimuli to determine potential dose-responses.  Our results demonstrate that each stimulus 
differentially affects BMMSC morphology, proliferation, and gene and protein expression.   
Morphologic changes in response to cyclic stretch were dependent upon the magnitude 
and frequency of stimulation, with higher magnitudes or frequencies generating a more 
elongated, spindle-shaped cell.  Cyclic stretch at 1%, 1 Hz was found to increase proliferation, 
while higher magnitudes or frequencies did not appear to affect proliferation.  Laminar shear 
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stress, on the other hand, caused a dramatic increase in cellular size, and decreased proliferation.  
As the magnitude of applied shear stress increase, both cell size and proliferation tended to 
decrease.  Cyclic hydrostatic pressure also had a very different effect on BMMSC morphology, 
resulting in a smaller, more rounded phenotype that did not express proteins associated with 
SMCs.  While cyclic pressure did not demonstrate any dose- or frequency-dependent changes in 
morphology or proliferation, we did find that there was a striking similarity to 1% 1 Hz cyclic 
stretch.  The similarities in morphology and proliferation between these two types of stimuli may 
point to common signaling mechanisms that occur as a result of low-level mechanical 
stimulation.   
The differentiation of BMMSCs towards a smooth muscle-like lineage, as determined by 
protein expression through immunohistochemistry, was most affected with either increasing 
magnitudes or higher frequencies of cyclic stretch.  With the exception of constitutive expression 
of flk-1 (VEGFRII) other EC-related proteins were detected by immunohistochemistry.  The 
expression of flk-1 protein did not appear to be affected by cyclic stretch, but did appear to be 
diminished by both cyclic pressure and laminar shear stress.   
Changes in gene expression by RT-PCR were difficult to interpret due to high variability, 
which we believe was related to our choice of endogenous control genes.  On average, our results 
indicated a general increase in most of the tested myogenic genes as a result of mechanical 
stimulation despite the lack of evidence in protein data for cyclic pressure and laminar shear 
stress.  While flk-1 gene expression appeared to correlate with our protein expression results, 
other EC-related genes tended to be increased for cyclic pressure, but EC-related gene expression 
data for cyclic stretch and laminar shear stress was decreased or unchanged. All the mature 
osteoblast and chondrocyte genes were either undetectable or strongly downregulated by the 
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applied mechanical stimuli.  Other trends in gene expression that were not specific to a particular 
lineage included the upregulation of FGF2, TGF-β, and collagen I in response to laminar shear 
stress.  ECM proteins including collagen I, III and elastin were also increased on average by 
cyclic pressure, while moderate stimulation by cyclic stretch seemed to increase elastin 
expression.   
6.1.3 Specific Aim 3 
Based upon the results of our 5 day experiments, we investigated the temporal evolution of the 
response to a single magnitude and frequency of each of the Mechanical Panel stimuli.  We also 
increased the cell seeding density to provide more biological materials for Western blotting and 
RT-PCR, which in previous experiments was limited by the low cell number in the systems.  In 
general, cyclic pressure and laminar shear stress increased EC-related gene expression starting at 
24 hours and continuing through 3 days.  Muscle-related gene expression was relatively 
unaffected in these earlier time periods, with the exception of cardiac troponin, which was 
strongly downregulated by cyclic pressure and laminar shear stress.  By 3 days, cyclic stretch 
was showing significant upregulation of desmin, and other vascular related genes including 
myocardin and cardiac troponin were on the rise.  Growth factor gene expression was similar to 
our earlier findings, with laminar shear stress upregulating FGF-2, TGF-β, and VEGF-A at both 
24 hour and 3 days.  Similarly, extracellular matrix gene expression, including collagen I, III and 
elastin, was also elevated for laminar shear stress at both 24 hours and 3 days.  Cyclic B1 
expression was significantly decreased under laminar shear stress at both 24 hours and 3 days, 
which was in agreement with the findings of our 5 day experiments.  Cyclic pressure also 
downregulated cyclin B1 in the 24 hour period, which was surprising given our previous 5 day 
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findings.  Conversely, cyclic stretch upregulated cyclin B1 expression at the 3 day time point.  
Considering that the experiments started at confluence, it was not surprising to find the 
diminished cyclin B1 expression which may be a product of contact inhibition.  However 
BMMSCs re-orient perpendicular to the direction of strain within 24 hours of cyclic stretch.  As 
a consequence of this migration they may have lost their contact inhibition, resulting in the 
observed increased cyclin B1 expression.   
In addition to changes in gene expression, we also attempted to quantify changes in 
protein expression with Western blotting.  However, due to problems with the resuspension of 
the solubilized protein, we were unable to detect proteins larger than 90 kDa in any of our 
samples.  The only protein that we were successfully able to probe for was calponin, but because 
of extremely large variability in expression, we were unable show any significant changes in 
expression for any of the applied stimuli at either 24 hours or 3 days.   
6.1.4 Specific Aim 4 
Similar to the study of the temporal evolution of BMMSC differentiation in response to 
mechanical stimuli, we designed a set of experiments to determine whether the differentiation of 
the BMMSCs following cyclic stretch would be reversed upon the removal of the applied 
stimuli.  Similar to Specific Aim 3, we performed RT-PCR for a variety of genes designed to 
determine the differentiation state of the cell.  Our results revealed that just 3 of the 30 genes in 
our assay - caldesmon, flk-1, and TGF-β - were significantly altered by the removal of the cyclic 
stretch stimulus.  Caldesmon and TGF-β were increased by the withdrawal of the stretch 
stimulus, while flk-1 was downregulated.  Our attempts to quantify protein expression were also 
impeded by the absence of high molecular weight proteins.  Western blots for calponin continued 
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to show relatively high variability, but on average increased with the removal of stretch.  
Although we have no statistical significance for our calponin results, because of the general 
trends in the gene and protein expression, we hypothesize that the BMMSCs are continuing 
down a myogenic lineage, possibly by utilizing autocrine/paracrine TGF-β signaling. 
6.2 APPLICATIONS FOR VASCULAR REGENERATIVE MEDICINE 
The overall goal for this research was to improve our understanding of how mechanical 
stimulation can be utilized to provide appropriate cues for stem cell differentiation into the 
vascular SMCs and ECs for use in regenerative medicine applications.  Our results have 
indicated that for mesenchymal cells derived from the bone marrow, mechanical stimulation 
tends to increase gene and protein expression for the myogenic lineage.  This was particularly 
evident for cyclic stretch, which we found to generate an elongated, spindle-shaped cell that 
expressed many of the proteins associated with contractile SMCs; namely SMA, calponin, and 
SMMHC.  Therefore, it would seem appropriate to think that stem cells impregnated into the 
wall of a tubular construct and exposed to the cyclic deformation resulting from pulsatile blood 
flow would preferentially head towards a smooth muscle lineage and not an undesired lineage 
such as bone, fat, or chondrocytes.  Furthermore, we have found that cyclic pressure and shear 
stress on average increase endothelial gene expression, particularly for the more mature proteins 
such as PECAM and vWF when these stimuli are applied to a confluent monolayer of cells.  
Therefore, we believe that implanting a vascular graft that is populated throughout its thickness 
with bone marrow-derived stem cells could ultimately establish an endothelial monolayer and a 
muscular wall based upon the cellular exposure to the local mechanical environment; namely 
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cyclic pressure, shear and stretch in the lumen, and cyclic stretch in the wall.  There is some 
evidence to support this recapitulation of the morphogenic processes of development.  Huang et 
al.[569] have demonstrated that embryonic stem cells seeded into a compliant micro-porous 
polyurethane tube and exposed to a gentle pulsing fluid flow developed both an endothelial 
lumen, and a muscular neointima based solely on the applied mechanical stimulation.  Our 
laboratory has also been able to provide some direct evidence that a single population of stem 
cells impregnated into porous, compliant polymer can develop both ECs and SMCs as a result of 
being implanted into the circulation [684].  However, although we may be able to generate cells 
that express genes and proteins that are considered appropriate markers of a mature phenotype, 
this in no way implies that the resultant cells are functionally equivalent to the native SMCs and 
ECs.  The real test for these tissue engineered vascular grafts will be their ability to prevent 
thrombotic occlusion and resist the overhealing hyperplastic response that is common to 
synthetic vascular grafts that lack the functional abilities promised by tissue engineered vascular 
grafts.   
6.3 ADVANTAGES OF METHODOLOGY 
Mammalian tissues, even those that aren’t associated with the musculoskeletal system, are under 
constant changes in compression, tension, and flexure as a result of movement, fluid flow, etc.  
The biggest advantage of our experimental setup was the concept of the Mechanical Panel and its 
utility in assessing the response of stem cells to one of several potential forces they may 
encounter in vivo.  Primary cultures of mesenchymal stem cells from the bone marrow typically 
contain a mixture of committed, partially-committed, and non-differentiated cells.  By applying 
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mechanical stimulation in parallel to unbiased population samples from a given set of stem cells, 
we can begin to capture the true effects of these stimuli because the heterogeneity at the start of 
each experiment is identical for each system.  Understanding how mechanical forces 
differentially affects stem cell differentiation, from basic morphology to complex genomic 
analysis, is just one part of the complex control system that we can harness to control stem cell 
behavior, both in vivo and in vitro, for therapeutic purposes.  Mechanical forces can potentially 
augment or reverse the effects of other biological signals such as growth factors, ECM 
composition, and pH.  While such effects may not drastically alter the response of a tissue-
committed cell, they may present potentially critical problems with stem cell therapies and 
warrant equal consideration. 
6.4 LIMITATIONS OF METHODOLOGY 
As stated previously, the BMMSCs utilized for these experiments were not a pure population of 
stem cells.  As a result, our interpretation of the effects of mechanical stimulation is clouded by 
the potential that only a population of the cells is responding to the mechanical stimulation.  
Despite this, our findings still indicate mechanical stimulation is an important stimulus for the 
generation of vascular cells in these particular cells, and thus has utility for vascular regenerative 
medicine. 
A major limitation with any study of gene expression is that transcriptional changes that 
are found (or not found for that matter) may not directly translate into changes (or lack of 
changes) in protein expression, which is the only true measure of biological change.  Post-
transcriptional and -translational modifications are known to be factors in the final protein levels 
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of many cell types including stem cells [685-687].  For instance, Tian et al. [685] have 
demonstrated through combined microarray and 2D-DIGE proteomic techniques that 
transcriptional changes in hematopoietic and liver cells can account for only 40% of the detected 
changes in protein expression.  Another study by Pratt et al. [688] evaluated the  turnover rate of 
proteins by examining the mass shifts of tryptic fragments of radiolabeled amino acid sequences.  
They discovered that the steady state degradation rates for 50 proteins were 2-10%/hour, which 
suggests that protein turnover should to be taken into account when trying to correlate changes in 
the proteome and transcriptome.  In our studies, we found differential changes morphology, 
proliferation, protein expression (by IHC), and gene expression that could not always be 
correlated and did not fit into tidy categories of gene expression (e.g., all EC-specific genes went 
up, or simultaneous expression of supposedly lineage restricted genes like myocardin or 
osteocalcin).  Furthermore, in a majority of the gene expression data, no statistically or 
biologically relevant changes were seen, despite the clear changes in morphology and 
proliferation.  These types of incongruities force us to acknowledge the presence of this 
multidimensional state of the cell involving the transcriptome and proteome that cannot be 
addressed by limited proteomic techniques such as immunohistochemistry and Western blotting.  
The need for systems biology approaches to analyzing biologic data are becoming more and 
more apparent as techniques and assays improve our ability to simultaneously measure the 
molecular processes of the cell.   
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6.5 FUTURE WORK 
Mechanical signals are just one of many different signaling mechanisms used by cells to respond 
to their environment.  Growth factors, extracellular matrix composition, pH, pO2, and other 
biochemicals also have an effect on cell biology.  Thus, in engineering terms, a cell is a dynamic 
multi-input, multi-output control system.  Current research is limited by a lack of understanding 
of the underlying cellular processes when multiple stimuli are utilized, instead relying on a 
“black box” approach [689].  Most established differentiation protocols for multipotent stem 
cells consist of a combination of multiple growth factors, exogenous chemicals, and mechanical 
stimuli without an understanding of potential synergies or antagonistic relationships [56, 524, 
525, 536, 537, 539, 595, 690].  Advances in analysis of intracellular signaling kinetics, 
genomics, and proteomics coupled with statistical modeling are showing great promise for 
predicting the final outcome of a multi-stimulus environment [691-693]. 
For example, by simultaneously analyzing the kinetics for the Akt, PKC, Smad, Erk, and 
JNK pathways (using a high-throughput kinase assay) as well as transcriptional changes for 
hundreds of genes (using TLDAs or cDNA microarrays) and subsequent proteomic alterations 
(using antibody microarrays or 2 dimensional difference in gel electrophoresis (2D-DIGE)) 
under our Mechanical Panel alone or in conjunction with chemical stimulation, we can build and 
train statistical models that can not only predict the various biometric outcomes, but also lead us 
to seek other previously unrecognized synergisms [691].  The techniques for these processes and 
others are already being developed and utilized in neuroscience, development, and stem and 
cancer cell biology [691-698].  By employing these systems biology approaches that take into 
consideration the vast amounts of cellular information at our fingertips, the resulting 
transcriptional and proteomic changes in stem cells from these multiple inputs may actually be 
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predicted.  Consequently, this has the potential to increase our ability to more precisely control 
stem cell behavior and tissue commitment for therapeutic applications.  Similar techniques can 
also be envisioned for tissue engineering applications as form of predictive quality control.  A 
given tissue engineered product could be sampled at various times throughout its incubation 
period for its transcriptome and proteome.  The results of the analysis could help to predict 
whether the product is progressing towards its target and terminated, saving thousands of dollars 
in wasted materials, or provide a prescribed adjustment to its culture protocol to put it back on 
track and avoid wasting the effort already placed into its development.   
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APPENDIX A 
A.1 ESTIMATION OF THE MAXIMUM VAPOR DENSITY 
The maximum vapor density (MVD, g/m3) at a given temperature was calculated according to:  
(A.1) 1222.52785.00143.0104104 23546 ++++= −− TTTxTxMVD
where T is the temperature (oC).  Equation (A.1) was obtained by fitting a fourth-order 
polynomial function to the data in saturated vapor density tables (Figure A.1) [610].  The MVD 
was used in Equation (2.6) to estimate the relative humidity for all cyclic pressure experiments.   
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Figure A.1:  Maximum vapor density curve generated from tabular data [610] and fit with a fourth order polynomial 
curve to extrapolate the maximum vapor density (g/cm3) possible at a given temperature. 
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APPENDIX B 
GROWTH OF BONE MARROW DERIVED MESENCHYMAL STEM CELLS 
B.1 SERUM SELECTION  
In order to maintain the tBMMSCs according to the protocols established by Javazaon et 
al.[613], we analyzed the growth curves of the tBMMSCs exposed to 2 different lots of fetal 
bovine serum that were similar to the serum lot currently in use by the TCGT.  Upon arrival from 
the TCGT, the tBMMSCs were thawed in standard FBS (Invitrogen) and allowed to attach to 
10cm Petri dish overnight.  The tBMMSCs were immediately subcultured, with a portion placed 
at 200 cells/cm2 into a 6 well dish (Falcon), and the remainder refrozen in α-MEM containing 
30% FBS (Invitrogen) and 10% dimethyl sulfoxide (DMSO, D2650, Sigma).  Those tBMMSCs 
subcultured into 6 well dish were treated in duplicate with two different lots of FBS (Atlanta 
Biologicals) as well as the standard FBS they were cultured in upon arrival.  The 6 well dishes 
were then placed in a robotic cell culture system in the Stem Cell Research Laboratories directed 
by Dr. Johnny Huard [699-703].  The robotic cell culture system is a custom-built device from 
Automated Cell, Inc. (Harmar, PA) that combines a motorized stage (Ludl Electronic Products, 
Hawthorne, NY) on an inverted microscope (Eclipse TE 2000, Nikon) with a sealed 
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bioenvironment to maintain 37oC, 5% CO2, and 95% humidity (Automated Cell, Inc.).  The 
system allows live cells in many regions of interest to be imaged (ES Cool Snap CCD, 
Photometric) with time-lapse photography.  The system is driven by CellMonitor (Automated 
Cell, Inc.) scanned each well to image 3 regions of interest per well every 10 minutes over 72 
hours.  The number of cells in each image were counted to create growth curves for each of the 
three sera used in this experiment (Figure B.1).  The serum lot J0133 was identified as having 
the best growth curve, and all subsequent tBMMSCs were expanded in this lot of serum.  
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Figure B.1:  Growth curves for serum selection experiment.  Lot J0133 had the greatest proliferation rate and was 
chosen as the lot of serum for subsequent use in the Mechanical Panel experiments.  The data is presented as the 
average and standard deviation of the replicates. 
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B.2 SEED LOT METHOD FOR SUBCULTURE 
All subsequent culture of tBMMSCs following serum selection was performed according to the 
Seed Lot Method [614], whereby early passage material was always available for the creation of 
new stock lines of cells. The process is depicted in Figure B.2.  Briefly, the initial culture of 
cells is expanded until sufficient numbers are attained to freeze 10 vials of cells at 250,000 
cells/mL.  The first 5 vials are used as the Working Lot 1, and the second 5 vials are the Seed Lot 
1.  After exhaustion of Working Lot 1, one vial of Seed Lot 1 is expanded to 5 new vials called 
Working Lot 2.  This process is repeated throughout all of the vials of Seed Lot 1 until the last 
vial, which is then used to make Working Lot 6 and Seed Lot 2.  For each experiment performed 
in Chapters 3.0, 4.0, and 5.0, one vial tBMMSCs was thawed, subcultured one to two times 
depending upon the number of cells needed for the experiment.  This ensured that each 
experiment was within a few passages of all the experiments performed in this dissertation.   
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 Figure B.2:  Seed lot method for culture of tBMMSCs adapted from the Cryopreservation Manual [614].  The 
initial culture is expanded into a see Lot and a Working Lot.  Each working lot is used for an experiment, ensuring 
that all experiments in a given study are within a few passages of each other. 
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APPENDIX C 
RNA, DNA, AND PROTEIN ISOLATION WORK FLOW 
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Figure C.1: Flow diagram demonstrating the sequential isolation of RNA, DNA and protein from TrizilTM for each 
component of  the Mechanical Panel. 
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APPENDIX D 
SCION ANALYSIS MACRO 
The Scion Analysis Macro was written in Microsoft Visual Basic (v6.3, Microsoft Corporation) 
and Microsoft Excel (v2003, Microsoft Corporation) to efficiently process the measured cell 
parameters (area, perimeter, major axis, minor axis, and angle) from Scion Image for each of the 
components of the Mechanical Panel for the experiments outlined in Section 3.2.3.  Through a 
series of user interfaces, the raw measurements from Scion Image for each Mechanical Panel 
stimulus were converted to the proper units, grouped according to the type of measurement, 
explored with basic statistics, and displayed graphically.   
 252 
D.1 USER INTERFACES 
The Start Menu (Figure D.1) allowed the user to start or continue an analysis.  By choosing 
“Start Analysis” the user is prompted to either choose to work with the current workbook, or 
import new data (as an Excel, Scion, or a text file).   
 
 
Figure D.1:  Screen shot for the Scion Analysis Macro Start Menu.  The raw data from Scion, arranged by columns 
in separate worksheets for each componentn of the Mechanical Panel is visible in the background.  
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The Options Menu (Figure D.2) then asks user to identify which of the possible measurements 
from Scion Image are found in the worksheets.   
 
 
Figure D.2:  Screen shot for the Scion Analysis Macro Options Menu.  The user has selected the Measured Values, 
indicated which calculated values are desired, and has entered the conversion factors.   
Selecting appropriate morphometric measurements enabled each of the three Calculated Values – 
Shape Index, Tortuosity Index, and Aspect Ratio – to be selected.  The user was also prompted 
for the conversion factor for their Images.  The Scion Calibration text box was the default 
calibration for Scion Image (72 pixels/inch), and the Conversion text box was the measured 
pixels per millimeter for the hemocytometer image for that experimental image set.  The 
program then converted all measurements of length from inches to micrometers using the 
following:  
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This process was repeated for the area measurements, which were in2.  The values entered by the 
user were stored in the Custom Document Properties of Excel and could be recalled if the data 
was re-analyzed.  After the unit conversion, each measured parameter was placed in its own 
worksheet.  Next, the selected Calculated Values were computed by creating arrays of measured 
parameters necessary for the calculation.  The Shape Index and Tortuosity Index was calculated 
using Equations (3.2) and (3.3), respectively.  The Aspect Ratio was simply the ration between 
the major axis and the minor axis, and was our main measure of cell shape prior to the use of the 
Shape Index.  Once the measured and calculated values were separated, the built-in descriptive 
statistics commands within Excel were called to evaluate data.  Graphs of the average values ± 
SEM were automatically generated for each of the measured parameters.  For the angle data, 
each measurement was copied to a temporary worksheet and placed in an appropriate 10o bin 
between 0o and 180o.  The frequency of occurrences in each bin was used to generate a 
histogram.  Next, a Statistics Menu (Figure D.3) prompted the user to choose any desired 
statistics to interrogate the data.  The F-test for variance, t-test, and z-test used the standard 
statistical functions in Excel to compare the variances or means, as appropriate, of each 
component of the mechanical panel.  The Chi-squared test utilized the angular frequency tables 
for each component of the mechanical panel to create the observed and expected frequencies 
before calculating the chi-sum and using the built-in Excel function CHIDIST to generate a p-
value for the distribution of the angular data for that experiment.  The Scion Analysis Macro 
results in an organized analysis of the data generated from Scion Image (Figure D.4).   
After the Scion Analysis Macro finished, the data could be saved and ready for import 
into the Experimental Database (see Appendix E).  The Scion Analysis Macro was extremely 
useful for examining each experiment for consistency and trends within itself.  However, the 
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greatest utility for the program was as a time-saver.  The Scion Analysis Macro performed 
approximately 2 hours worth of data handling in 2 minutes.  Other features of the Scion Analysis 
Macro that were not utilized for this study, but were built for future work include the ability to 
create separate average graph values for experiment components that have a common string in 
their name.  For example, if a mechanical panel experiment was performed using different ECM 
proteins such as collagen I, elastin, and laminin, separate average value graphs could be created 
for each ECM protein to compare its effect on each component of the Mechanical Panel.  
Likewise, all similar Mechanical Panel components could be graphed together to compare 
differences in ECM coating.   
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Figure D.3:  The Statistics Menu prompts the user to choose from a variety of statistical tests to analyze the data.  
Each selected statistical test is peformed sequentially on each pair of the available components of the Mechanical 
Panel.   
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 A) 
B) 
C) 
D) 
 
Figure D.4:  Format of the data following the completion of the Scion Analysis Macro.  Each measured 
morphometric parameter is listed as a separate  worksheet tab as well as a Statistics tab.  For example, the Angle 
Statistics tab contains the (A) descriptive statistics, (B) average value graph, (C) statistical analysis, and  
(D) histogram, and of the angle data.   
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APPENDIX E 
EXPERIMENTAL DATABASE 
In order to keep track of the large amount of information generated from each Mechanical Panel 
experiment, a database was created to perform the following tasks: 
1. Track the cell culture identification numbers for the tBMMSCs used in each 
experiment. 
2. Store the Mechanical Panel parameters for easy grouping of the data in 
queries. 
3. Identify which biological assays had been performed store their results or 
hyperlink to the raw data.   
4. Keep track of all samples generated and their storage location. 
5. Provide a framework to export experimental parameters and values to SPSS 
statistical software. 
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E.1 GENERATION OF THE FOURTH NORMAL FORM 
The database was designed in Microsoft Access (v2003, Microsoft Corporation) and was in 
fourth normal form.  For a review of relational theory and the nomenclature used throughout this 
appendix, the reader is directed to an excellent review of the topic by Kent [637] as well as 
“Developing Quality Complex Database Systems: Practices, Techniques and Technologies” by 
Shirley Becker [704].  The database was built using 47 tables, 39 queries, 20 forms, 16 reports.  
Visual Basic (v6.3, Microsoft Corporation) was used to manipulate the forms and enter and 
retrieve data from the tables.   
By definition, all normal forms are additive, so by being fourth normal, it is implied that 
the Experimental Database is also first, second, and third normal.  First normal form indicates 
that repeating fields are eliminated.  This is best exemplified by the Mechanical Panel, which 
contains up to five experimental components (Figure E.1).  By converting (A) into (B) and (C), 
searching for all experiments for ones that had CP easily returns a list containing the ExpID for 
each experiment.   
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(C) 
 
Experiment 
Name
Mechanical 
Panel 
Components
Trexp01
CP, CS, LSS, 
Control
Trexp03
CP, CS, LSS, 
Control
Database
Trexp02
CS, LSS, 
Control
ExpID
Experiment 
Name
1 Trexp01
2 Trexp02
3 Trexp03
Experiment Table ∞
(A) 
(B) 
DatID ExpID
Mecahnical Panel 
Component
1 1 CP
2 1 LSS
3 1 CS
4 1 Control
5 2 CP
6 2 CS
7 2 Control
8 3 CP
9 3 CS
10 3 LSS
11 3 Control
Mechanical Panel Database
Figure E.1:  Conversion of the Mechanical Panel to a first normal form Database. The infinity symbol denotes the 
“many” table for the one-to-many relationship.   
 
Second normal form indicates that redundant fields are eliminated.  To convert Figure E.1 to 
second normal form, a new table listing CP, LSS, CS, and Control only once is created with a 
junction table to link it to the Experiment Table (D).   
 
DatID ExpID MPID
1 1 1
2 1 2
3 1 3
4 1 4
5 2 1
6 2 3
7 2 4
8 3 1
9 3 3
10 3 2
11 3 4
Experiment-Component
MPID Component
1 CP
2 LSS
3 CS
4 Control
Component Table
∞
DatID
Experiment 
Name
1 Trexp01
2 Trexp02
3 Trexp03
Experiment Table
∞
(D) (E) 
(F) 
 
Figure E.2:  The configuration in Figure E.1 is converted to second normal form through a junction table (E) 
connecting (D) and (F).  The infinity symbol denots the “many” table for the one-to-many relationship. 
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Third normal form is created by eliminating columns not dependent on a primary key.  The 
configuration of our database in Figure E.2 does not violate third normal form unless we begin 
to consider other data necessary for the database, such as the genes assayed by PCR.  Each RQ 
value generated by RT-PCR is linked to a specific gene.  However, the primary key which 
identifies each RQ value does not have a relationship with the gene name.  Therefore, that 
information must be moved to a different table.  This was important for the instance where we 
changed several genes on the second TLDA.  New genes were added which did not exist before 
and others were removed.  Without third normal form, gene available for analysis that had no 
current RQ value would not be listed at all.  This concept is illustrated in Figure E.1. 
 
 
PCRID RQ Gene Name
1 24 vWF
2 0.5 Calponin
3 56 Collagen II
4 12 Desmin
5 2 Cyclin B1
6 0.02 Osteocalcin
7 1 VEGF-A
PCR Tables
PCRID RQ GeneID
1 24 1
2 0.5 2
3 56 3
4 12 4
5 2 3
PCR Tables
GeneID GeneName
1 vWF
2 Calponin
3 Collagen II
4 Desmin
Gene Table
∞
(H) 
(I) 
(G) 
 
Figure E.3:  Representation of third normal form.  Gene names which would be non-existant in the database prior to 
registering an RQ value are stored independent from the PCR tale.  The infinity symbol denots the “many” table for 
the one-to-many relationship. 
 
The final step for the creation of the Experiment Database was to achieve fourth normal form.  
For a database to be in fourth normal form, no table can contain two or more one-to-many or 
many-to-many relationships that are not directly related.  This prevents the creation of dummy 
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records when an expected endpoint is not generated.  For example, each Mechanical Panel 
experiment consists of several components – CS, CP, LSS, and Control.  This is a one-to-many 
relationship.  Furthermore, each component of the Mechanical Panel can generate 3 biological 
samples – RNA, DNA, and protein.  This creates a one-to-many relationship with a given 
experiment component and a many-to-many relationship between the experiment and the 
biological samples.  To efficiently organize this data for searching, these details should be stored 
as separate rows in separate tables with independent primary keys.  These tables are joined 
together by separate junction tables, which contain only the primary keys for the two tables they 
are joining.  This configuration for three tables is indicated in Figure E.4.  Another reason to 
organize the database in this fashion is to avoid update errors.  If a single junction table had been 
used, deletion of a sample from one side would either force both samples to be deleted or force 
the junction table to create a dummy value in its place.  Multiple junction tables containing the 
field ID numbers for a particular endpoint and its corresponding experiment identifier also allow 
for easy querying of the results for any specific set of independent conditions, such as a list of all 
the experiments with 5% CS, PCR results, and IHC results (see Figure E.11 as an example). 
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Figure E.4:  Relationships view of Storage Detail and tblExperiment tables to the Experiment Detail table in the 
Experiment Database.  The Primary Key is in bold type.  Junction tables (denoted by Jx) are used to connect the 
one-to-many relationships that exist between the primary keys.  The infinity symbol denots the “many” table for the 
one-to-many relationship. 
 
E.2 USER INTERFACES 
In addition to efficiently storing data for fast retrieval, the Experiment Database provided the 
means to extract large quantities of data from Excel spreadsheets containing the morphometric 
analysis for a given experiment, or the RQ values for the 32 genes on the TLDA card.  User 
interfaces were designed to efficiently navigate through the database and enter and retrieve data.  
The main form (Figure E.5) displays all the relevant information about an experiment at a 
glance.  It displays the types of mechanical stimulation used for an experiment as well as the 
magnitudes and frequencies of each stimulus.  The presence of assay results or stored samples is 
denoted by check-boxes that are activated as soon as data is stored in the relevant tables.  Several 
command buttons provide quick access to reports or queries.  For example, The “Sample 
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Processing Reports” section provides tables similar to those shown in Figure E.6.  Moving into 
the PCR Form demonstrates the functionality for the database to pull the RQ data for all TLDA 
genes and place them into the proper text boxes (Figure E.7).  Other main data-entry forms, 
including those for the morphometric data, proliferation data, storage form, and experiment 
search form are depicted in Figure E.8, Figure E.9, Figure E.10, Figure E.11.   
The PCR form represents the ideal reason for creating a fourth normal form database.  
The PCR data was not originally part of the experiment database, but shortly after deciding to 
use TLDAs to perform RT-PCR, the form depicted in Figure E.7 was a necessity if we were 
going to effectively manage 570 data points per experiment generated by the PCR data.  By 
being in fourth normal form, the Experiment Database is modular, and new assays or endpoints 
that become part of the experimental plan can be seamlessly incorporated with all the other 
information linked to main experiment detail.  
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Figure E.5:  The main form displaying Experiment 16.  As soon as an experiment number is chosen, the remaining 
fields self-populate to relate the information about that experiment stored throughout the database.  Quick launch 
buttons are also provide to show various reports or query results, and launch stored hyperlinks to files and folders.  
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Figure E.6:  Protein for Western blotting report generated by the Experiment Database from the Main Form.  The 
report lists the experiment details as well as storage location, concentration, and yield and calculates the volume 
required for 20μg of protein. 
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Figure E.7:  The PCR Results Form is reached from the Main Form.  All RQ values for each of the genes and 
components of the mechanical panel (570 text boxes in total) are instantly obtained from the Data File as the push of 
a button and stored in the PCR Results Table. 
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Figure E.8:  Morphology Form from the Experiment Database.  The “Get Data” button extracts the average values 
from each sheet that was created from the Scion Analysis Macro (see Figure D.4).  The “Normalize Data” check 
box divides each value by the control value, and stores the normalized data in a separate table.   
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Figure E.9:  The Nuclear Form imports the average cell density measurements for each component of the 
Mechanical Panel from an Excel spreadsheet containing the raw cell counts.  The “Normalize Data” check box 
divides each value by the control value, and stores the normalized data in a separate table.   
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Figure E.10:  The Storage Form displays the locations for biological samples generated from a given experiment.   
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Figure E.11:  The Experiment Search Form searches the database for the values in the drop-down boxes and check-
boxes.  Selecting any of the resulting values retrieves the data for that experiment and places it in the Main Form.   
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APPENDIX F 
CELL CYCLE ANALYSIS 
Because the decrease in cell density reported for LSS (see Figure 3.14) could be caused by 
either a true inhibition of proliferation or a selective removal of proliferating cells by the flowing 
media, the cell proliferation marker Ki67 was probed by immunohistochemistry.   
F.1 METHODS 
tBMMSCs subjected to either CS-10, CP-120, LSS-5, or control conditions were assayed for the 
cell proliferation marker Ki67 using immunohistochemistry protocols outlined in Section 3.2.4.4.  
Following termination of each stimulus, tBMMSCs were rinsed with ice cold PBS and fixed in 
4% paraformaldehyde followed by 3 washes in PBS.  The cell membrane was permeabilized for 
15 minutes with 0.1% TritonX in PBS.  Non-specific binding of the antibody was blocked using 
a 5% BSA solution in PBS for 1 hour at RT.  The fixed and permeabilized samples were 
incubated with Anti-Ki67 (Santa Cruz) diluted 1:100 in PBS/BSA/Gly for 1 hour at Rt.  After 3 
washes in PSB/BSA/Gly, the samples were incubated for 1 hour at RT with the secondary 
antibody, goat anti-mouse conjugated to Alexa Fluor 488 (Sigma) diluted 1:500 in 
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PBS/BSA/Gly.  After 3 washes of PBS/BSA/Gly, DAPI (Sigma) was added to stain the nucleus.  
The samples were washed 5 times in PBS and then mounted on microscope slides using gelvatol 
for imaging on an epifluorescent microscope (E800, Nikon).  The proliferation index was 
calculated by counting the number of nuclei positive for Ki67 and dividing by the total number 
of nuclei.  Five fields of view were imaged per experiment and averaged to create an average 
proliferation index for that experiment.  A paired t-test with α=0.05 was used to compare each 
stimulus.   
F.2 RESULTS 
The average proliferation index ± SD are reported for the control (38% ± 2%, n=2), CP-120 
(52% ±7%, n=2), CS-10 (35% ± 7%, n=2), and LSS-5 (5% ± 6%, n=2).  Representative images 
are shown in Figure F.1.  The results demonstrate that LSS has a lower proliferative index 
(p<0.10) than control, CP, or CS samples, and provides evidence tBMMSCs exposed to LSS 
demonstrate the majority of LSS cells were arrested in the G0 phase of the cell cycle.  Although 
the observed drop in cell density compared to controls may have resulted from removal of 
proliferating cells by fluid flow, the extremely low number of cells arrested at G0 points more to 
a direct inhibition of proliferation by LSS.   
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Figure F.1:  Representative Ki67 staining for Mechanical Panel experiments (n=2).  Green=Ki67.  Red=nuclei 
stained with DAPI.  All images taken at 100x.   
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APPENDIX G 
EVALUATION OF 18S AS AN ENDOGENOUS CONTROL 
In the TLDAs for our initial Mechanical Panel experiments (see Section 3.2.3), we utilized the 
expression of 18s rRNA as the endogenous control gene for several reasons, including its relative 
popularity in the genomic literature and the fact it was required to be present on all TLDAs 
produced by ABI.  However, in examining two consecutive control samples, which should have 
behaved in a similar manner, we noticed identical CT values for the flk-1 gene expression even 
though there was a large shift in the CT for 18s. (Figure G.1).  Because each TLDA received 
approximately the same cDNA mass (400ng per sample) and the change flk-1 gene expression 
was within 0.3 cycles, the large change in 18s rRNA prompted our deeper investigation into the 
validity of 18s as an endogenous control gene for our experiments involving the Mechanical 
Panel (see Section 4.2.2.2.1). 
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 Figure G.1:  ΔRn vs. cyclic time for 18s (A, B) and Flk-1 (C-D) in two control samples from Experiment 9 (A,C)  
and Experiment 10 (B,D).  A 4 cycle shift in 18s, which translates to more than a 10-fold increase in mRNA 
transcripts by the 2ΔΔCt method, did not result in a similar shift in the expression of Fkl-1.   
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APPENDIX H 
DYNAMIC RANGE TESTING FOR TAQMAN® LOW DENSITY ARRAYS 
H.1 METHODS 
The dynamic range of the TaqMan® Low Density Array (TLDA) was assessed by performing the 
reverse transcriptase (RT) reaction with a starting mass of RNA that spanned at least 4 logs.  The 
RNA used for the dynamic range tests was Universal Rat RNA (636658, Clontech, Mountain 
View, CA) to ensure that all genes queried would show detectable amplification within 40 
cycles.  The Universal Rat RNA is reported by the manufacturer to contain quantifiable amounts 
of RNA for more than 90% of the rat transcriptome.  The RT reaction was initialized with 1, 10, 
100, and 1000 ng of universal RNA using techniques described in Section 3.2.4.5.4 and then 
loaded into the TLDA and analyzed by RT-PCR (see Section 3.2.4.5.5.1).   
H.2 RESULTS 
The results of the dynamic range test are presented in Figure H.1.  For each target gene, there 
was an approximately linear relationship between the log transformation of that starting mass 
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and the threshold cycle (CT) of detection as determined by the SDS software.  Based upon the 
curves, the mass of RNA necessary to achieve a CT of at least 30 cycles for all target genes 
would require at least 100 to 1000 ng of RNA to be loaded for each sample.  Therefore, 
whenever possible, the core facility was instructed to load 400ng of RNA per sample into the 
TLDA.  It was also evident from these results that 18s was expressed at a much higher level than 
nearly all the target genes.   
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Figure H.1:  Dynamic range assessment for the 32 genes chosen for the TLDA card.  Each gene was tested against 
different starting RNA masses that spanned 4 logs.   
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APPENDIX I 
COMPARISON OF ENDOGENOUS CONTROLS 
PCR data from one experiment was analyzed by SDS software using either 18s or Gusb as the 
endogenous control.  The RQ values for Aggrecan were compared as an example.  By using 18s 
as the endogenous control, the RQ values for pressure and stretch were increased 88% and 40%, 
respectively, while the RQ values for shear stress were decreased 27% (Table I.1).   
 
 
Table I.1:  Comparison of the RQ values for Aggrecan when either 18s or Gusb are used as the endogenous control 
for ΔΔCT evaluation.  The relative change in expression is constant for all genes in a given set because all genes are 
normalized to the single CT value for that stimulus. 
 
 Gusb Endogenous 18s Endogenous 
Gene Name Pressure Shear Stretch Pressure Shear Stretch
Endogenous Control (CT value) 23.10 24.44 23.59 6.75 6.73 6.81 
Aggrecan 0.98 0.84 0.85 1.84 0.62 1.19 
Percent difference from Gusb    +88% -27% +40% 
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APPENDIX J 
WESTERN BLOT ENDPOINTS 
J.1 SMOOTH MUSCLE ALPHA-ACTIN 
SMA, which was successfully detected by IHC in the 5 day Mechanical Panel experiments, was 
proposed to be studied by Western blotting in Specific Aims 3 and 4.  Following several attempts 
and troubleshooting steps, we have been unable to accurately, and reproducibly target SMA in a 
Western blot.  Initial attempts using the antibody from Chemicon (MAB1536) were thought 
successful since only a single band appeared on the blot (Figure J.1).  However, upon closer 
examination of the molecular weight of this protein, we discovered that it was much too large to 
be SMA.  Our measurements indicated its molecular weight to be approximately 68kDa, whereas 
SMA has a reported molecular weight of 42 kDa.  A separate SDS page gel was run, stained with 
Coomassie Brilliant Blue, and the 70kDa band was excised.  A tryptic digestion and mass 
spectrometry analysis of the band was carried out by Dr. Andy Amoscato in the Department of 
Pathology.  The resulting amino acid sequences were compared to other known sequences 
obtained by tryptic digestion. The tryptic digests from our sample matched to a 70kDa serum 
albumin precursor protein known as Phi AP3.  In addition to serum albumin precursor, the first 
ten amino acids for SMA were also present, which helped to explain why this particular band 
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was staining for SMA by Western blotting at 70kDa.  The presence of these two molecules has 
previously been identified as part of a redox sensing mechanism in SMCs [705].  We are as yet 
unsure why this process may be occurring in BMMSCs, since the protein band has appeared in 
every cell lysate from both the tBMMSC and BMMSCs isolated by Hamilton et al.[526].   
 
70kDa 
A-10 5μg
 
Figure J.1:  Representative Western blot of SMA.  The far left lane contains the A-10 cell lysate, which was used as 
a positive control.  The remaining lanes contain increasing masses of pooled tBMMSC protein from several 
Mechanical Panel experiments, which was used to perform the initial Western blot testing.  The arrow points to the 
70kDa Phi AP3 band which appears prominently in our tBMMSCs.   
 
 
 
20μg 10μg  1μg 
(40μg) 
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 In addition to the Phi AP3 band in the BMMSCs, the A-10 cell lysates displayed a 
constant non-specific staining the entire length of the lane.  We made several attempts to inhibit 
this non-specific binding by changing blocking solutions, antibody concentrations, incubation 
temperatures, and the antibody itself.  Using SuperBlock (Pierce), a 1:180,000 dilution of SMA 
from Sigma (clone 1A4), and a 45oC primary antibody incubating temperature reduced the 
general non-specific staining to several distinct bands (Figure J.2), which was an improvement 
over the previous blot (Figure J.1).  However, the strongest bands for the BMMSCs appeared at 
37 kDa and 60 kDa, the positive control stained strongest at 37 kDa.  These results led us to 
abandon our attempts to measure changes in SMA expression by Western blot. 
 
 284 
  
Figure J.2:  Western blot for SMA depicting non-specific staining.  A-10 cell lysates were used as a positive 
control.  All lanes were loaded with 40μg of total protein. 
J.2 SM-MHC 
SM-MHC, which was weakly detected by IHC in the 5 day Mechanical Panel experiments, was 
proposed to be studied by Western blotting in Specific Aims 3 and 4.  Using the same antibody 
from Dako, we attempted to detect SMMHC in our cyclic stretch experiments, using A-10 cell 
lysates as the positive control.  We were unable to detect any signal from the 50μg of positive 
control and hypothesize that the problem rests with the transfer protocol.  We have tried multiple 
different protocols that included high voltage transfer, addition of SDS to the transfer buffer, and 
extended transfer times.  These changes were based upon the recommendation of the positive 
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control manufacturer, but have thus far been unsuccessful.  A representative Western blot for 
SM-MHC is shown in Figure J.3.   
 
200 kDa 
 
 
Figure J.3:  Western blot for SM-MHC.  The positive control (A-10) was loaded at 50μg of total protein and failed 
to generate any signal at 200 kDa, which is the appropriate molecular weight for SM-MHC.  
J.3 PECAM 
We were encouraged by the PCR results for PECAM under LSS and CP (Table 3.6) despite not 
being able to detect PECAM by IHC in our initial 5 day experiments (see Figure 3.20).  PECAM 
Western blots were transferred using recommended high molecular weight protocols.  Using 20 
μg of the positive control (Jurkat cell lysates), we were able to detect a weak positive signal 
(Figure J.4).  However, the same loading mass of our pooled experimental samples, were 
negative for PECAM.   
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Figure J.4:  Representative Western blot for PECAM using the positive control (Jurkat cell lysate) as well as pooled 
experimental protein.  Jurkat total protein was loaded at 20μg, and the pooled expeirmental proteins were loaded at 
the masses indicated in the figure.   
 
Our next step was to increase the mass of the Jurkat positive control protein to 50μg and use 
40μg of the same CP and LSS samples that registered signal by PCR.  This resulted in a stronger 
signal for the positive control, but the CP and LSS samples still did not show any signal for 
PECAM (Figure J.5).  This has led us to conclude that either our experimental samples either 
contain very minor amounts of PECAM, or our protein extraction technique is not optimized for 
hydrophobic membrane-bound proteins. 
 
 
Figure J.5:  Western blot for PECAM for 50μg of Jurkat, and 40μg each of the CP and LSS samples.   
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J.4 FLK-1 
Flk-1 was the only EC-related protein detected by IHC in the 5 day experiments (Figure 3.19).  
Because it was constitutively expressed, we felt confident we could detect flk-1 by Western blot 
in our 24 hours and 3 day experiments.  Our first Western blots for flk-1 using the positive 
control (ECV304 cell lysates), were successful, but the signal was extremely weak (Figure J.6)   
 
5 µg 10 µg 20 µg 
150 kDa 
 
 
Figure J.6:  Western blot for flk-1.  ECV304 cell lysates were loaded at 25 μg total protein mass.  Pooled 
experimental samples were loaded at the masses indicated in the figure.   
 
We increased the amount of protein up to 50μg per lane and used modified transfer protocols for 
high molecular weight proteins (see Table 4.5 for parameters), which was the maximum amount 
of protein we could reasonably load without sacrificing our ability to perform other Western 
blots.  While the signal for the positive control sample increased, we were not able to detect any 
signal from our experimental samples (Figure J.7).  Taking into consideration that flk-1 gene 
expression was present in these samples, that previous IHC data clearly showed constitutive 
expression of flk-1 protein, and that we have a good signal for the positive control (indicating the 
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transfer process was adequate), we conclude that our protein solubilization method was not 
optimized for hydrophobic proteins. 
 
150 kDa 
 
 
Figure J.7:  Flk-1 Western blot for the positive control (ECV304) and three experimental samples.  All prpotein 
was loaded at 50μg per lane.   
 
J.5 SILVER STAIN 
To test the hypothesis that we had difficulty solubilizing the higher molecular weight proteins, 
we used a silver stain (#161-0449, Bio-Rad), which is capable of detecting nanograms of protein.  
Approximately 20μg of protein was loaded in each lane.  Three lanes were loaded with protein 
extracted using T-PER (#78510, Pierce), which was used in a few very early experiments.  The 
remaining 6 lanes were loaded with protein extracted using the methods described in Section 
4.2.2.3 and were representative of the various time points and stimuli used throughout this 
dissertation.  SDS-PAGE was performed as described in Section 4.2.2.4.1, and silver staining 
was performed according to the manufacturer’s protocols.  The results of the silver stain (Figure 
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J.8) indicate that we do have some higher molecular weight protein coming into solution from 
the TrizolTM isolations, but it is clear that the amount of these proteins makes up a very minor 
fraction of the total protein.  The greatest mass of protein occurs at 70k kDa, which coincides 
with the Phi AP3 protein identified in Section J.1.  Also, 2/3 of the 3 day time point samples 
show almost no protein between 80 and 300 kDa.  Thus, there is obvious heterogeneity in the 
isolation procedure.  Given that transfer efficiency is always much less than 100%, it is not 
unreasonable to conclude that the fraction of high molecular weight protein is low enough to 
require greater than 50-100 μg total protein in order to transfer sufficient quantities to detect by 
Western blot.  Loading this much protein would cause severe lane distortion because of the high 
mass of the Phi AP3 protein.  Potential alternatives include immunoprecipitation of the desired 
high molecular weight protein to improve our ability to load higher quantities or 
immunoprecipitation of the Phi AP3 protein to remove it from the total protein before SDS-
PAGE.   
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Figure J.8:  Silver stained SDS page gel loaded with 20μg of total protein from various experiments.   
T-PER Trizol
TM 
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